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I 
Optochemical Genetics 
Timm Fehrentz, Matthias Schönberger, and Dirk Trauner 
Department of Chemistry, Ludwig-Maximilians-Universität, and Center for Integrated 
Protein Science, 81377 Munich, Germany.  
 
 
Transmembrane receptors allow a cell to communicate with its environment in 
response to a variety of input signals. These can be changes in the concentration of 
ligands (e.g. hormones or neurotransmitters), temperature, pressure (e.g. via 
acoustic waves or touch), transmembrane potential, or light intensity. Many 
important receptors have now been characterized in atomic detail and our 
understanding of their functional properties has markedly increased in recent 
years. As a consequence, these sophisticated molecular machines can be 
reprogrammed to respond to unnatural input signals. In this review, we will show 
how voltage-gated and ligand-gated ion channels can be endowed with synthetic 
photoswitches. The resulting artificial photoreceptors can be used to optically 
control neurons with exceptional temporal and spatial precision. They work well 
in animals and might find applications in the restoration of vision and the optical 
control of other sensations. The combination of synthetic photoswitches and 
receptor proteins contributes to the field of optogenetics and adds a new 
functional dimension to chemical genetics. As such, we propose to call it 
“optochemical genetics”.  
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“The trick then is not to use the clumsy and inefficient techniques of classical organic 
chemistry by themselves but to make use of Nature’s tools.” 
Sir Francis Crick, 1999[1] 
1. Introduction 
Nature’s molecular devices are unsurpassed in their beauty, efficiency and ability to 
integrate into complex systems. This is not entirely surprising, given that they have 
evolved over billions of years. Organic chemistry, by contrast, is about two hundred 
years old. The synthesis of complex molecules is barely a third of that age and far 
from being a mature and efficient technique. Nevertheless, synthetic chemistry has 
made remarkable progress over the last decades and many molecules have been 
created that have no structural or functional counterpart in Nature. 
Still, what we can make today comes nowhere near to what Nature can achieve. The 
drugs we synthesize are comparatively simple molecules and the switches, motors, 
and machines we forge are conceptually beautiful but pale in comparison with 
Nature’s devices.[2] These have been studied in great detail with various biophysical 
methods and our understanding of how they work has dramatically increased in 
recent years. Some famous examples of molecular machines that have now been 
elucidated in atomic detail include ATP synthase,[3] the ribosome,[4] RNA 
polymerase,[5] various molecular motors,[6] or ion channels that control nervous 
activity.[7] Although they operate on a scale where the peculiarities of quantum 
mechanics apply, they can be often described in terms of relatively simple and 
intuitive mechanical models. 
This much-improved understanding of Nature’s molecular machines opens the door 
for their functional manipulation using synthetic chemistry. Just as macroscopic 
engines can be taken apart, “souped up”, and fitted with an ignition key, 
nanomachines can be manipulated and endowed with additional features and 
control elements. This can be done to a certain extent at a genetic level, i.e. through 
classical protein engineering, but also by adding and attaching synthetic molecules. 
The trick is then not to use the traditional techniques of synthetic organic chemistry 
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by themselves, but to make use of them in combination with Nature’s tools. This 
approach creates hybrid devices that can be controlled with unnatural input signals 
and can be easily integrated into highly complex biological systems. As such, they 
not only function in vitro or in single cells but also in complex cellular networks, even 
in neural tissues and in behaving animals. 
In this review, we will show how the paradigm - that Nature’s molecular machines 
can be harnessed with synthetic chemistry - can be applied to a set of transmembrane 
proteins that play key roles in neurophysiology. To this end, we will first review 
some of the elementary machinery that is involved in sensory perception, synaptic 
transmission, and the generation of action potentials. We will then discuss in general 
terms how it can be reprogrammed to become sensitive to a very useful stimulus - 
light - and how the resulting artificial photoreceptors can be used to control and 
study neural networks. This is also the goal of “optogenetics”, a new field of 
neuroscience that is currently undergoing rapid expansion.[8] We will show how the 
addition of a chemical component complements and extends optogenetics and how 
“optochemical genetics” contributes to the dissection and functional enhancement of 
nervous systems in new and exciting ways.[9] 
 
 
2. Transmembrane receptors and their role in neurobiology 
Transmembrane receptors underlie cellular communication, including the electrical 
and chemical communication within and in-between neurons. For the purposes of 
this review, we define these receptors as transmembrane proteins that respond to 
changes in an input signal, be it light-intensity, pressure, voltage, temperature or the 
concentration of a small ligand. These include ion channels (ionotropic receptors), G-
protein coupled receptors (metabotropic receptors) and receptor-linked enzymes. For 
many years, these proteins were considered to be very difficult to study with 
structural methods, particularly with X-ray crystallography. This perception changed 
in 1998, when MacKinnon disclosed the X-ray structure of KcsA, a potassium 
selective ion channel sensitive to changes in pH.[10] Since this groundbreaking work, 
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representatives of several fundamental receptor classes have been characterized in 
atomic detail, including G-protein coupled receptors (GPCRs),[11] ionotropic 
glutamate receptors (iGluRs),[12] trimeric ATP receptors (P2X),[13] voltage-gated ion 
channels,[14] and pentameric ligand-gated ion channels (pLGICs).[15] For convenience, 
these receptors are grouped according to their symmetry in Fig. 1. Note that these 
receptors can exist as homomultimers, but often assemble as heteromultimers 
composed of several similar, but not identical, subunits.  
 
  
Figure 1. Selected transmembrane receptors of different symmetry characterized by X-
ray crystallography and electron microscopy. Each receptor is shown in side- and top-
view (from the extracellular side) and fitted to the same scale. Left to right: Rhodopsin, a G-
protein coupled receptor responsible for vision (pdb 1U19). GluA2, a glutamate-gated ion 
channel involved in excitatory neurotransmission (pdb 2KG2). P2X4, an ATP-gated cation 
channel that mediates pain sensation (pdb 3H9V). Kv1.2, a voltage-gated potassium channel 
involved in controlling cellular excitability (pdb 2A79). nAChR, a nicotinic acetylcholine 
receptor that mediates the communication between nerves and muscles (pdb 2BG9).  
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With the exception of rhodopsin,[11b] none of the receptors shown in Fig. 1 are 
inherently light-sensitive. Three of them, GluA2,[12] P2X4,[13] and the nicotinic 
acetylcholine receptor,[15a] are ligand-gated ion channels that respond to changes in 
the concentration of neurotransmitters or extracellular metabolites. Voltage-gated ion 
channels, such as Kv1.2,[16] are opened and closed by changes in transmembrane 
potential. They can be also influenced by ligands, however, such as channel blockers. 
As a consequence, all of the receptors shown in Fig. 1 can be regulated in one form or 
another by a small molecule. Provided this small molecule can be persuaded to 
change its activity in response to light, the whole receptor-ligand assembly could be 
transformed into a photoreceptor. 
Before we address this topic, however, it may be worthwhile to briefly review how 
some of these receptors are involved in neurotransmission and the all-important 
generation of action potentials (APs).[17] These can be studied with electrophysiology, 
a very powerful technique that allows for microsecond to millisecond resolution. The 
generalized shape of an AP and a schematic view of a typical neuron are shown in 
Fig. 2. Ligand-gated cationic ion channels, such as ionotropic glutamate receptors (in 
the human central nervous system) or nicotinic acetylcholine receptors (in the 
periphery) are responsible for the initial depolarization of the postsynaptic 
membrane. Binding of the neurotransmitter to its respective channel leads to pore 
opening, allowing sodium and potassium ions to pass. Given the resting potential of 
the neuron and the tightly controlled relative concentration of sodium and potassium 
on either side of the membrane, this will lead to a net influx of positive charge, which 
changes the membrane potential (see Fig. 2). Once a certain value has been reached 
(typically around   – 40 mV), voltage-gated sodium channels begin to open. As 
sodium rushes in, the membrane is further depolarized and the transmembrane 
potential inverts its sign (up to + 50 mV). The neuron is quickly repolarized, 
however, as the voltage-gated sodium channels inactivate and voltage-sensitive 
potassium channels begin to open after a brief delay. Once those are inactivated, the 
cell regains its resting potentials through the action of transporters and pumps, such 
as Na/K-ATPase. 
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Figure 2. Neurotransmission in a nutshell. a) The action potential: i) the transmembrane 
potential of a neuron at rest; ii) a neurotransmitter binds to a ligand-gated ion channel, e.g. a 
glutamate receptor (iGluR), and evokes an excitatory postsynaptic potential; iii) voltage-gated 
sodium channels (NaV) respond and further depolarize the membrane, but quickly inactivate; 
iv) voltage-gated potassium channels (KV) follow suit and repolarize the membrane, even 
beyond its resting potential (v); vi) the undershoot is removed through the concerted action of 
channels that are open at the resting potential and ATP-driven ion pumps. b) A representative 
neuron from the visual cortex. The dendrites, the soma and the axon are clearly visible. The 
soma resides in layer 2/3 (L2/3) and is much less extended than the axon, which spans 
several layers of the cortex. c) The most important neurotransmitters and neuromodulators. 
 
Ion channels can have both excitatory and inhibitory effects on neurons, depending 
on whether they make the transmembrane potential less or more negative when 
opened. This is not only dependent on the charge of the ions they conduct but also 
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physiological conditions, non-selective cation channels and sodium channels will 
depolarize, whereas potassium channels hyper- or repolarize cells when opened. 
Chloride channels, such as GABAA or glycine receptors are generally inhibitory on 
AP firing.[17a] 
In addition to these primary ion channels, there are receptors that perform a more 
modulatory role and influence the shape, duration and frequency of action 
potentials. These receptors can also be ion channels (such as KCNQ channels)[18] or, 
more often, G-protein coupled receptors (GPCRs).[17a, 19] In comparison to ion 
channels, GPCRs are “slow acting”, since their effect is mediated by heterotrimeric 
G-proteins, enzymes, second messengers, and transcription factors. Notably, the 
same neurotransmitter, e.g. glutamate, acetylcholine or GABA, can act on both 
ionotropic receptors and metabotropic receptors. Even neuromodulators that 
primarily target metabotropic receptors, such as serotonin, have an occasional ion 
channel target.[20] 
3. Lighting up the brain 
Amongst different input signals that can actuate a receptor, light stands out for a 
variety of reasons: light can be modulated in its intensity within femtoseconds, can 
be focused onto very small areas (on the order of its wavelength) and can carry 
enough energy to trigger molecular motions. As such, it is unsurpassed in its 
temporal and spatial precision and in its ability to remote-control molecular devices 
and systems, including neural systems. 
Light has been used for ages to glean information from the environment. Visual 
systems have emerged at almost all levels in evolution and have been greatly 
enhanced by human technology, such as microscopy. This is still a highly active area 
of research as new imaging technologies continue to be developed.  Recent examples 
include superresolution microscopy[21] and two-photon imaging.[22]  As a 
consequence of these technical advances, neurons can now be described in incredible 
detail, action potentials can be visualized with fluorescent calcium sensors, and the 
activity of many neurons in a network can be monitored simultaneously in live, 
behaving animals. [23] 
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Light, however, can also be used to put information into systems - provided suitable 
photoreceptors are present. As in imaging, this can be done with exquisite temporal 
and spatial precision and the optical setups needed are largely the same. If the light 
intensities are not too high and the wavelengths are not too short, it can be done with 
little tissue damage, especially when compared with the invasiveness of multiple 
electrodes. The usefulness of light as an input signal for neuroscience was realized by 
none other than Sir Francis Crick, who stated in 1999: “The ideal signal [to study and 
control a brain] would be light, probably at an infrared wavelength to allow the light 
to penetrate far enough. This seems rather far-fetched but it is conceivable that 
molecular biologists could engineer a particular cell type to be sensitive to light in 
this way.” [1] 
It did not take long for molecular biologists to take up this challenge, which gave rise 
to a new field called “optogenetics” (Fig. 3).[8a, 8b] In essence, optogenetics is an effort 
to control neurons, or other cells of interest, with genetically targeted photoreceptors. 
Due to this genetic component, the sensitivity to a stimulus and not the stimulus 
itself can be precisely located. Therefore, the light beam itself does not need to be 
spatially controlled with very high resolution and light scattering is less of an issue 
than it is in imaging. 
The targeting of innately “blind” neurons with genetically encoded photoreceptors 
has been achieved in several ways. Historically, the first system used was 
“ChARGe”, which essentially consists of the primary components of the Drosophila 
visual cascade (rhodopsin, the associated heterotrimeric G-protein, and arrestin).[24] 
This multicomponent system was shown to trigger APs when heterologously 
expressed in dissociated hippocampal neurons. This was quickly followed by early 
optochemical systems, which will be discussed in much more detail below. In 2004, a 
natural photoreceptor called channelrhodopsin-2 (ChR2) was introduced, which has 
since established itself as the most practical and popular tool.[25] ChR2 is an excitatory 
cation channel isolated from the alga Chlamydomonas reinhardtii.[25a] It can be activated 
with blue light and is rapidly deactivated once the light is gone, which allows for the 
control of AP firing with high precision.[26] Like the rhodopsins, it uses retinal as a 
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photoswitch, but unlike the mammalian visual pigments, the retinal is not excised 
after photoswitching. Therefore, ChR2 can be repeatedly used to trigger action 
potentials. As an added advantage, retinal is endogenously produced in many 
tissues and does not need to be added externally.[25b] 
Shortly after the excitatory photoreceptor channel ChR2, an inhibitory counterpart, 
namely a light-driven chloride pump called Natromonas pharaonis halorhodopsin 
(NpHR) was introduced.[27] NpHR can be stimulated with bright yellow light and is 
capable of silencing neurons, also with millisecond resolution. Importantly, due to 
little spectral overlap, ChR2 and NpHR can be expressed and used in the same 
neuron simultaneously.[8b, 27] Variants of ChR2 and NpHR with modified spectral and 
kinetic features continue to be developed,[28] and other systems, such as light-driven 
proton pumps, have been recently discovered that can control neuronal activity with 
light.[29] 
Since its inception at the beginning of the new millennium, optogenetics has found 
many applications in dissecting neuronal circuitries and has helped to answer 
fundamental questions in neuroscience. As a testament to its enthusiastic reception 
by the scientific community, it was deemed “Method of the Year” in 2010.[8a, 8c] In 
addition to its important role in basic neuroscience, optogenetics has, within a few 
years, also found its first applications in clinical research. For example, ChR2 and 
NpHR have been used to investigate the mechanism of deep brain stimulation, 
which ameliorates the symptoms of Parkinson disease.[30] A second study was aimed 
at Retinitis pigmentosa, which involves the loss of photoreceptor cells. Here, the light 
sensitivity of the retina could be restored by expressing NpHR, which resulted in 
visually guided behavior in previously blind mice.[31] In another application of ChR2 
and NpHR, cardiac pacemaker cells of zebrafish could be optically stimulated or 
inhibited, enabling the control of heart beat patterns.[32]  
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Figure 3. Optogenetics. Schematic drawing of ChR2, a light-gated ion channel. The 
chromophore 13-trans-retinal (shown here conjugated as a Schiff base) undergoes 
isomerization with blue light and thermal relaxation, gating the channel. b) Shining blue light 
on ChR2 triggers inward currents of ChR2. c) Mouse behavior controlled with blue light. Note 
the glass fiber cable that delivers light deep into the brain.[8b] 
4. Optochemical genetics 
Given that the molecular tools used in optogenetics are mostly derived from bacteria 
and protozoa, they work amazingly well in the neurons of worms, flies and furry 
animals. These neurons, however, express numerous receptors on their own that are 
easily accessible on their extracellular side but not inherently photosensitive. The 
challenge then is to persuade endogenous receptors to become sensitive toward light.  
Three general strategies have emerged to do just that using small synthetic molecules 
(Fig. 4). The simplest and oldest approach employs caged-ligands (CL approach).[33] 
Here, a ligand is endowed with a protecting group that renders it ineffective. This 
protecting group is rarely a true molecular cage (in the sense a chemist would use 
this term) but typically a photolabile moiety that masks a functional group crucial to 
the ligand-receptor interaction. Photochemical cleavage of the protecting group then 
sets the active ligand free and triggers the desired biological effect. 
Caged ligands have indeed been applied to great effect in neuroscience. Caged 
glutamate, for instance, has been very useful for unraveling neural systems and two-
photon cages have enabled the stimulation of single synapses due to the spatial 
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precision that can be achieved with two-photon techniques.[34] The photosensitization 
of P2X2 receptors and TRPV1 channels with caged ATP and capsaicin, respectively, 
was the first approach shown to work in living animals (in this case decapitated fruit 
flies, to ensure that the visual system was inactivated).[35] 
There are, however, certain functional disadvantages associated with caged ligands. 
Uncaging is a unidirectional process and it is difficult, if not impossible, to “stuff the 
beast back into the cage”. Unless one is interested in tonic effects, one can only hope 
that the ligand leaves the active zone as quickly as possible or is cleared by either a 
reuptake pump or a deactivating enzyme. The former exists for glutamate itself but 
not for more selective synthetic agonist and antagonists. In addition, uncaging 
produces byproducts, i.e. the remnants of the protecting group, which can be toxic. 
The background release of the neurotransmitter, e.g. through thermal hydrolysis, can 
also be a problem, as can be the fact that some caged compounds have off-target 
effects, for example as antagonists on other receptors. 
Some of these shortcomings can be overcome with a second approach that we call the 
photochromic ligand (PCL) approach. Here, the ligand carries a photoswitchable 
side-chain that can be switched between two configurations. As the photoswitch 
toggles between these states, the efficacy of the ligand changes, triggering the desired 
biological effect in a reversible fashion. The ligand can change its efficacy upon 
photoswitching and could even be an agonist in one form and an antagonist in the 
other. 
PCLs have all the advantages of small-molecule drugs, including their ease of 
application and fast tissue distribution. As with drugs, selectivity between receptor 
subtypes can be a challenge, but this can often be overcome through systematic 
variation of the molecule. In addition, one could be concerned that their 
photoisomers show relatively small differences in efficacy. However, in our 
experience PCLs work remarkably well in complex systems that have nonlinear 
responses, particularly in neural networks. Here, it is often the case that small 
changes in the activity of a modulator have dramatic effects on the output. Since the 
AP is an “all or nothing” response that is triggered only when a certain threshold is 
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reached after a complex cellular integration, compounds that subtly influence this 
integration can have pronounced effects.  
Of course, there are situations where receptor-subtype selectivity and cellular 
targeting is highly desirable. In this case, a third approach, which we call the 
photoswitched tethered ligand approach (PTL approach), can be employed. Here, 
the ligand is covalently attached to its receptor through a tether that contains a 
photoswitch. As the photoswitch toggles between long and short forms, the local 
concentration and/or efficacy of the ligand changes, triggering a biological response 
in a reversible fashion. Importantly, PTLs can be genetically encoded, since the point 
of attachment is an engineered cysteine residue or any other encodable chemical 
motif that allows for specific bioconjugation. Since the PTL is covalently tethered, its 
local concentration at the site of attachment is very high in the active form of the 
photoswitch, which means that the affinity of the ligand is not a major concern. In 
fact, low-affinity ligands are usually preferred to ensure that photoswitching 
removes the ligand from the binding site. 
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Figure 4. Three strategies used in optochemical genetics. a) A ligand binds to a generic 
receptor (not necessarily the clamshell-like receptor domain shown here), triggering a 
biological response. b) A caged ligand (CL) is broken apart with light, thus releasing its active 
form. c) Caged capsaicin, used to stimulate TRPV1 channels. d) A photochromic ligand (PCL) 
reversibly acts on a receptor. e) 4-GluAzo, a PCL that functions as “reversibly caged 
glutamate”. f) A covalently attached photoswitched tethered ligand (PTL) can optically 
regulate a receptor. g) MAG-1, a typical PTL in its unconjugated form. 
The PTL approach is essentially a variant of optogenetics, since it combines a 
genetically encodable receptor with light to precisely control neural activity. As 
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opposed to “classical” optogenetics, a synthetic component, i.e. a reactive chemical, is 
needed, which is not endogenously produced, but needs to be synthesized and 
supplied by a chemist. The PCL and the CL strategies, on the other hand, are more 
akin to “chemical genetics”.[36] Chemical genetics attempts to address every protein 
target with a selective small molecule ligand.  Although such pharmacological 
control has a rapid onset, it still not fast enough for many applications in 
neuroscience, where millisecond precision is required. This limitation can be 
overcome by optically controlling the small molecules that function as ligands. 
Taken together, the CL, PCL and PTL approaches provide the basis for what we call 
“optochemical genetics”. It is an effort to control neural activity (or any network 
activity) with light and light-responsive synthetic molecules, with or without a 
genetically determined component. It shares with chemical genetics a certain desire 
to overcome the limitations of conventional genetic manipulation, but it also 
acknowledges that the targeted expression of proteins can be very powerful.  
The variant used depends on the exact application one has in mind. For therapeutic 
applications, where a certain lack of selectivity can be tolerated or is even 
desirable,[37] the PCL approach may be more suitable. On the other hand, in the 
analysis of functional pathways, e.g. in neural circuitry mapping, the genetically 
targeted transfection of a specific cell is clearly advantageous. In addition, PTLs 
could be extremely useful in the functional dissection of closely related receptor 
subtypes, since selectivity can be achieved through covalent attachment to 
genetically engineered isoforms (Fig. 5). Following conjugation, tonic activation or 
inhibition of the receptor can be prevented through action of the photoswitch. 
Overall, this PTL approach to selective pharmacology bears a certain resemblance to 
the “bump-hole” technique, which has been used so successfully in dissecting the 
human kinome.[38] In both cases, engineered proteins and unnatural ligands are 
needed. The PTL approach, however, not only provides a precise answer to the 
question “who”, but also to “when” and “where”. 
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Figure 5. The PTL approach to selective pharmacology. a) Chemical genetics and 
pharmacology generally aim at individually targeting receptors and receptor isoforms. This 
requires ligands that bind with high affinity and selectivity. b) In optochemical genetics, 
selectivity can be achieved through genetic engineering of a bioconjugation site. In addition, 
the photoactivatable ligand can have low affinity to the receptor subtype. 
 
Caged ligands have been mostly developed by other groups and have been 
extensively reviewed elsewhere,[33] which is why our discussion here will focus on 
synthetic photoswitches, i.e. on PTLs and PCLs. Among different photoswitch 
architectures, azobenzenes have so far proven to be the most versatile and reliable 
ones.[39] This is due to several functional features that distinguish them (Fig. 6). For 
instance, their geometries in their cis and trans states are well defined and the 
conformational space that can be mapped by both isomers has relatively little 
overlap. Substituents in the 4 and 4’ positions are substantially closer in their cis form 
than in their trans form, an effect that can be amplified further by appropriate 
substitution. Although azobenzenes are axially chiral in their cis -form, which is not 
planar, they are typically not optically active due to facile racemization and they do 
not generate stereocenters upon switching between a long and short form. They 
often display high extinction coefficients and quantum yields, meaning that light of 
relatively low intensity can be used for photoisomerization. In addition, azobenzenes 
undergo photoswitching at very fast rates, which prevents intersystem crossing and 
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formation of triplet diradicals. These would react with triplet oxygen to generate 
singlet oxygen, a highly reactive and cytotoxic species, which is also damaging to the 
chromophore itself. Consequently, azobenzenes are relatively photostable and can be 
switched over many cycles. Their spectral tuning through substitution is 
straightforward and follows well-established rules. While most azobenzenes used to 
date are isomerized to their cis form with UV-A or deeply violet light (315-380 nm), 
red-shifted versions that are less harmful upon prolonged tissue application are also 
known (see below). Finally, azobenzenes are relatively easy to synthesize and 
modify, as several synthetic strategies are available, including diazonium coupling, 
Mills reactions, and transition metal catalyzed cross-coupling strategies.[40] One 
potential disadvantage is their comparatively low solubility, but this can be usually 
overcome with appropriate functional group, in particular with charged substituents.  
Notably, azobenzene photoswitches are marked by photostationary states that are a 
function of the wavelength. While they can exist 100% in the thermodynamically 
more stable trans form (also the dark-adapted form) and their photostationary 
cis:trans ratios can exceed 9:1 at short wavelengths (Fig. 6), it is practically impossible 
to push them fully into the cis state through irradiation. Therefore, the background 
activity of the remaining trans isomer is a concern, but for the reasons stated above 
this is often not a problem in neural networks. In fact, the dependence of the 
photostationary ratio on the wavelength also offers an opportunity to tune the 
response by gradually tuning the color. The thermal bistability of photoswitches can 
be further influenced through appropriate substitution. PTLs wherein one end of the 
cis azobenzene interacts with the protein covalently and the other non-covalently 
show slow thermal relaxation, at least on a neurobiological time scale. On the other 
hand, certain red-shifted azobenzene PCLs can revert to their dark-adapted state 
within milliseconds.[41] 
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Fig. 6. The logic of azobenzene photoswitches. a) Azobenzenes change their 
configuration and length upon irradiation with different wavelengths. They revert thermally or 
photochemically to their thermodynamically more stable state, which is usually the trans-state.  
b) The mercaptoethanol conjugate of MAG-1, a model for the tethered PTL. c) The 
photostationary cis:trans ratio of the MAG-1 conjugate, as a function of wavelength.  
 
Once a photoswitch has been chosen, the design of PTLs and PCLs is 
straightforward, provided both structural coordinates for the receptor and extensive 
structure-activity relationship data for the ligands are available. The latter is often the 
case, since neuropharmacology is a well developed field. Today, one cannot 
complain about a lack of the former either, since relevant structures appear in the 
literature almost every week. 
The design of PCLs and PTLs is closely intertwined. It typically starts out with a 
structure of a ligand, gleaned from the crystal structure or from the pharmacology 
literature. From this, it is often immediately clear where and how to attach the 
photoswitch to the ligand and which stereochemistry to choose at the point of 
attachment. In an intermediate stage, we sometimes synthesize a so-called “tether 
model”, which retains one phenyl ring of an azobenzene. This is then extended to a 
full-blown PCL that contains the entire chromophore and, finally, after addition of an 
electrophilic functional group, to the corresponding PTL. In general, extensive 
structure-activity data are sufficient to design a PCL with a reasonable chance of 
success, whereas X-ray structures are normally needed for a PTL. The latter requires 
cysteine sites for covalent attachment, and choosing those can be difficult without 
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structural coordinates. Increasingly, sophisticated computational tools are used for 
that purpose. 
Since most PTLs used to date are cysteine-reactive compounds, unspecific labeling of 
the cell-surface might be a concern. However, one has to bear in mind that reduced, 
accessible cysteines are rare on the surface of cells and the bioconjugation typically 
proceeds via affinity labeling. This means that the non-covalent interaction of the PTL 
with its ligand-binding site precedes covalent bond formation, enhancing the rate 
and selectivity of labeling, which will also depend on the state of the photoswitch. In 
addition, cells seem to be remarkably tolerant toward molecules attached to their 
surface, as long as they do not interfere with vital cell/cell interactions.[42] 
The design of suitable PTLs and PCLs also goes hand in hand with their syntheses. 
These can present considerable challenges since the chemistry of photoswitches 
needs to interface with the chemistry of polar and charged ligands, which requires 
intricate protecting group operations. In the case of PTLs, this is acerbated by the 
presence of an electrophile, which should be introduced into the molecule as late as 
possible. The syntheses have to be practical and efficient enough to support a 
sustained biology program that includes in vivo investigations and, eventually, 
behavioral studies in animals. 
In the following paragraphs, we will show how optochemical genetics can be applied 
to some of the most basic molecular machines involved in synaptic transmission: 
voltage-gated potassium channels and ionotropic glutamate receptors. To this end, 
we will first discuss their innate functions and systemic roles in some detail and then 
show how they can be converted into hybrid photoreceptors through covalent or 
non-covalent attachment of azobenzene photoswitches. Afterward, we will address 
other targets, such as the nicotinic acetylcholine receptor (nAChR) or the P2X4 
receptor, where this has been previously done to a limited extent. Finally, we will 
address a few receptors that have not yet been converted into photoreceptors, but 
which are “sitting ducks” for the optochemical approach. 
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5. Voltage-gated potassium channels 
Together with voltage-gated sodium channels (Nav), voltage-gated potassium 
channels (Kv) modulate cellular excitability and play a key role in the generation of 
action potentials.[17c] Kv channels are transmembrane proteins that assemble as 
tetramers from four single polypeptide chains that are known as α-subunits.[43] In 
humans, 40 genes encode 12 α-subunit families (Kv1 to Kv12).[44] Within each 
subfamily, different genes exist as indicated by an additional number, e.g. Kv1.2. This 
diversity is further increased by heterotetrameric α-subunit assembly, which results 
in a very large number of potential combinations. Kv1 channels additionally interact 
with intracellular tetrameric β-subunits that alter gating behavior.[44] 
To date, several potassium channels have been elucidated in atomic detail with X-ray 
crystallography. The first structure to be reported was KcsA, a simple bacterial 
channel from Streptomyces lividans. Its disclosure in 1998 stands as a milestone in 
biophysics.[10] Subsequently, the structures of a calcium-gated potassium channel 
(MthK),[45] several inward-rectifier potassium channels (e.g. Kir3.1),[46] a sodium and 
potassium-conducting channel (NaK),[47] and several prokaryotic and eukaryotic 
voltage-gated potassium channels have been reported.[14b, 16] The structure of Kv1.2, a 
mammalian voltage-gated ion channel that modulates the electric excitability of 
neurons, in its open form is shown in Fig. 7.[14b] In this representative structure, the 
voltage-sensors, the pore, and both the inner and outer vestibule of the channel are 
clearly visible (the β-subunit is removed here but present in Fig.1). Each single 
subunit contains an intracellular tetramerization domain, a voltage sensor domain 
(with helices S1-S4), and a pore domain (containing helix S5, a short pore helix, a 
pore loop and the C-terminal helix S6).[43]  Both the N- and the C-termini are located 
in the cytosol but the N-terminal domain is not resolved in the structure. 
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Figure 7. Structure and function of voltage-gated potassium channels. a) A highly 
schematic drawing of Kv channels illustrates their functional cycle and channel block. b) A 
single Kv1.2 subunit showing the extracellular S1-S2 linker, the voltage-sensing domain, the 
pore domain embedded in the membrane, and the intracellular T1-domain (pdb 3LUT). The β-
subunit has been removed and the ball-peptide is not resolved in this structure. c) Two of the 
four subunits, indicating the architecture of the selectivity filter and the inner vestibule. d) 
Expanded view of the TEA binding sites in the inner and outer vestibule (pdb 2BOB and 
2BOC). e) Chemical structures of extracellular and intracellular potassium channel blockers. 
 
Like most ion channels, Kv channels have three elementary functions that are 
physically represented by protein domains and their movements: first, an “activation 
gate” that interacts with the input signal (i.e. voltage) and opens the channel, second, 
a “selectivity filter”, which determines which ions can pass through the channel and 
third, an “inactivation gate”, which is responsible for their desensitization. 
Activation is initiated by the voltage sensor once the membrane potential reaches –40 
mV. The S4 helix of the voltage sensor domain in each subunit contains several 
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positively charged residues, usually arginines, that move across the membrane as the 
cell depolarizes. This movement is mechanically coupled with a hinged motion of the 
inner helix bundle (S6) of the pore-domain, which opens a gate through which the 
ions can pass.[7, 43-44]  Driven by the electrochemical gradient, the ions then permeate 
the selectivity filter generating a current that is specific for Kv channels. The 
selectivity filter is essentially a stack of backbone carbonyls that compensate for the 
hydration sphere of the cation as it passes through. This compensation is 
energetically more favorable for potassium ions than sodium ions.[7]  
There are two native mechanisms of inactivation of Kv channels called N-
type- and C-type-inactivation. N-type inactivation is mediated by the 
positively charged intracellular N-terminus, which functions like a “ball” (or 
plug) on a chain. Once the voltage gate is opened, the N-terminus follows the 
outward K+ current. This pushes the “ball” into the inner vestibule of the 
channel and blocks further ion conduction.[48] In comparison, slow or C-type 
inactivation depends on permeant ions and blockers and is believed to occur 
through a conformational change near the extracellular pore region.[48a, 49] In a 
physiological context, fast sodium channel inactivation and Kv channel 
currents repolarize neurons after an AP and determine the duration and 
frequency of APs.[50] 
Kv channels can be blocked by Cs+, small organic cations, and venom peptides. 
Venom peptides, such as agitoxin-2, are produced by some of the most dangerous 
animals known, e.g. the death-stalker scorpion, certain sea anemones, or the green 
mamba.[44, 51] These peptides bind to the outer vestibule of the channel and literally 
plug its pore from the extracellular side, usually with a protonated lysine side chain. 
Typical small organic Kv channel blockers are quaternary ammonium ions, such as 
tetraethylammonium (TEA) and 4-aminopyridine (4-AP) (Fig. 7).[17c, 52]   
Interestingly, Kv channels feature both an internal and external binding site for 
quaternary ammonium ions.[53] External TEA mimics the protonated lysine side chain 
that functions as the plug in agitoxin-2, whereas internally applied TEA acts similar 
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to the positively charged ball peptide involved in N-type inactivation. This blockade 
requires opening of the activation gate. Therefore, charged blockers that act from the 
internal side are called “open channel blockers” or “use-dependent blockers.”[17c] The 
KcsA structure was also solved in the presence of analogues of TEA, which helped to 
exactly locate its intracellular and extracellular binding sites.[53] 
6. Photosensitizing voltage-gated ion channels 
With their structures elucidated and their functions reasonably well understood, 
voltage-gated potassium channels have become prime targets for optochemical 
genetics. The first system to emerge was the “photoisomerizable azobenzene-
regulated K+ channel” (SPARK), which is an example of the PTL approach (Fig. 8).[54] 
Due to its hyperpolarizing effect, it was later renamed H-SPARK. H-SPARK consists 
of the channel blocker MAQ (maleimide-azobenzene-quaternary-ammonium) 
covalently attached to a genetically introduced cysteine on an extracellular loop of a 
Kv1-type channel. The location of this cysteine (E422C) could be determined based on 
existing X-ray structures and previous experiments with “molecular tape 
measures.”[55] Once attached, MAQ essentially functions as TEA on a leash that can 
be lengthened or shortened with light. MAQ was designed to block the channel in its 
elongated trans-state, i.e. at 500 nm or in the dark, whereas the block would be lifted 
in the cis-state of the photoswitch, i.e. at 380 nm. To make H-SPARK an effective 
modulator of membrane potential, slow and fast inactivation of the channel had to be 
deleted using genetic engineering. The activation voltage was shifted from -35 mV to 
-70 mV through another point mutation (L366A), leading to a constantly open 
channel before conjugation of trans-MAQ. As a result, in the dark or under 500 nm 
light, the potassium channel is blocked. Illumination with 380 nm unblocks the pore 
and the resulting outward current leads to re- or hyperpolarization of the membrane. 
To our amazement, SPARK not only worked in excised patches from Xenopus oocytes 
but also in excitable cells, such as dissociated hippocampal neurons.[54] Indeed, when 
SPARK was introduced in 2004, it was the first system that allowed for optical 
silencing of neuronal activity.  
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Figure 8. SPARK, the light-sensitive potassium channel. a) A highly schematic view of H-
SPARK, the hyperpolarizing channel. b) A schematic view of D-SPARK the depolarizing 
variant. c) The chemical structure of MAQ, the PTL used for SPARK. d) Reversible light 
control of potassium currents by H-SPARK. Irradiation in the UV range unblocks channels 
while 500 nm light induces block. By convention, outward currents are plotted upwards. e) 
Light depending induction of AP firing, by H-SPARK expressed in neurons. This is the original 
recording of the first experiment where neuronal activity was controlled reversibly by a PTL. 
 
As a complement to the silencing H-SPARK, we also engineered a depolarizing 
version, termed D-SPARK.[56] A single additional mutation (V443Q) was sufficient to 
convert the potassium selective H-SPARK into a nonselective cation channel. With 
this mutation in the selectivity filter, the permeability ratio of K+/ Na+ ions changes to 
0.7 and Na+ influx into the cell dominates the net effect on the membrane potential. 
After attachment of MAQ, the channel depolarizes the membrane upon UV 
illumination instead of hyperpolarizing it, thus allowing for AP-firing rather than 
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silencing. This is a nice case of “sign inversion,” which is often encountered in 
neuroscience.  
The diversity of K+ channels, the lack of selective pharmacology, and the success of 
H/D-SPARK provided the motivation to extend the PTL strategy to other members of 
the family.[57] Kv1.3, which is involved in membrane repolarization after AP firing of 
neurons and has immunosuppressive effects when blocked, became the next channel 
to be rendered light sensitive by attachment of MAQ. Its very low affinity for TEA 
could be overcome by introducing a point mutation (H401Y). Both Kv3.1 and Kv7.1 
could be converted into photoreceptors in a similar fashion. Based on their fast 
deactivation, Kv3.1 channels play an important role in generating high frequency 
APs, which occurs in neurons of the auditory brainstem and the cerebellum. Finally, 
the PTL concept could be applied to the small conductance Ca2+-activated K+ channel 
2 (SK2), a channel that is naturally sensitive to voltage and an intracellular ligand.[57] 
Taken together, these studies provide a first example for the PTL-driven selective 
pharmacology discussed in Fig. 5. 
As an alternative to PTLs, PCLs offer a way to control native Kv channels and 
neuronal activity with light. For this purpose, the cysteine-reactive maleimide group 
of MAQ was replaced with various moieties. This yielded a series of photochromic 
blockers, termed XAQs, which display different pharmacological and photophysical 
properties.[58] These compounds include the benzoate BzAQ, the propyl derivative 
PrAQ and the acrylamide AAQ (Fig. 9). Detailed investigations showed that the 
XAQs act as use-dependent, photochromic open channel blockers. This also applies 
to AAQ, which does not react with the extracellular surface of native channels, as 
initially hypothesized. To reach the inner vestibule, the amphiphilic XAQs have to 
cross the membrane or they can be added to the cytosol through a patch pipette.  
External application of AAQ and BzAQ to cells or tissues blocks Kv channels in the 
trans-state of the photoswitch, i.e. in the dark or under 500 nm irradiation, while 380 
nm light relieves the block. Interestingly, PrAQ preferentially blocks in its cis-state 
(i.e. at 380 nm), which is another instance of sign-inversion.  
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Structurally as well as functionally, XAQs resemble the well-known analgesic 
lidocaine or its permanently charged derivative QX-314, with the important 
difference that their efficacy is light dependent. Like lidocaine, XAQs can be simply 
added to nervous tissues, which makes them very attractive for therapeutic 
applications. After a brief waiting period, they reliably control action potential firing 
(Fig. 9). When added to cerebellar slices, AAQ controls the activity of Purkinje 
neurons, mostly through its effect on inhibitory interneurons known as basket 
neurons.[58b]  AAQ also has effects on the heartbeat of the medicinal leech Hirudo 
medicinalis.[58b]  In this animal, central pattern generator interneurons (co-called HN 
cells) control the frequency of heart contractions. Earlier studies indicated that K+ 
channels play a crucial role in HN cell burst firing. After applying AAQ, the activity 
of HN neurons could be modulated with light. Interestingly, burst periods decreased 
under 380 nm light illumination, whereas 500 nm light extended the period.    
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Figure 9. PCLs for voltage-gated ion channels. a) A schematic depiction of a XAQ that 
functions as a photochromic open-channel blocker on Kv channels.  b) The chemical 
structures of BzAQ, AAQ and PrAQ, three typical XAQ PCLs for potassium channels. c) 
AAQ reversibly blocks potassium currents of a Kv1 family channel. d) AP firing of 
hippocampal neurons controlled by AAQ. e) Controlling the heart beat of a leech with AAQ. 
 
A major goal of our program is to shift the absorption and action spectra of PTLs and 
PCLs toward the red, which would allow for deeper tissue penetration and would 
diminish phototoxicity. This can be easily done through chemical derivatization of 
the azobenzene chromophore. For instance, introduction of an electron-donating 
substituent yielded XAQs that can be isomerized to their cis-isomers with blue light. 
As an added advantage, these compounds revert to their trans-form in the dark 
within milliseconds, effectively turning themselves off (Fig. 10). Therefore, it is not 
necessary to toggle between two different wavelengths.  An example for this type of 
compound is DENAQ, whose action spectrum peaks at 480 nm. Interestingly, its 
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analog PhENAQ does not act as a blocker in the trans-state but rather in the cis-state 
(another case of sign inversion). It can also be switched to the blocking state with 
blue light and reverts to the inactive state automatically. Therefore, neuronal firing 
could be triggered with irradiation and quickly silenced by turning the light off.[41] 
 
 
Figure 10. Red-shifted photochromic blockers. a) The chemical structures of DENAQ and 
PhENAQ, two red-shifted XAQs. b) Action spectrum of DENAQ. c) Controlling neuronal firing 
with PhENAQ. 
7. Ionotropic glutamate receptors 
Ionotropic glutamate receptors (iGluRs) play a central role in synaptic 
transmission.[17a, 50, 59] Located primarily in postsynaptic membranes, these ligand-
gated ion channels respond to the neurotransmitter glutamate released from vesicles 
on the presynaptic side. Upon glutamate binding, iGluRs generate a depolarizing 
current, which results in an excitatory postsynaptic potential (EPSP). With their 
fundamental involvement in neuronal communication, iGluRs are associated with a 
wide variety of neurological diseases, including Alzheimer’s disease, epilepsy and 
neuronal damage from stroke, and have therefore been very important 
neuropharmacological targets.[60] 
All ionotropic glutamate receptors in higher animals assemble as tetramers and 
allow permeation of monovalent cations with little selectivity (Fig. 11). Some are also 
permeable to calcium. Based on functional differences and their response to synthetic 
ligands, they can be classified into N-methyl-D-aspartate (NMDA) receptors and 
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non-NMDA receptors. The latter can be divided into three subgroups, namely so-
called AMPA, kainate- and δ-receptors.[50, 61] 
AMPA receptors, named after a selective agonist, form homo- and heteromeric 
channels composed of GluA1-GluA4 subunits.[50, 61] AMPA receptors exhibit fast 
activation and deactivation kinetics - events occur within milliseconds - and initiate 
depolarization as a first response to synaptic glutamate release close to a 
postsynaptic site within the dendritic tree. This feature makes them the principle 
molecular component of fast excitatory synaptic transmission.[50, 61] 
By contrast, kainate receptors play a role in the modulation of neuronal excitability 
rather than in fast excitatory transmission.[61-62] Their mode of action, however, is not 
as well understood as in the case of AMPA receptors. Homo- and heteromeric 
channels assemble from so-called GluK1-GluK5 subunits. Delta receptors assemble 
as homomeric receptors of GluD1 or GluD2 subunits. The function of these receptors, 
however, remains largely unknown.[61] 
NMDA receptors assemble as obligate heterotetramers from a pool of seven 
subunits. Activation requires not only simultaneous binding of glutamate and 
glycine (or D-serine), but also an elevated membrane potential of greater than  –30 
mV. This renders NMDA receptors coincidence detectors, since they are sensitive 
both to the release of ligands by the presynaptic neuron (and from glial cells) [50, 61]  
and changes in voltage on the postsynaptic side. In addition, NMDA receptors are 
not only permeable for Na+ and K+, but also for Ca2+ ions. These activate various 
intracellular targets, such as the Ca2+/calmoduline-dependent protein kinase II 
(CamKII). As such, NMDA receptors are involved in the strengthening of synapses, 
which is believed to underlie learning and memory.[63] 
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Figure 11. Ionotropic glutamate receptors. a) A highly schematic illustration of glutamate 
receptor gating.  b) X-ray structure of single GluA2 subunit indicating the TMD including M1-4, 
and the extracellular LBD and TMD. c) The fully functional tetrameric GluA2 channel co-
crystallized with an antagonist (yellow) (pdb 3KG2). d) Expanded view of a GluA2 LBD co-
crystallized with glutamate emphasizing the clamshell (pdb 1FTJ). e) The chemical structures 
of various agonists and antagonists for iGluRs. 
 
A single iGluR subunit contains an extracellular amino-terminal domain (NTD), a 
ligand-binding domain (LBD), a transmembrane domain (TMD), and an intracellular 
carboxyl-terminal domain (CTD). The NTD is involved in subtype-specific assembly 
and modulation of the receptor. The LBD provides a binding site for agonists (and 
antagonists). Two subdomains called D1 and D2 form the LBD in a clamshell-like 
arrangement. The TMD is composed of three transmembrane helices, M1, M3, M4 
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and a pore helix M2. The CTD plays a role in channel localization, stabilization and 
targeting for degradation. [50, 61] 
X-ray crystallographic studies on GluRs began with soluble versions of LBD 
clamshells carved out of the full-length receptors through clever protein 
engineering.[64] These structures were obtained in conjunction with various ligands 
and proved to be remarkably insightful, since they could explain the activity of 
agonists, antagonists and modifiers that affect desensitization. [61]  For instance, they 
showed that the binding mode of glutamate to the LBD clamshell is highly conserved 
in glutamate receptors and that degree of clamshell closure is roughly correlated 
with the activity of a partial or full agonist. [61]  In line with this logic, antagonists, 
such as DNQX, bind to the clamshell but do but allow it to close tight enough to 
trigger the biological effect. [61]  This “foot-in-the-door” mechanism of antagonism 
also explains why relatively small changes in the molecular structure can turn an 
agonist into an antagonist. 
In a recent breakthrough in structural biology, the first crystal structure of a full-
length homomeric GluA2 receptor was determined at 3.6 Å resolution (Fig. 11b).[12] 
This AMPA receptor was co-crystallized with a strong competitive antagonist, 
resulting in a closed, non-conducting state of the receptor. The structure confirmed 
that the subunits arrange as a dimer of dimers with an overall C2-symmetry. The 
TMD architecture resembles an “inverted” K+ channel”, which is linked to a ligand-
sensor (the LBDs) instead of a voltage-sensor.   
The activation cycle of glutamate receptors can be divided into an inactive resting 
state, an active non-desensitized state and an inactive desensitized state. The LBDs of 
the four subunits are arranged in such a way that two clamshells on either side of the 
C2-axis are sitting back to back. Glutamate binding to the LBD of the inactive 
receptor initiates closure of the clamshell cleft. The movement of the lower lobe of 
the clamshell (D2) during this event rearranges the connector between the LBD and 
the TMD, which exerts a mechanical force that opens the channel. However, this 
active non-desensitized state creates tension at the LBD interface. This tension can be 
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lifted by dissociation of the agonist or by rearrangement at the LBD dimer interface 
that leads to a closed, desensitized state.[61]
8. Sensitizing ionotropic glutamate receptors toward light 
Just as the outer vestibule of Kv channels had provided a suitable platform for the 
attachment of MAQ, the structurally well-characterized extracellular clamshell of 
glutamate receptors presented an opportunity to explore tethered ligands. In this 
case, we opted for an agonist, instead of a blocker or antagonist. This approach 
yielded LiGluR, the “light-gated ionotropic glutamate receptor,” which combines a 
genetically engineered kainate receptor (GluK2) with a PTL called MAG-1 (Fig. 
12).[65]  MAG-1 consists of a maleimide for covalent attachment, an azobenzene 
photoswitch and a substituted glutamate as the ligand. Once MAG-1 is attached to a 
cysteine at the LBD of GluK2 (L439C), light-induced cis- and trans-isomerization of 
the azobenzene moiety results in reversible binding of the tethered agonist and 
translates into opening and closing of the channel.  
The design of LiGluR was based on the crystal structure of a closed GluK2-LBD 
containing the agonist (2S,4R)-4-methyl glutamate (pdb 1SD3).[62] This structure 
suggested the existence of a small “exit tunnel” from the bound ligand to the surface 
of the closed clamshell. It was therefore hypothesized that a tethered glutamate with 
this stereochemistry could bind to the LBD and still activate the receptor as an 
agonist or at least a partial agonist. To support this hypothesis, a so-called tether 
model (T-Mod) was synthesized. Using calcium imaging in HEK293 cells, we 
showed that the tether model, and later MAG-1, indeed act as agonists.[65] Other 
crystal structures, such as the one of the partial agonist domoic acid bound to GluK2 
(pdb 1YAE) also facilitated the design of suitable PTLs.[66] 
Once the tether model was found to work, the molecule was extended to MAG-1 by 
installing the azobenzene photoswitch and adding a maleimide as an electrophile for 
cysteine conjugation. In order to find a suitable attachment site for this maleimide, 
several cysteine mutants of GluK2 were generated by site-directed mutagenesis. 
After screening about a dozen mutants, L439C turned out to be the best position for 
MAG-1 attachment and light-dependent channel activation. [65] 
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Since it was not clear whether and how the attachment of the PTL to the protein 
would affect its azobenzene photophysics, the optimal wavelength for activation and 
inactivation was determined experimentally (Fig. 12).  It was found that 380 nm light 
gave the maximum current, whereas 500 nm led to the fastest channel closure. 
Interestingly, this observation corresponds very well to the photostationary states of 
MAG-1 in solution (Fig. 11).  In addition, the thermal relaxation of cis-MAG-1 bound 
to the channel was found to be much slower than in solution, probably due to the 
non-covalent interaction of the glutamate ligand with the clamshell, which stabilizes 
the cis-configuration. 
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Figure 12. The light-gated glutamate receptor, LiGluR. a) A highly schematic illustration of 
LiGluR. b) The chemical structure of 4-methyl glutamate and the “tether model” (T-Mod), two 
important milestones on the way to LiGuR. c) The chemical structure of MAG-0, MAG-1 and 
MAG-2, three PTLs used.  e) The action spectrum of LiGluR. By convention, inward currents 
are plotted downwards. The phototunability of the system is apparent. f) LiGluR controls AP 
firing with millisecond precision. A very brief UV–flash induces a train of APs, demonstrating 
the cis stability of the system. f) LiGluR enables AP firing with up to 50 Hz. g) Controlling the 
escape reflex in zebrafish. 
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When expressed in neurons, which contain the full machinery to generate APs, 
LiGluR allows for the optical control of neuronal firing with millisecond 
resolution.[67] At a given intensity, brief light pulses (1-5 ms) alternating between 380 
nm and 500 nm are sufficient to generate reproducible patterns of APs. In dissociated 
hippocampal neurons, APs can be induced with a frequency up to 50 Hz without 
missing a beat (Fig. 12).[67] Based on the cis-stability of MAG, it is possible to induce 
constant AP firing for seconds following a single 380 nm light flash that lasts only a 
few milliseconds. Thus, long illumination periods leading to toxic side effects can be 
avoided.[67-68] 
Compared with SPARK, LiGluR shows some fundamental functional differences. 
Both irradiation and depolarization are needed to open the SPARK channel 
(corresponding to a logic AND gate). By contrast, in LiGluR, either soluble glutamate 
or light is sufficient to allow ions to flow along their electrochemical gradient 
(corresponding to a logic OR gate). LiGluR is a light-powered molecular machine, 
since the energy of the photoisomerization translates into the free energy released 
upon ligand binding, triggering clamshell-closure and channel opening. It can be 
reset through slow thermal isomerization or active photoswitching with a longer 
wavelength. SPARK, on the other hand, is a more passive system, since the tethered 
blocker functions as an extracellular gatekeeper but does not trigger large molecular 
motions per se. These need to be generated by membrane depolarization, which 
moves the voltage sensor and opens the voltage gate. 
One of the hallmarks of our systems in general and LiGluR in particular is their 
remarkable flexibility and tunability. This is evident at the level of the photoswitches 
and also at the level of the protein. In addition to MAG-1, further derivatives called 
MAG-0 and MAG-2 with different length and flexibility were synthesized and 
additional attachment sites were generated by site-directed mutagenesis. This “mix 
and match” approach led to some interesting results. For instance, MAG-0 anchored 
at L439C provided the biggest change in effective concentration in competition with 
the antagonist DNQX. By comparison, MAG-1, our original PTL, and MAG-2 are 
less effective.[69] 
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In another case of “sign inversion,” we found that the point of attachment can 
determine whether a PTL activates the channel in the cis- or in the trans form of the 
photoswitch (Fig. 13).[69] MAG-0 bound to L439C, our original attachment site, acts as 
a cis-agonist but becomes a trans-agonist when attached to L486C. This is somewhat 
surprising given that these two sites are only a few Ångstroms apart in the X-ray 
structures of GluK2. As a consequence of this inverted wavelength sensitivity, 
transfection of neurons with L486C, followed by MAG-0 attachment, triggers AP 
firing at 500 nm and not at 380 nm, as previously observed.  
 
 
Figure 13. Sign-inversion through variation of LiGluR. a) MAG-0 attached to 439C 
activates with 380 nm, whereas MAG-0 attached to 486C induces neuronal firing at 500 nm. 
b) Schematic drawing of HyLighter, a hyperpolarizing light-gated glutamate receptor. c) 
HyLighter can be used to silence neurons. Evoked AP firing can be stopped and re-induced 
by 380 nm and 500 nm light pulses, respectively, demonstrating the bistability of the system. 
 
Just as H-SPARK could be converted into D-SPARK, LiGluR, a light-gated 
depolarizing ion channel, could be converted into a hyperpolarizing ion channel, 
which we call HyLighter.[70] As before, this could be achieved by changing the ion-
selectivity of the transmembrane domain through genetic manipulation. However, in 
the case of HyLighter, not a single point mutation, but the exchange of a whole 
protein domain was necessary. HyLighter combines the GluK2-derived 
photosensitive LBD of LiGluR with the potassium-selective TMD of a prokaryotic 
glutamate receptor, SGluR0, which contains the signature GYG motif of K+ 
channels.[71] Expression of HyLighter in hippocampal neurons showed that inhibition 
of neuronal firing can be reversibly turned on and off by irradiation with 380 nm and 
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500 nm light, respectively. The main advantage of HyLighter in comparison to fully 
genetically encoded hyperpolarizing systems is the thermal stability of cis-MAG-1 
bound to the LBD. Therefore, in analogy to LiGluR, a single 380 nm light flash of a 
few milliseconds is sufficient to prevent neurons from firing for second to minutes.  
One of the big surprises in the development of optochemical systems was how 
quickly they could be transferred to animals and could be used to dissect behavior. 
[70] The first in vivo experiments with LiGluR were performed in zebrafish larvae. 
Zebrafish at this stage of development are fully transparent, which is a necessary 
requirement for reaching neuronal circuits with light. To implement LiGluR, iGluK2-
L439C was genetically encoded in small subsets of neurons, which are involved in 
touch sensation and located at the head and trunk of the animals. For the delivery of 
the photoswitch to the tissue of interest, it was enough to bath the larvae a solution 
containing MAG-1. Following this treatment, an escape reflex initiated by touching 
the trunk with a pipette tip could be controlled by optical activation of LiGluR. This 
reflex could be suppressed by brief illumination with 365 nm light and restored with 
488 nm light. HyLighter could be applied to zebrafish larvae in a similar way.[67] In 
more sophisticated subsequent studies, LiGluR was genetically targeted to a single 
type of cell and used to elucidate the functional role of so-called Kolmer–Agduhr 
neurons - a mystery unsolved for 75 years. They turned out to be the central pattern 
generators of locomotion in the early development of vertebrates.[72]     
In addition to PTLs, PCLs turned out to be applicable to glutamate receptors as well 
(Fig. 14). Their design was based on the extensive pharmacology of iGluR agonists, 
antagonists and blockers, but was also supported by the LBD X-ray structures. 
Replacement of the naphthyl moiety of LY339434, a know agonist of GluK1 and 
GluK2, with an azobenzene gave a molecule that we call 4-GluAzo. This compound 
turned out to be a highly effective photochromic agonist of certain kainate 
receptors.[73] Application to GluK1 and GluK2 channels expressed in HEK293 cells 
demonstrated the reversible control of inward currents in a light dependent manner. 
In this case, the trans-state of the azobenzene preferentially activates the receptors 
and 4-GluAzo showed a slightly higher selectivity for GluK1 than for GluK2. When 
42 
 
applied to dissociated rat hippocampal neurons, 4-GluAzo functioned as “reversibly 
caged” glutamate.[73] AP-firing could be triggered by changing from 380 to 500 nm 
light and stopped by switching back to the lower wavelength. In subsequent work, 
the burst-firing of cerebellar Purkinje neurons could be effectively controlled with 4-
GluAzo.[74] 
Detailed biophysical studies will be needed to understand how 4-GluAzo and other 
PCLs work. In particular, it would be interesting to know whether the 
photoisomerization can take place while they are attached to their binding sites or 
whether have to dissociate before switching can occur. X-ray crystallographic studies 
could also provide important insights into the binding modes of PCLs  (and PTLs) 
and guide their further development. 
  
 
 
Figure 14. The PCL logic applied to ionotropic glutamate receptors. a) Schematic view of 
a PCL operating on LiGluR. b) The structures of LY-339434 and its derivative 4-GluAzo, a 
PCL that targets kainate receptors. c) Controlling AP firing of hippocampal neurons with 4-
GluAzo.  
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9. Pentameric ligand-gated ion channels 
Pentameric ligand gated ion channels (pLGICs) also play important roles in synaptic 
transmission.[50] As opposed to mammalian glutamate receptors, they can have both 
excitatory and inhibitory effects on the postsynaptic cell, which can be a neuron or a 
muscle cell. The superfamily of pLGICs includes nicotinic acetylcholine receptors 
(nAChR), γ-aminobutyric acid receptors (GABAA and GABAC), 5-hydroxytryptamine 
receptors (5-HT3) and glycine receptors (GlyRs).[75] Due to the fact that all pLGICs 
subunits feature an extracellular disulfide bond in a conserved region, they are 
sometimes also called Cys–loop receptors. GABAA and GABAC are chloride-selective 
ion channels that mediate fast inhibition of neuronal activity in the brain and the 
retina.[76] 5-HT3, a serotonin receptor, is an excitatory cation channel that modulates 
neurotransmitter release. Like GABAA receptors, GlyRs have an inhibitory effect on 
neuronal communication. They are ligand-gated chloride channels that are mostly 
expressed in the spinal cord and the brain stem (Fig. 15).[77] 
Nicotinic acetylcholine receptors are excitatory cation channels that are expressed 
throughout the mammalian nervous system and at the neuromuscular junction. [78] 
Five classes of subunits exist for the muscle-type receptor, called α1, β1, γ, ε and δ.[50, 
78b] Together, they form a cation-selective pentameric ion channel with (α1)2β1γδ 
stoichiometry. In contrast, the neuronal types are composed of α2-α10 and β2-β4 
subunits and can form both heteromeric (e.g. (α4)2(β2)3) and homomeric (e. (α7)5) 
pentamers. Notably, only α7, α8 and α9 form homomers when expressed 
heterologously.[78b, 79]  
Each subunit of the nAChR is divided into an extracellular, N-terminal ligand-
binding domain, a transmembrane region with four transmembrane spanning helices 
and an intracellular region (Fig. 15). Both the N- and C-terminus are located in the 
extracellular space. The transmembrane helices of five single subunits line up to form 
the pore of the ion channel. The (α1)2β1γδ receptor at the neuromuscular end-plate has 
two ligand bindings sites located between α-γ and α-δ subunits, which have distinct 
affinities for the neurotransmitter acetylcholine (Ach). Both binding sites must be 
occupied to open the channel pore.[50, 78b] 
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Figure 15. Pentameric ligand-gated ion channels (pLGICs). a) A highly schematic view of 
nAChR-gating. b) Crystal structure of the acetylcholine-binding protein (AChBP) co-
crystallized with nicotine (pdb 1UW6). c) A single subunit of a pLGIC, showing the 
transmembrane domain, the extracellular ligand-binding domain and the Cys-loop (pdb 
3P4W). d) Endogenous ligands that gate pLGICs. e) Other well-known ligands of pentameric 
ligand-gated ion channel that have been co-crystallized with the AChBP.  
 
The structural biology of the nAChR has a long history, since it was accessible from 
the electric organ of the ray Torpedo californica well before the advent of molecular 
cloning and heterologous expression.[17c, 50]  Using electron microscopy, a structural 
model of the Torpedo nAChR could be gradually built and ultimately refined to 4 Å 
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resolution.[15a, 80]   More recently, X-ray structures of two bacterial homologues, GLIC 
and ELIC, were solved in their closed and open states, respectively, which provided 
a detailed view of the pentameric assembly and shed some light on channel 
gating.[15b, 15c]  Unfortunately, none of the abovementioned receptors were crystallized 
and elucidated in conjunction with agonists or antagonists. 
The X-ray structure of two acetylcholine binding proteins, isolated from the sea 
snails Limnia stagnalis (L-AChBP) and Aplysia californica (A-AChBP) provided more 
insight into the interaction of pLGICs with their ligands.[81] These soluble proteins are 
homologous to the extracellular ligand-binding domain of pLGICs, but lack their 
transmembrane domain. Sequence alignment of L-AChBP with various pLGICs gave 
a 20-24% match with nAChR subunits and a 15-18% match to the 5-HT3, GABAA, 
GABAC and glycine receptor subunits.[81b] The X-ray structures of L-AChBP co-
crystallized with the agonists nicotine and carbachol showed that the cationic ligands 
binds at the interface between two subunits in an “aromatic box” made up mostly of 
tyrosine and tryptophan side chains. This confirmed the importance of cation-pi 
interactions that had been previously proposed based on intricate biophysical studies 
with labeled amino acids.[81c]  One side of the binding site is covered by the so-called 
C-loop, which closes like a flap upon agonist binding. This flexible C-loop also 
carries a cystine disulfide at its tip but is not to be confused with the Cys-loop, which 
is located closer to the membrane.  
Subsequently, other ligands for pLGICs, such epibatidine (an agonist for nAChR),[81d] 
lobeline (a mixed agonist/antagonist for nAChR),[81d] methyl-lycaconitine (an 
antagonist for nAChR),[81d]  as well as strychnine (an antagonist for GlyR), [82]   were 
co-crystallized with the A-AChBP. These structures showed that the C-loop indeed 
acts as an induced-fit sensor for ligands, and that the degree of C-loop closure 
correlates with agonist vs. antagonist activity. How this movement is mechanically 
linked with the opening of the channel is still matter of debate. 
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10. Photosensitizing pentameric ligand-gated ion channels 
The nicotinic acetylcholine receptor has been studied for many decades, since it was 
the first ligand-gated ion channels to be isolated and characterized as a protein.[17c] It 
occurs in high concentrations in the electric organs of certain fish, such as the ray 
Torpedo electroplax or the eel Electrophorus electricus, which is why it could be 
investigated with biophysical methods that were not applicable to other types of 
receptors at the time. This may be the reason why the nAChR was also the first 
receptor to be photosensitized, both with a PCL and a PTL.[83]   Amazingly, this was 
done in the early 1970s, well before the advent of molecular cloning, heterologous 
expression, modern structural biology, and patch-clamp electrophysiology. It took 
more than three decades to repeat this achievement with other types of receptors! 
The PCL used in this case was an azobenzene called Bis-Q, which bears a quaternary 
ammonium ion (Q) on either side of the chromophore. This simple, symmetric 
molecule functions as a photoswitchable version of the natural agonist 
acetylcholine.[83] Trans-Bis-Q activated nAChRs in Electrophorus electricus, whereas 
the corresponding cis-isomer was found to be less active. The activity of the two 
isomers was assayed by measuring the transmembrane potential of Electrophorus 
electroplaques, which are specialized cells from its electric organ. The system was 
later used to determine the opening and closing rates of nAChRs.[84]    
The corresponding PTL system was based on careful reasoning and a bit of luck, 
because the native receptor could be used without genetic manipulation. It turns out 
that nAChRs possess a disulfide bond on the tip of their C-loops in the -subunits, in 
close proximity to the ligand-binding site (Fig. 16). This disulfide could be reduced 
without greatly affecting the function of the receptor, providing a reactive thiol for 
covalent of attachment of a PTL.[83]  The PTL was a benzylic bromide, called QBr, 
which also carried the requisite quaternary ammonium ion for receptor activation. 
Conveniently, QBr could be obtained through a slight modification of the synthetic 
protocol used to make Bis-Q. Once attached to nAChRs, QBr could be used to 
reversibly stimulate Electrophorus electroplaques, frog-muscles and rat myoballs with 
light.[85] 
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Of course, in the 1970s and 80s the light-activated nAChR could not be 
heterologously expressed and genetically targeted, and it was therefore never used 
to control AP-firing. Similarly, Bis-Q was mostly seen as a tool to study the innate 
function of nAChRs and not as a practical way to optically control nervous systems 
or animal behavior. However, with detailed structures and the modern tools of 
molecular biology now available, it is highly likely that light-gated nAChRs will soon 
resurface and be used in optochemical genetics. In addition, PCLs and PTLs for other 
pLGICs are bound to be developed. 
 
 
Figure 16. Photosensitizing the nicotinic acetylcholine receptor. A highly schematic 
depiction of a) a PTL reversibly acting on a nAChR, and b) a PCL controlling a nAChRs.  c) 
The structure of BisQ, a PCL, and d) QBr, a PTL. 
11. An abundance of targets 
From the preceding paragraphs it is clear that a wide variety of receptors from 
different structural classes can be rendered photosensitive using synthetic PTLs and 
PCLs. Still, the vast majority of potential candidates with sufficient structural and 
pharmacological data have not yet been investigated and opportunities abound to 
explore the optochemical genetics of these targets. For instance, given the many 
structural and functional similarities between voltage gated potassium (Kv), sodium 
(Nav) and calcium channels (Cav), the photochromic open-channel blockers discussed 
above could be applied to the latter as well. In addition, Nav and Cav channels have 
extensive pharmacology of their own, which could be exploited to design more 
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selective PCLs. The long-awaited X-ray structure of a Nav channel has just been 
reported and could greatly facilitate the design of corresponding PTLs.[86]  
Even if one were confined to clamshell-bearing receptors, there would be a large 
number of interesting targets to work on. Clamshell-like ligand binding domains 
have appeared early in evolution and are a prime example for how a successful 
structural motif has been used again and again in different functional contexts.[87] 
Originally evolved as bacterial periplasmic binding proteins (such as the well-known 
maltose binding protein or amino-acid binding proteins), clamshells have been 
subsequently integrated as functional and structural domains into prokaryotic and 
eukaryotic transmembrane proteins. Apparently, they were first captured by 
bacterial ABC-transporters that initially interacted with soluble periplasmic binding 
proteins in a non-covalent fashion. At some point, they made their way into ion 
channels, such as ionotropic glutamate receptors. These include several prokaryotic 
glutamate-gated channels,[71] a plant receptor,[88] and one that was recently found in a 
comparatively simple eukaryotic rotifer.[89] As discussed above, glutamate-gated ion 
channels have then assumed a major role in the fast synaptic transmission of higher 
animals. However, glutamate-binding clamshells can also be found in metabotropic 
glutamate receptors (mGluRs), which are Family C GPCRs.[90] This large and 
important class also includes GABAB receptors [91] and T1R taste receptors[92] and are 
found in many places in neurophysiology. The clamshell of several of these mGluRs 
has been characterized by X-ray crystallography in atomic detail and their 
pharmacology is very well developed (Fig. 17).[93] Therefore, they are logical next 
targets for manipulation with PTLs or PCLs. Finally, clamshell-like ligand binding 
domains have been found in certain receptor-linked enzymes, which represent the 
third major class of receptors involved in signal transduction, aside from ion 
channels and GPCRs.  An example is the ANP receptor, the clamshell-dimer of which 
has been crystallized bound to the atrial natriuretic peptide (Fig. 17).[94] Clamshell-
containing receptor tyrosine kinases have also been recently described.[95] 
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Figure 17. Clamshell-like LBDs as potential targets for optochemical genetics. a) The 
clamshell of the maltose-binding protein, a typical periplasmic binding protein (pdb 1ANF). b) 
The extracellular clamshell of mGluR3 with an agonist (pdb 2E4X). c) The extracellular 
clamshell of mGluR1 with an antagonist (pdb 3KS9). The clamshell-dimer of the ANP 
receptor, a receptor-linked enzyme (pdb 1YK0). d) The chemical structures of ligands for 
clamshell-containing receptors. 
The X-ray structure of a full-length family B GPCR that includes the transmembrane 
domain has not yet been reported. In contrast, several GPCRs belonging to family A 
have been recently elucidated with X-ray crystallography (Fig. 18). These receptors 
comprise the largest class of GPCRs and have a ligand-binding site that is embedded 
more or less deeply within the membrane. They include such important 
pharmacological targets as adrenergic receptors (e.g. 2A),[96] adenosine receptors 
(e.g. A2A, which is a target of the antagonist caffeine),[11c] and dopamine receptors (e.g. 
D3).[11d] Rhodopsin, the photoreceptor used in animal vision, also belongs to this 
category.[11b] In this case, however, the photoswitch retinal is covalently bound in an 
inactive form (11-cis) and undergoes photoisomerization to the active form (all-trans), 
followed by hydrolysis and recycling, instead of reversible binding. As such, it 
resembles a PTL to a certain extent. Given this analogy, it is entirely conceivable that 
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well-characterized ligands for other class A GPCRs could be replaced with PTLs and 
PCLs, turning them into photoreceptors. 
 
 
Figure 18. Family A GPCRs as potential targets of optochemical genetics. a) Rhodopsin, 
a natural photoreceptor with a covalently attached photoswitch (pdb 1U19). b) The 2 
adrenergic receptor bound to the inverse agonist carazolol (pdb 2RH1). b) The A2A 
adenosine receptor bound to the agonist UK-432097 (pdb 3QAK). c) The D3 dopamine 
receptor bound to the antagonist eticlopride (pdb 3PBL). Protein domains used to facilitate 
the crystallization have been cut off. d) Chemical structures of the co-crystallized and 
endogenous ligands for the receptors depicted above. e) Isomerization of 11-cis retinal to 
all-trans retinal in rhodopsin. 
 
Trimeric ion channels are also interesting targets, since they have recently been 
structurally characterized in atomic detail and have good pharmacology (Fig. 19). 
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They include purinergic receptors (P2X receptors), acid–sensing ion channels (ASICs) 
and epithelial sodium channels (ENaCs). The ionotropic P2X receptors are non-
selective cation channels that are activated by extracellular adenosine 5’-triphosphate 
(ATP). They are widely expressed in the nervous and immune system and are 
involved in numerous neurological functions, such as pain sensation.[97] 
The first X-ray crystal structure of a P2X receptor, the zebrafish P2X4 receptor, was 
solved in its closed state at 3.1 Å resolution.[13] The structure confirmed the trimeric 
channel architecture and provided important insights into the ion-conducting pore. 
The position of the ATP binding site was proposed to be located between each 
subunit at the outer extracellular surface of the receptor. However, the P2X4 structure 
was solved without ATP or an antagonist bound (e.g. the aza-azobenzene PPADS), 
leaving the exact binding mode of ligands undefined.  
One particular P2X-receptor, P2X2, holds a special place in the development of 
optochemical genetics. After heterologous expression, this cationic channel could be 
optically stimulated with caged ATP. Published in 2003, this was one of the first 
systems shown to work in neurons. Since ATP is hydrolyzed rapidly, even in the 
extracellular space, photostimulation could be carried out repeatedly and with 
relatively good temporal resolution. Incidentally, caged ATP is also one of the first, if 
not the first caged ligand.[35]  
ASIC channels belong to the epithelial sodium channel/degenerin (ENaC/DEG) 
family. They are ligand-gated trimeric cation channels that are activated by 
extracellular protons and favor Na+ over K+ by a factor of ten. Isoforms of ASICs are 
distributed throughout the mammalian central and peripheral nervous system. They 
play important physiological roles, e.g. in the detection of tissue acidosis during 
ischemia.[98] Two crystal structures of homotrimeric ASIC channels have been 
recently reported.[99] Unfortunately, this is not yet the case for ENaC, a heterotrimeric 
channel that is constitutively open and is extremely selective for sodium. It plays a 
key role in sodium reabsorption and salt taste perception and is the target of widely 
used diuretics, such as amiloride.[100]   
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Figure 19. Trimeric ion channels as potential targets for optochemical genetics.  a) The 
ASIC1 channel (pdb 3HGC). b) The P2X4 receptor (pdb 3H9V). c) Chemicals acting on 
trimeric ion channels. Amiloride: a blocker for ASIC and ENaC channels. PPADS: an 
antagonist of purinergic receptors. Caged ATP: a CL for P2X2 receptors. 
 
Transient-receptor potential channels (TRP channels) have been identified as major 
molecular players in sensory perception.[101] They are tetrameric cation channels that 
are polymodal and sensitive to a wide variety of input signals, including 
temperature, small molecules and ligands. One famous member of this large 
superfamily is TRPV1, which is activated upon heating but also responds to 
capsaicin, the active component of chili peppers,[102] Therefore, on a molecular level, 
“hot” as in “hotplate” and “Red Hot Chili Peppers” are really the same thing. In one 
of the first applications of optochemical genetics, TRPV1 was heterologously 
expressed in neurons and stimulated with caged capsaicin and light (see Fig. 4b/c).[35]    
TRP channels are not only responsible for sensing heat and coldness but may play a 
role in sensing pressure as well.[101] As such, they could have physiological roles in 
mechanoreception (touch), balance, pain, the regulation of blood flow, and 
hearing.[103] The regulation of pressure-sensors with light would indeed be a very 
interesting exercise. This has not yet been done with a TRP channel, but proof of 
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principle has been given with a comparatively simple bacterial mechanoreceptor 
isolated from Myxobacterium tuberculosis (Fig. 20).[104] This homopentameric channel, 
called MscL, was crystallized in its closed form and its structure was elucidated by X-
ray crystallography.[105] If the tension of the membrane in which it is embedded 
exceeds a certain value, it opens to form a very large pore, thus functioning like a 
valve that relieves osmotic pressure in the bacterium. The closed gate of the channel 
is formed by a ring of five hydrophobic residues that prevent ions and other solutes 
from passing through.  Detailed biophysical investigations had shown that 
replacement of these hydrophobic residues with charged amino acids leads to a 
constitutively open channel, presumably due to electrostatic repulsion.[106] In a first 
approach toward photosensitization of MscL, a caged carboxylic acid was covalently 
attached to a cysteine replacing the hydrophobic residues at the gate. Upon 
irradiation with UV light, the cages were cleaved and the resulting negative charges 
triggered the opening of the channel. In a second stage of development, the caged 
acids were replaced with a covalently attached spiropyran/merocyanine (SPMC) 
photoswitch. Switching from the comparatively non-polar SP state to the highly 
polar MC state resulted in opening of the valve. This process was reversible over a 
few cycles.[104] Although this system was developed as a “nanovalve” for drug 
delivery and may never find its way into neurobiology, it is nevertheless a very nice 
example for the optical control of channel activity and it involves both cages and 
photoswitches. Interestingly, photoswitchable lipids have also been used to change 
the membrane tension with light and reversibly activate MsCl.[107]100] Indeed, 
photoswitchable lipids may provide yet another general way to influence the 
function of transmembrane proteins and cells with light.  
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Figure 20. Photosensitization of a bacterial mechanosensitive ion channel. a) The 
structure of MsCl in its closed form in side and top view (pdb 2OAR). b) A caged acid used to 
trigger MscL opening. c) The SP and MC form of a photoswitch, used to reversibly gate MscL.
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12. Summary and Outlook 
From the preceding sections it is clear that there is certainly no shortage of protein 
targets that could be addressed with optochemical genetics. These include naturally 
occurring photoreceptors, such as the channelrhodopsins, which could be fitted with 
synthetic switches to tune their spectral properties. However, many variants of 
synthetic molecules attached to naturally blind receptors are also conceivable. For 
instance, all of the PTLs and PCLs presented herein are either agonists or blockers, but 
it should be possible to turn them into antagonists or find photochromic molecules that 
function as channel openers. In addition, photoswitchable cross-linkers could be 
developed that could be hooked up to two cysteines.[108] These have been used with 
great success to control the helical content of peptides[108b, 109] and they have already 
found applications in governing the activity of proteins.[[110]] It is entirely possible that 
this approach could be extended to transmembrane receptors, providing yet another 
way to control neural activity with light. 
Other types of photoswitches, such as hemthioindigos or SPMCs, could be 
systematically explored an applied toward neurobiological relevant receptors. But even 
if one sticks with azobenzenes, much could be done, since azobenzenes can be easily 
tuned toward specific photophysical and thermal requirements. For instance, the red-
shifted variants that operate far in the visible range of the spectrum and turn 
themselves off in the dark need to be further developed. Perhaps, one could even push 
the spectral sensitivity of azobenzenes into the near infrared, in keeping with Sir 
Francis’ grand challenge. Even if it is not possible to develop single-photon switches 
that respond to these wavelengths,  one could explore two-photon photoswitches that 
would also allow for the precise activation of PCLs in very small volumes. These could 
be used, for instance, to photochemically stimulate a single synaptic spine, which can 
be simultaneously monitored with two-photon fluorescence imaging. 
Light, however, is not the only “unnatural” input signal that could be considered. For 
instance, one could reprogram a ligand-gated ion channel to respond to an orthogonal 
ligand, i.e. a molecule that does not interact with native receptors. This has already 
been done with much success with kinases and GPCRs and it should be possible to 
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extend this approach to other types of receptors.[111] One could even speculate about 
sensitizing ion channels to signals that can deeply penetrate tissues, such as 
radiofrequency electromagnetic fields or static magnetic fields. 
Yet as tempting as these speculations are, light is, and will remain, the most interesting 
input signal for neuroscience. The technology needed to quickly modulate its 
wavelength and intensity is highly developed and new ways to deliver light with 
spatiotemporal control and deep within tissues continue to emerge. These includes 
digital micromirror arrays[112] and fiber-optic microendoscopy.[113] At the same time, 
genetic targeting through viral transfection is becoming increasingly precise and 
effective, and the application of synthetic photoswitches will certainly benefit from 
new drug delivery techniques. Thus, we expect that many neurobiological questions 
will be tackled with optochemical genetics in the future. 
Much could be learned, for instance, about the innate function of receptors and their 
many Isoforms since the optical control of genetically defined receptor subtypes could 
clarify their individual contributions to various physiological processes (cf. Fig. 5). So 
far, this has been carried out with a variety of Kv channels (cf. section 6) but we 
anticipate that the optochemical genetic approach can be more broadly applied. Simple 
pharmacological approaches frequently fail due to a lack of selectivity, and genetic 
knock-out strategies are often inconclusive because of compensatory effects. Therefore, 
a knock-in animal, wherein the receptor of interest is substituted with a simple cysteine 
mutation for PTL attachment and can be conditionally activated and deactivated with 
light could be very useful. 
In addition to basic neuroscience research, where the goal is to understand existing 
systems through systematic perturbation, one could apply optochemical genetics to 
what one could call “synthetic neurobiology”. Here, the emphasis lies on rewiring 
nervous systems and altering their components to create new forms of neural 
processing or sensory perception. For instance, the receptors that underlie our sense for 
temperature or mediate pain sensation could be reprogrammed to become 
photoreceptors. The mechanoreceptors responsible for our sense of hearing and 
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balance could be engineered in a similar fashion. Perhaps, the day is not far where taste 
receptors and odorant receptors can be stimulated with light! 
This may sound a bit outlandish but such a philosophy may actually lead to useful 
human therapies. A premier therapeutic target would be the retina, which can be easily 
reached with light, viruses and small molecules. In many forms of blindness, such as 
retinitis pigmentosa, the natural photoreceptor cells of the retina, i.e. the rods and 
cones, have been destroyed but its remaining layers are largely intact. Their neurons 
express numerous receptors that could be persuaded to become light sensitive using 
PTLs or PCLs. Indeed, first attempts to use optochemical genetics in vision restoration 
are very promising (Fig. 21). In a recent study, LiGluR was expressed in the retinal 
ganglion cells of blind mice after transfection with adeno-associated virus (AAV). 
Following injection of MAG-0 into the vitreous body, the retinal ganglion cells, which 
communicate directly with the brain trough the optical nerve, responded to light-
stimulation. This information was relayed to the visual cortex and, as a consequence, 
the pupillary reflex as well as natural light-avoidance behavior of the animals was 
restored.[114] First experiences with PCLs have also been promising and bode well for 
applications of synthetic photoswitches in human therapy. 
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Figure 21. Restoring visual responses with synthetic photoswitches. a) Cross-section of a 
mouse eye with the retina shown in orange b) A schematic diagram of the retina that shows its 
layered architecture. RGC: retinal ganglion cell, AC: amacrine cell, BP: bipolar cell, HC: 
horizontal cell, PH: photoreceptor cells (rods and cones)  c) and d) Electrical activity of RGCs 
expressing LiGluR before addition of MAG (c) and after addition if MAG (d). 
 
For us, it is simply amazing that our attempts to teach old receptors new tricks have 
gone from a proof of principle to studies in vision restoration within seven years. This 
pace is likely to increase, as numerous new targets are on the horizon and a growing 
number of neurobiologists, biophysicists and chemists are drawn into the field. We are 
convinced that these highly collaborative efforts will yield many useful tools, with 
which to study neural networks or treat disorders of the nervous system. But 
usefulness aside, optochemical genetics will always remain an incredibly rewarding 
intellectual exercise and a nice demonstration that the complexities of life can be 
harnessed with comparatively simple synthetic chemistry (Figure 22). 
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Figure 22. Harnessing the complexities of life. a) A dog (a natural creature slightly modified 
through breeding) with a leash (a crude device used to control its behavior, with mixed 
success). b) LiGluR (a complex receptor slightly modified through genetic engineering) on a 
comparatively simple synthetic leash. 
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Abbreviations 
AMPA 2-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid 
AP action potential 
Cav voltage-gated potassium channel 
CL caged ligand  
GABA γ-aminobutyric acid 
GPCR G-protein coupled receptor 
Kv voltage-gated potassium channel 
MscL Large-conductance mechanosensitive channel from M. tuberculosis 
Nav voltage-gated sodium channel 
NMDA methyl-D-aspartate  
pLGIC pentameric ligand-gated ion channel 
PTL Photoswitchable tethered ligand 
PCL Photochromic ligand 
SPMC spiropyran/merocyanine photoswitch 
TEA Tetraethylammonium ion 
TRPV1 Transient receptor potential channel, e.g. subtype V1 
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Novel molecular platforms for ENaC modulators are claimed in six patents 
(WO2012035158(A1); WO2009074575(A2); WO2011028740(A1); WO2009150137(A2); 
WO2011079087(A1); WO2008135557(A1)). These ENaC inhibitors may be used in 
order to block transepithelial sodium and consequently water absorption across 
airway epithelia. This may result in airway re-hydration and enhanced mucociliary 
clearance in patients with cystic fibrosis (CF) lung disease. All inhibitors resemble 
the classical ENaC blocker amiloride but follow different strategies to increase 
structural diversity in a sterically tolerant region. These substitutions can be 
modified in order to 1) enhance potency of ENaC inhibition; 2) reduce epithelial 
permeability; and 3) broaden applicability in order to be used as potential drugs for 
CF therapy. Most of the claims and patent data are supported by the currently 
available literature. The patents deliver a solid chemical basis for a variety of 
chemical modifications of the ENaC inhibitor amiloride. These modifications may 
result in the development of a novel, applicable ENaC inhibitor which may have 
lasting effects on diseased airways and may achieve airway re-hydration and 
enhanced mucociliary clearance in CF lung disease. 
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1. Introduction 
The Epithelial Sodium Channel (ENaC) is a sodium-selective, non-voltage gated ion 
channel consisting of three subunits, α,β,γ, and δ[1] which likely assemble as a 
heterotrimer in the plasma membrane[2]. This “classical” ENaC is found in various 
epithelia including those of the lung. In addition to the three classical ENaC subunits 
there is a fourth δ-subunit[3] which can replace the α-subunit and, together with β and 
γ, form ENaC-like ion channels with different pharmacological and biophysical 
properties[4–6]. The physiological role of δ-subunit containing ENaCs is as of yet 
insufficiently demonstrated; however, it is speculated that these channels may play an 
important role in the central nervous system. [6, 7]  
In epithelia ENaCs represent the rate-limiting step for the uptake of sodium ions into 
epithelial cells and are thereby key factors in the transepithelial absorption of sodium. 
According to the classical epithelial transport model by Ussing and colleagues[8], 
sodium ions enter the epithelial cells via ENaCs located in the apical membrane. The 
driving force for this sodium entry is an electrochemical gradient which is mainly 
generated and maintained by the basolaterally located Na+/K+-ATPase as well as 
various types of basolateral potassium channels. The sodium ions which enter the cells 
via ENaCs are eventually pumped out at the basolateral membrane of the epithelium 
due to the activity of the Na+/K+-ATPase. This transepithelial net-movement of sodium 
ions creates osmotic forces which drive the transepithelial absorption of water. 
Therefore, ENaC is crucial for the physiology of sodium and water homeostasis in 
various organs – including the lung. [9] 
All pulmonary epithelia are covered by a thin layer of liquid which is critical for lung 
physiology. In the airways, this so-called airway surface liquid (ASL) is important for 
mucociliary clearance.[10] The periciliary liquid (PCL) is a part of the ASL and 
surrounds the cilia of airway epithelial cells (Figure 1). According to the recently 
suggested “gel-on-brush model”, the PCL contains tethered macromolecules which 
form a brush-like structure.[11] Due to these macromolecules, gel-like mucus forms a 
distinct layer on top of the PCL and serves as a trap for inhaled particles and 
pathogens. Due to ciliary beat and movement of the PCL, this mucus layer moves 
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continuously towards the larynx and thereby transports particles/pathogens out of the 
lung – a mechanism referred to as mucociliary clearance.[10, 12]  
The liquid contents of the mucus layer and the PCL determine the efficacy of 
mucociliary clearance. The gel-like mucus layer serves as a liquid reservoir which 
helps maintain the PCL hydrated. However, when the mucus layer becomes severely 
dehydrated, liquid cannot be further transferred into the PCL. This results in squeezing 
of the cilia and failure of mucociliary clearance.[11–13] This indicates that the hydration 
status of the ASL/PCL critically determines mucociliary clearance in the airways. 
Given the importance of ENaC for transepithelial salt and water absorption, ENaC 
activity and ASL/PCL homeostasis are also connected.[14] The salt-wasting syndrome 
type 1 pseudohypoaldosteronism (PHA1) is caused by mutations in ENaC subunits 
which lead to a decreased ENaC activity.[15] Aside from salt loss, patients with PHA1 
display an increased ASL volume in the airways.[16] By contrast, transgenic mice which 
overexpress ENaCs in the airways show a reduced ASL volume, impaired mucociliary 
clearance and develop cystic fibrosis (CF)-like lung disease.[17] In addition, mutations 
that lead to increased ENaC activity have been identified in patients which develop 
CF-like symptoms (atypical CF).[18, 19] ENaC can thus be considered a regulator of 
sodium and water homeostasis of ASL/PCL. This makes ENaC an interesting 
molecular target for pharmacotherapy of Cystic Fibrosis lung disease.[20] 
Cystic Fibrosis is the most common genetic disorder in the Caucasian population and 
is caused by mutations which lead to impaired function of the chloride channel CFTR 
(cystic fibrosis transmembrane conductance regulator). Despite its prevalence, the 
molecular mechanisms belying how impaired CFTR activity leads to pathogenesis and 
eventually CF-disease are still not completely understood.[14, 21] The pulmonary 
manifestations in cystic fibrosis patients are airway obstruction by thick and viscous 
mucus and chronic lung inflammation. These are the result of an airway ASL/PCL 
dehydration which leads to impaired mucociliary clearance and reduces the capability 
to remove mucus as well as pathogens out of the lung.[11, 12] Therefore, a well-accepted 
approach for the treatment of CF is the re-hydration of the airways in order to restore 
mucociliary clearance.[22] Air-way re-hydration can be achieved by the inhalation of 
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hypertonic saline or interference with ENaC-mediated salt and, consequently, liquid 
absorption across the airway epithelium. 
Hypertonic saline will re-hydrate the airways by drawing fluid osmotically into the 
ASL (the PCL as well as the mucus layer). This would consequently avoid squeezing of 
the cilia and enhance mucociliary clearance. Beneficial effects due to the inhalation of 
hypertonic saline are indicated by results from clinical trials in CF patients[23] and have 
been summarized in a review article by Goralski et al..[22] Furthermore, preventive and 
late treatment with hypertonic saline effectively reduced mucus obstruction in the 
ENaC-overexpressing mouse model.[24] This indicates that hypertonic saline is an 
effective approach in order to re-hydrate the airway surfaces in CF. 
In contrast to drawing water into the ASL by hyperosmotic agents, a reduction of 
liquid absorption by the airway epithelium can increase the liquid content of the ASL. 
This may be achieved by pharmacological interference with transepithelial sodium 
absorption and suggests that inhibitors of ENaC are potential pharmacological tools for 
decreasing fluid absorption across airway epithelia and thereby may contribute to 
airway re-hydration and stimulation of mucociliary clearance. 
This patent evaluation addresses novel ENaC blockers and their potential use as 
therapeutic tools for treating condition in which inhibition of ENaC is desired. 
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Figure 1. ENaC inhibitors as a tool for airway re-hydration in cystic fibrosis. A) Normal 
airways exhibit a balanced periciliary liquid (PCL) allowing efficient ciliary beat and mucus 
clearance from the airways. PCL volume is maintained by a balance of ENaC-mediated sodium 
and, consequently, water absorption as well as chloride secretion (not shown). B) In CF 
airways, the lack of chloride/water secretion as well as an enhanced sodium absorption leads to 
PCL depletion and impaired mucociliary clearance. ENaC inhibitors such as amiloride may be 
used in order to reduce sodium/water absorption and thereby re-hydrate the PCL and enhance 
mucociliary clearance. 
 
 
2. Chemistry 
Amiloride was disclosed in the 1960s as a potassium sparing diuretic able to inhibit 
transepithelial sodium absorption.[25–28] Decades later, ENaC was discovered as the 
primary protein target responsible for the diuretic effect[1, 29] and many other ion 
channels and transporters were also identified as amiloride sensitive. The molecular 
design of amiloride has been proven to be highly successful in blocking ENaC activity 
and in many cases novel ENaC blockers are amiloride derivatives or highly resemble 
the 3,5-diamino pyrazine (Figure 2).  
Years of optimizing amiloride structure activity relationships have taught us that first, 
a protonated and thus positively charged guanidinium is needed for ENaC block and 
second, substitution at the guanidine nitrogen with hydrophobic moieties enhance 
potency.[30] Both of these finding are mirrored in the herein reported patents for new 
ENaC blockers, which follow different strategies of generating new molecular design 
platforms. Interestingly, the 3,5-diamino pyrazine core with a halogen or halogenoid in 
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6-position and a carboxy functional group in 2-position remains unchanged in all cases. 
In contrast, the apparent high structural tolerance for substituents extending from the 
center of positive charge allows for creative chemical design. These modifications may 
be used to modify bioavailability and pharmacodynamics, more specifically addressing 
certain organs or directing drug metabolism.  
In compounds of series I, the guanidine is part of an imidazolidine, which forms a 
spiro cycle with an N-acyl-piperidine. The concept of integrating the guanidine into a 
heterocycle has in fact been followed by Novartis before as seen in series II. In this case, 
ring size has been varied from imidazolidines (5-membered) to 1,3-diazepanes (7-
membered). Series I and II utilize an acyl guanidine as represented by amiloride, which 
would be protonated at physiological pH to a large extend leading to ENaC block. In 
their non-protonated form, however, these molecules would be comparatively 
permeable to membranes. Series III to V would instead install peralkylated nitrogen 
atoms leading to a permanent positive charge. Interestingly, this charge is one bond 
length further away from the pyrazine core as compared to the above described acyl 
guanidines. Series III and IV feature ethane-1,2-diamines, which are connected to the 
canonical pyrazinic acid through an amide bond. The permanent positive charge is 
then installed by quaternarization of the distal amine functionality. This feature 
resembles known cation channel blockers such as tetraethylammonium or QX-314. In 
physiological investigations, quaternary amine ENaC blockers have been shown to be 
comparable or superior to amiloride in terms of potency and efficacy.[31, 32] As a 
consequence of their permanent charge, these molecules have starkly increased 
polarity. This translates into higher solubility and hindered passive penetration across 
cell membranes or, for instance, the blood brain barrier. It has been hypothesized that 
as such quaternary amine ENaC blockers could be a promising platform for nebulizers 
enhancing mucociliary clearance in CF.[31] Series V again features molecules with a 
permanent positive charge, however, carried by an amidine. In this case it is 
represented by an N-alkylated benzimidazole. This patent is the only one in which the 
pyrazinic acid may be transformed to an amide or ester (in all other cases: amides), 
which might result in different hydrolysis rates. While all above mentioned structural 
platforms outline different strategies of generating a diamino pyrazine with a basic or 
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positively charged substituent in 2-position, series VI represents bivalent ligands. Two 
amiloride or amiloride like molecular fragments are presented on either side of a 
linker, which can be varied in lengths and flexibility. 
 
 
Figure 2. The canonical blocker amiloride and patents on new chemical structures for ENaC 
block. Abbreviations and residues are reported identical to the patent literature.  
 
3. Biology and action 
Amiloride inhibits human lung ENaC with an IC50 value in the submicromolar range 
(~100 nM).[33] The high affinity towards ENaC makes amiloride an interesting 
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pharmacological tool for the interference of sodium absorption across airway epithelia. 
Various clinical trials have investigated the potential of amiloride inhalation in order to 
re-hydrate ASL/PCL and enhance mucociliary clearance in CF patients.[34–38] However, 
conflicting data have been reported and amiloride failed to become a therapeutic 
option due to its instability and rapid clearance from the airways.[38, 39] 
Two amiloride-derivatives, benzamil and phenamil are more potent inhibitors of ENaC 
and sodium transport,[1, 40–42] however, they were not more effective than amiloride.[40] 
Despite the higher affinities of phenamil/benzamil for ENaC, their stability in the 
airways was low.[40] Third generation derivatives of amiloride were subsequently 
designed by substitutions at the guanidine nitrogen.[43] Those compounds displayed 
both higher affinity (IC50 values below 10 nM) and lower reversibility of ENaC block. 
One of those compounds, compound 552-02 (N-(3,5-diamino-6-chloropyrazine-2-
carbonyl)-N’-4-[4-(2,3-dihydroxy-propoxy)phenyl] butyl-guanidine methane-
sulfonate), was able to enhance mucociliary clearance in sheep and conserved ASL 
volume on CF bronchial epithelial cells.[44] These studies indicated its potential 
suitability for CF therapy and made 552-02 being investigated in clinical phase 1 and 2 
trials (NCT00274313).  
This example demonstrates that the guanidine nitrogen in amiloride can be substituted 
in order to alter the pharmacodynamics of the molecule without losing the potency of 
ENaC block. This is also mirrored in the herein addressed patents which are all 
effective blockers of ENaC (with IC50 values generally below 10 µM). Compounds of 
series III to V are especially interesting due to the installation of a permanent positive 
charge. Unprotonated amiloride is lipid soluble and can accumulate in or cross 
epithelial cells [30]. The cationic character of compounds III to V should decrease 
epithelial permeability, a major limitation for the airway efficacy of amiloride, 
phenamil and benzamil.[40] Furthermore, it has been hypothesized that the cationic 
character of the compounds makes them especially suitable for dry powder or 
nebulizer applications – which are desired in CF therapy.[31, 32] 
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4. Expert Opinion 
The herein addressed patents represent novel interesting chemical platforms for small 
molecule ENaC blockers. The known structural freedom for lipophilic substitution 
beyond the guanidine nitrogen of amiloride has been translated into novel molecular 
designs. The guanidine may be part of different heterocycles which are further 
substituted. Alternatively, the guanidine may be replaced by a permanently charged, 
that is, peralkylated, amidine or amine which again may be further extended by 
various substituents. These substitutions allow a variety of chemical modifications 
which may achieve an enhanced potency of ENaC inhibition and a decreased epithelial 
permeability and thus clearance from the airways. As we learned from clinical trials 
using amiloride or its first generation derivatives benzamil/phenamil, both features are 
desired for an effective ENaC inhibitor which could be used for the treatment of CF 
lung disease. All of the discussed compounds are potent inhibitors of ENaC in airway 
epithelia (mainly tested in human bronchial epithelial cells), however, most of the data 
addressing the pharmacodynamics and potency of these ENaC inhibitors arise from 
electrophysiological recordings on airway epithelial preparations in Ussing chambers. 
It has to be kept in mind that the liquid environment in Ussing chambers is very 
different from the in vivo situation in the airways where air and mucus are obstacles to 
be overcome. Some of the compounds have already been evaluated with more 
physiological methods such as nasal potential measurement in guinea pigs.[31, 32] 
However, mucus becomes a way greater obstacle in the diseased CF airway. Thus 
appropriate animal models which develop CF-like symptoms such as the ENaC-
overexpressing mouse[17] or the recently developed CFTR knock-out pig[45, 46] should be 
considered for the evaluation of the efficacy of these ENaC inhibitors in promoting 
airway re-hydration and mucociliary clearance in CF lung disease. 
In addition to the choice of a disease-relevant model the timing of treatment is an 
important aspect which needs to be addressed. This is evident from a study which 
demonstrated that preventive but not late amiloride therapy has beneficial effects in 
ENaC-overexpressing transgenic mice.[20, 47] Amiloride may thus still have a potential 
for preventive therapy, especially in countries which conduct newborn screening for 
CF. This may also apply for the herein addressed novel small molecule ENaC 
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inhibitors and their efficacy in “preventive versus late” therapy should be investigated. 
Despite the potential of amiloride for preventive treatment of CF, Mall and colleagues 
recently highlighted that there is lack of data concerning the toxicity of amiloride in 
infants and its impact on neonatal development.[24] These aspects need to be addressed 
when novel ENaC inhibitors and their putative use for preventive CF treatment are 
evaluated. 
Taken together, the herein addressed patents provide a broad basis for a variety of new 
generation ENaC inhibitors. These novel molecules may lead to enhanced 
pharmacodynamics and open new doors for applicable ENaC inhibitors with sustained 
effects on diseased airways. Such inhibitors may achieve ASL/PCL re-hydration and 
enhance mucociliary clearance in CF patients. 
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Amiloride is a widely used diuretic that blocks Epithelial Sodium Channels 
(ENaCs). These heterotrimeric transmembrane proteins, assembled from β, γ 
and α or δ subunits effectively control water transport across epithelia and sodium 
influx into non-epithelial cells. The functional role of δβγ−ENaC in neural 
processing and in the periphery is still poorly understood. Herein, we introduce a 
photo-switchable version of amiloride, termed PA1, that enables the optical control 
of ENaC channels, in particular the δβγ−isoform. It was used to demonstrate the 
functional expression of δβγENaC in a model for human lung epithelium. 
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Introduction 
The Epithelial Sodium Channel (ENaC) is a constitutively open sodium-selective ion 
channel that lacks voltage sensitivity and mediates sodium absorption across various 
epithelia.1 Classical ENaCs are heterotrimers composed of three subunits, α, β and γ, 
which assemble as a sodium selective ion channel in the plasma membrane (Fig. 1).2,3 In 
renal epithelia, ENaCs are important players in Na+ reabsorption by the kidney and in 
maintaining extracellular volume and blood pressure. Gain-of-function mutations 
cause a hereditary form of hypertension (Liddle syndrome), whereas loss-of-function 
mutations give rise to the salt-wasting syndrome pseudohypoaldosteronism type 1.4,5 
ENaC-mediated sodium absorption by the pulmonary epithelium drives lung liquid 
clearance and is thus a critical regulator of pulmonary water content. Increased ENaC 
activity in the airways is the cause for cystic-fibrosis-like lung disease, whereas 
decreased ENaC activity in the distal lung leads to impaired alveolar fluid clearance 
and the development of pulmonary edema.6-9 As such, ENaCs are a primary target for 
drugs that affect electrolyte and water homeostasis, such as diuretics or edema 
medications.10-13 
An additional ENaC δ-subunit has been identified in 1995.14 There is only scarce 
knowledge about its physiological function, however, it can assemble with the β and γ 
subunits to form channels with high open probability.14-16 Expression of δENaC and 
other ENaCs has been confirmed in various non-epithelial tissues, most prominently 
the central nervous system of primates.17-20 It has been speculated that δ-containing 
ENaCs play a role in communicating ischemic and hypoxic signals in neurons, as well 
as adjusting nervous excitability.21,22 Complicating its analysis, mice and rats do not 
have a gene for the δ-subunit. Furthermore, no pharmacological tools are available for 
functional differentiation between α and δ-containing ENaCs. Thus, in contrast to αβγ, 
little is known about the physiological function of δβγENaC and in particular the 
(putative) function of δENaC in the brain is obscure.22 
ENaCs belong to a large group of ion channels, the ENaC/degenerin (ENaC/deg) 
protein family that also includes neuronal acid sensing ion channels (ASIC).23,24 The 
latter has recently been elucidated with X-ray crystallography, which confirmed a 
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trimeric architecture that probably applies to all channels of the family (Fig. 1).25 Every 
individual ENaC subunit comprises only two trans-membrane helices (TM 1,2) with 
relatively short intracellular C and N-termini and a large, cysteine-rich, extracellular 
domain. 
 
 
Figure 1. Epithelial sodium channels (ENaCs) and their blockers. a, Schematic drawing of a 
heterotrimeric αβγENaC and δβγENaC, respectively. Each subunit contains two transmembrane 
helices TM1 and TM2, relatively short C and N-termini at the intracellular site and a large 
extracellular loop. b, Chemical structure of amiloride and more potent derivatives phenamil, 
benzamil and 01. c, Proposed structures of photo-switchable amiloride derivatives containing 
an azobenzene functional group. d, Photo-isomerization of Photo-amiloride-1 (PA1). 
Illumination with 400 nm induces isomerization to cis-PA1, which is the thermodynamically less 
stable form. The cis-isomer can relax back to the trans-state thermally, or spatiotemporally 
controlled using 500 nm light. 
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Although ENaC/deg channels respond to a variety of input signals, none of them are 
inherently sensitive toward light. In recent years, our group has succeeded in 
developing a range of synthetic photo-switches that can confer light sensitivity to 
native or slightly modified receptor proteins. These can either function as freely 
diffusible photochromic ligands (PCLs) or as photo-switchable tethered ligands (PTLs) 
that are covalently attached to the target protein.26 Using either strategy, we have been 
able to effectively turn voltage-gated potassium, sodium, and calcium channels, 
ionotropic and metabotropic glutamate receptors as well as nicotinic acetylcholine 
receptors into photoreceptors.27-31 
We now show that an entirely new class of transmembrane proteins, viz. trimeric 
ENaC/deg channels, are amenable to the PCL approach. To this end we have designed, 
synthesized and characterized a small series of photo-switchable azobenzene 
derivatives of amiloride and identified one candidate that can be used to control 
δβγENaC-activity with light. Our photochromic ligands provide insights into the 
structure-activity relationships of ENaC blockers and could be used to functionally 
discriminate between isoforms. 
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Results and Discussion 
Design and Synthesis of Photoamilorides. Amiloride was introduced as a potassium 
sparing diuretic in the 1960s without particular knowledge of its molecular target.32 
ENaC in kidney epithelia was subsequently established as the ion channel primarily 
responsible for the potassium sparing diuretic effect.3 To date, countless amiloride 
analogs have been synthesized and tested, providing insights into its structure-activity-
relationships.33,34 Most importantly, it has been found that lipophilic substitution at the 
terminal guanidine nitrogen boost both potency and selectivity for ENaC. In fact, the 
potency gained by an aromatic substituent increases with linker length, Fig. 1b.35 
Accordingly, we designed photochromic amiloride derivatives that have an 
azobenzene unit directly attached to the guanidine, which gave photoamiloride-1 
(PA1) and photoamiloride-2 (PA2) resembling the drug phenamil, Fig. 1. Phenamil is 
known to irreversibly block ENaCs to a certain extent, possibly through cell uptake, 
and has been used to determine channel density.36 In addition, we designed 
compounds photoamiloride-3 (PA3) and photoamiloride-4 (PA4), which bear an 
azobenzene moiety linked through an ethylene spacer and resemble the known 
amiloride analogue 01.37 In PA2 and PA4, the azobenzenes are further substituted in 
the 4´-position with a diethylamino substituent, which is known to red-shift the action 
spectra for photo-switching.38 The photo-switching of PA1 between its trans and cis 
configuration is shown in Fig. 1c. 
The synthesis of the shorter photoamilorides PA1 and PA2 started from 4-nitroaniline 
s1, which was oxidized using oxone and condensed with a respective aniline using 
Mills conditions (see supporting information). Sodium sulfide reduction then yielded 
4-amino azobenzenes 02 and 03, respectively, which were converted to aryl guanidines 
s4 and s5 using cyanamide (Fig. 2a). The resulting guanidine hydrochlorides were 
deprotonated and condensed with an active ester of pyrazinic acid 4a, which yielded 
PA1 and PA2, respectively. 
To generate the requisite phenethylamine building blocks for the longer 
photoamilorides, primary amine s6 was first chemoselectively protected to 05, then 
condensed with commercially available nitrosobenzene s7 in a Mills-reaction and 
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subsequently deprotected to yield 06 (SI, Fig. 2b). Alternatively, oxidation of 05 and 
condensation with p-diethylamino aniline s8 followed by deprotection gave 
azobenzene 07. With two azobenzene-amine building blocks in hand, the guanidine 
functional moiety was installed using carboxamidine s9. The resulting guanidinium 
salts were deprotonated via basic work-up and directly added to an ethanolic solution 
of ester 09. Heating to reflux then yielded PA3 and PA4, respectively. Interestingly, 
attempts to furnish PA3 or PA4 under the same coupling conditions as PA1 and PA2 
(and vice versa) failed. Likewise, attempts to condense 4-amino azobenzenes 02 and 03 
with carboxamidine s9 did not yield the corresponding guanidines. 
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Figure 2. Photo-switchable amiloride (PA) synthesis and characterization. a, synthesis of 
PA1 and PA2 starts with 4-amino azobenzenes 02 and 03, respectively. Reaction with 
cyanamide installs the guanidine functional group. Guanidines (s4 & s5) can be coupled to the 
active ester of 4b (HATU activation) yielding PA1 and PA2. b, Synthesis of PA3 and PA4 starts 
from boc-protected phenethylamine 05, which can be either condensed with nitrosobenzene s7, 
or oxidized itself to condense with 4-aminodiethylaniline s8. After acidic deprotection, primary 
amine building blocks 06 and 07 are functionalized to guanidines, which can react with ester 4a 
yielding PA3 and PA4. c, X-Ray structure of PA1 indicates an extended hydrogen bond 
network, a slightly rotated azobenzene and the guandine double bond directed to the latter. d, 
Ideal wavelengths for photo-switching were investigated using UV/Vis. Generally, the more 
conjugated candidates PA1 and PA2 are more red-shifted than their corresponding homologs 
PA3 and PA4. Substitution with the electron donating diethylaniline functionality leads to a red-
shift compared to unsubstituted candidates (PA2 and PA4 vs. PA1 and PA3). e) IC50 values of 
PAs in their dark-adapted trans form as determined in dose response experiments using 
microelectrode recordings. PA4 is the most and PA2 as the least potent ENaC blocker. All PA 
molecules are more potent on the αβγ isoform. PA2 discriminates the most between αβγ and 
δβγENaC with 23 fold selectivity for the former. 
a
b
c
PA1
Switching wavelengths (nm)
αβγ δβγ δ/α
PA1 90 390 4.3
PA2 346 8000 23.1
PA3 36 80 2.2
PA4 4 14 3.5
λ(cis) λ(trans)
PA1 400 500
PA2 440 600
PA3 360 500
PA4 420 560
IC50 values (nM)
d e
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A single crystal X-ray structure of PA1 is shown in Fig. 2c. It provides the first 
structural data of an amiloride derivative substituted at the terminal guanidine 
nitrogen and reveals an extended hydrogen-bonding network involving an amine on 
the pyrazine, the adjacent carbonyl, and the guanidine.  
 
Photophysical Characterization of Photoamilorides. To determine absorption maxima 
and the optimal wavelengths for photo-switching, solutions of PA1-4 (50 µM, 
dissolved in DMSO) were irradiated at different wavelengths using a monochromator 
(Till Photonics Polychrome 5000), Fig. S1. DMSO was chosen as a solvent to slow down 
thermal relaxation in order to resolve absorption spectra of cis and trans-isomers for 
red-shifted candidates.39 Thus, it was possible to identify wavelengths leading to the 
highest cis and trans-content for each molecule (Fig. 2d).  
 
Electrophysiological Characterization of Photoamilorides in the Dark. To identify the 
amiloride derivative that would be the best photochromic ENaC blocker, we 
performed microelectrode recordings on Xenopus oocytes expressing human αβγ and 
δβγENaCs for all molecules (Fig. S2). Without monochromatic illumination and at 
dimmed room light (i.e. trans-enriched), a series of increasing ligand concentrations 
was applied, followed by full block using a 100 µM amiloride solution. This enabled 
both the determination of IC50 values and the relative block compared to the full 
blocker amiloride (Fig. S2 & Fig. 2e). It was found that all photochromic ligands 
synthesized are ENaC blockers with higher affinity for α-containing than δ-containing 
ENaCs. PA4 is the most potent molecule with IC50 values of 4 and 14 nM for αβγ and 
δβγENaC, respectively. The weakest blocker is PA2 with an IC50 of 346 and 8000 nM, 
respectively. For comparison, amiloride has IC50 values of 100 nM and 2600 nM on αβγ 
and δβγENaC channels in a similar experimental setting.22 
The structure-activity relationships of our small molecular series revealed interesting 
trends (Fig. 2e). As hypothesized above, the addition of a C-2-linker markedly 
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increased ligand affinity, as PA3 and PA4 are substantially more potent than their 
shorter analogues. Addition of a substituent in 4’-position in PA4 further increases 
potency compared to the unsubstituted PA3. However, this trend is reversed when 
there is no linker between the guanidine and the azobenzene moiety.  
It can be argued that the flexible linker in PA3 and PA4 enables the azobenzene moiety 
to optimally interact with amino acids in the vicinity of the amiloride binding site. 
Affinity is increased by the diethylaniline substituent suggesting an extended 
hydrophobic pocket in line with previous studies.37 In contrast, with no flexible linker 
(as in PA1), the stiff azobenzene functional group is forced into a comparatively 
unfavorable orientation. The additional loss in affinity by addition of the diethylaniline 
functionality (PA2) suggests that an extension in this particular region results in 
repulsive interactions. Interestingly, this effect is more pronounced on δβγENaC 
yielding in a 23-fold decrease in potency, compared with a 2 to 4-fold decrease in the 
case of αβγENaC channels (Fig. 2e). This new finding could be helpful for developing 
an amiloride derivative that is selective for αβγ or δβγENaC. 
 
Photocurrents elicited with PA1. To investigate which compound elicits the most 
pronounced photoeffect, we first performed electrophysiological recordings on ENaC-
expressing Xenopus oocytes in combination with monochromatic illumination. Each 
compound was applied at concentrations higher than the previously determined IC50 
values in order to obtain an on-off-like photoeffect. Illumination wavelengths were 
then switched in 1 min intervals while perfusion was stopped (Fig. S3). When PA1-4 
was applied to the αβγ or δβγENaC isoform, compound PA1 emerged as an excellent 
photochromic blocker, especially of the δβγ isoform, where effects were not only more 
pronounced, but also more robust, Fig. 3. Illumination with 400 nm immediately 
triggered a strong reduction in current. This effect could be reversed by switching back 
to 500 nm light (Fig. S4a). Thus, PA1 functions as a cis-blocker of the δβγENaC. This 
observation adds to the trend of an increased potency going from the 4’-substituted 
PA2 to the shorter PA1 and the even shorter cis-PA1. We found that the overall 
switching amplitude evoked by PA1 is consistent between 1 and 10 µM and decided to 
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settle on 10 µM as a working concentration, which allows photoswitching close to the 
amiloride baseline (Fig. S4b). Control experiments using oocytes expressing ENaC 
channels showed no innate sensitivity to light (Fig. S5). Likewise, ENaC expressing 
oocytes blocked by a 100 µM solution of amiloride did not react to varying 
illumination, even though applied wavelengths are known to evoke amiloride 
fluorescence.40 
Fig. 3a shows the effect of PA1 on δβγENaC–mediated current in real time. 
Wavelengths and consequentially currents were switched in 10 and 5 second intervals, 
respectively. With light-mediated activation, perfusion-induced mechanical effects can 
be avoided, which has been recently demonstrated for ENaCs, as well as other 
members of the ENaC/deg family.41-43 
The photostationary state of azobenzenes, i.e. their cis/trans-ratio, is a function of the 
illumination wavelength, which allows for controlling their effective concentrations 
with light. As a consequence, the degree to which δβγENaC channels are blocked by 
PA1 also depends on the wavelength applied (Fig. 4b, S6). Switching in 20 nm steps 
between a given wavelength and 500 nm results in a graded effect on the current, 
which is not dependent on the order applied. In line with our previous UV/VIS 
experiments, 400 nm light emerged as the most effective blocking wavelength.  
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Figure 3. PA1 photo-switching. a, Reversible block of of δβγENaC currents evoked by photo-
isomerization of PA1 (10 µM). b, Action spectrum of PA1. Wavelengths were switched between 
500 nm and 400 + x(20)nm (x = 0,1,2,3). Largest photo-switchable currents are observed when 
500 and 400 nm are used as illumination wavelengths for cis and trans-isomerization. c, Photo-
switching of PA1 tested on amiloride-sensitive current (IA) of αβγ (left) and δβγENaC (right) 
expressing Xenopus oocytes by two electrode voltage clamp (TEVC) recordings. Perfusion was 
stopped and illumination wavelengths were switched between 500 and 400 nm in 1 min 
intervals. Current values were taken at the end of each interval and averaged (n = 12 and 10, 
respectively). Error bars indicate SEM, significance refers to switching from 400 nm to 500 nm 
(*: p < 0.05). There is a reversible photo-switching-effect on both αβγENaC and δβγENaC. 
However, the amplitude of PA1 evoked photoswitching is higher on δβγENaC. 
Photoswitching evoked by 10 µM PA1 could be detected on both αβγ and δβγENaC 
expressing oocytes (Fig. 3c). However, switching events were generally more robust 
and amplitudes were higher on δβγENaC. Given the interesting and vaguely 
understood role of existence δβγENaC, especially in primates, we next turned to 
HEK293t (HEK) cells as a mammalian expression system. Additionally, in the light of a 
smaller and transparent cell, we expected faster and more pronounced effects 
compared to the non-transparent pigmented oocytes where only a fraction of the 
membrane surface can be illuminated. As depicted in Fig. 4, PA1 is an excellent 
photoswitch for δβγENaC expressing HEK cells. 
In line with the data from Xenopus oocytes, 400 nm translates into a rapid block of 
ENaC currents, which can be released repeatedly with 500 nm. As expected, this 
process occurs on the time scale of only a few seconds (Fig S7). In current clamp mode, 
the action of PA1 on δβγENaC translates into a pronounced and fast light-dependend 
change in membrane potential. Interestingly, this effect was also found in Xenopus 
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oocytes even though no starting potential could be set so effects were only driven by 
the chemical potential (Fig. S8). A comparison of δβγ and αβγENaC expressing HEK 
cells revealed that the average amplitude of photocurrents is ∼180 pA on the former 
and ∼10 pA on the latter isoform (Fig. S9). Likewise, the average change in membrane 
potential was ∼57 mV for δβγENaCs and ∼4 mV for αβγENaCs in HEK cells. Thus, the 
general trends and effects that were found in Xenopus oocytes could also be observed 
in HEK cells, however, much more pronounced and faster, as was expected from the 
smaller transparent system that can be entirely illuminated.  
When addressing the thermal stability of the thermodynamically less stable cis-PA1, 
we found that after being switched to cis using 400 nm, PA1 relaxes back on a fast time 
scale even without additional energy. Thus, our novel optical tool can be operated by 
turning on and off a simple light source emitting between 380 and 400 nm. As 
determined in oocytes, Fig 3b, intermediate wavelengths between 400 and 500 nm 
translate to graded effects. We were thus able to induce current and voltage steps in 
δβγENaC expressing HEK cells by switching between 400, 433, 466 and 500 nm, 
respectively.  
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Figure 4. Switching δβγENaC in HEK cells using 10 µM PA1. a, Photoswitching mediated by 
PA1 on δβγENaC expressing HEK cells. By switching between 400 and 500 nm both large 
currents (upward deflection = inhibition) and potentials (downward deflection = 
hyperpolarization) can be controlled by light. b, The average current amplitude of 
photoswitching (∆IP) is 182 pA on for δβγENaC and 9 pA for αβγENaC. The average ampitude of 
light mediated membrane potential (∆VP) is 57 mV and 4 mV, respectively (currents and 
potentials were recorded from the same cell, n = 10 biological repeats from 3 independent 
transfections, holding potential was -60 mV). c, Comparison between light-induced and thermal 
relaxation. d, Action spectrum of PA1 on δβγENaC expressing HEK cells demonstrates graded 
effects on both currents and membrane potential. e, PA1 can be used as a tool for not only 
hyperpolarization, but also depolarization. f, PA1 can be loaded into HEK cells by short 
incubation. After 1 min incubation at room temperature (rt) in 10 µM PA1 (yellow petry dish) and 
subsequent wash (blue petry dish), cells are ready for photo-experiments using the patch clamp 
technique. 
 
To further determine the potential of PA1 as a phototool for adjusting membrane 
potential, we set the starting potential in current clamp mode at -70 mV under blue or 
green light illumination (Fig. 4e). Starting from these conditions, PA1 can be used not 
only to hyperpolarize (switching from 500 to 400 nm), but also to depolarize a cell 
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(switching from 400 to 500 nm). This feature is especially interesting as de- and 
hyperpolarization are key triggers in cell communication including action potential 
firing and vesicle release. Therefore, the δβγENaC-PA1-system could be used as a 
mammalian derived tool for investigating cellular communication that roots in de or 
hyperpolarization, or as a trigger in optical screening platforms.  
In the course of our switching experiments using PA1 on δβγENaC expressing HEK 
cells, we found that photoswitching remains, even after wash out of PA1 from the 
external recoding solution (Fig. S10). There are different mechanisms by which this 
observation could be explained. First, protonated PA1 could stay in the channel pore, 
second, PA1 could be integrated into the membrane forming a reservoir and third, PA1 
could be internalized and act from inside the cell. To exclude that this finding results 
from PA1 contamination in the tubing or recording chamber, we pre-incubated 
coverslips with HEK cells that were transiently transfected with δβγENaC for 1 min at 
room temperature in 10 µM PA1 (Fig. 4f). Coverslips were then washed 3 times and 
investigated using patch clamp experiments.  
Interestingly, we obtained a fully functional photoswitchable system with strong, 
persistent ENaC-photo-currents. Up to this point, no perfusion and only a very small 
amount of PA1 was needed to perform an experiment with ENaC under optical 
control. Figure 4f further illustrates the rapid robust and reversible action of PA1 on 
δβγENaC that would be difficult to achieve with conventional tools. Intriguingly, cells 
prepared in such manner could be blocked and unblocked by amiloride without 
affecting photoswitching (Fig S11). This rules out a place of enrichment were PA1 and 
amiloride compete such as the channel pore.  
To test if PA1 may be internalized by the cell and act from the inside, we loaded PA1 
through the patch pipettel (Fig. 12). Photoswitching was possible instantaneously and 
a reversible amiloride block was conserved. Additional PA1 delivered by perfusion did 
not enhance the photo-effect. It is thus possible that PA1 acts from inside the cell or 
within the membrane. In fact, recent investigations point out an amiloride binding site 
in the transmembrane region.44  
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In contrast to lipophilic amiloride derivatives such as phenamil, the innate light-
mediated reversibility of PA1 allows for block and unblock even after cell uptake. The 
three different modes of PA1 delivery – perfusion, incubation and loading through the 
patch pipette – allow for versatile applications.  
With the ability of PA1 to switch ENaC currents and to differentiate between αβγ and 
δβγENaC in HEK cells, we next wanted to employ PA1 in a mammalian cell model, 
which endogenously expresses ENaC subunits. Human H441 bronchiolar epithelial 
cells were the model of choice since these cells were (a) human, (b) express all ENaC 
subunits including δENaC,16 and (c) form a polarized epithelium which allows the 
electrophysiological assessment of sodium transport across an intact cell monolayer. 
Furthermore, despite the molecular evidence for δENaC expression in pulmonary 
epithelia, a functional contribution of this isoform to transepithelial sodium transport is 
highly controversial.22  
To address the functional role of δβγENaC in these cells, we measured the 
transepithelial potential of H441 monolayers which were cultured on permeable 
membrane supports. First, we determined the magnitude of the overall amiloride-
sensitive transepithelial potential (VE) (in average ~4 mV, Fig. 5c). We then exchanged 
the apical bath solution for 10 µM PA1 and switched between 400 and 500 nm, and 400 
nm and dark (694 nm) for three cycles, respectively. Results were identical for the 
different wavelength protocols and the overall magnitude was ~0.4 mV of photo-
sensitive transepithelial potential (Fig. 5b).  
This finding hints towards a small amount of functional δβγENaC. To investigate 
whether the photoeffect comes from δβγENaC or is a small effect on αβγENaC, we 
addressed the lithium conductivity of either isoform. The ratio between lithium and 
sodium conductivity is 0.64 for δβγENaC and 2.0 for αβγENaC.45 Thus, we expected 
decreased photoeffects for the δ-containing isoform and increased effects for the latter 
when sodium is replaced by lithium. We verified this hypothesis using Xenopus 
oocytes (Fig. 5d), which had shown photoeffects for either isoform before. Likewise, 
δβγENaC-photocurrents were significantly reduced in HEK cells by extracellular 
lithium (Fig S13).  
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When sodium was substituted by lithium at the apical side of the H441 monolayer, 
PA1-mediated photoeffects decreased from 0.4 to 0,15 mV for both wavelength 
protocols, Fig. 5c. Thus, the photo-sensitive fraction of VE is due to δβγENaC rather 
than αβγENaC. These data strongly indicate functional δβγENaC in H441 cells and 
underline the ability of PA1 for functional differentiation between αβγ and δβγENaC. 
 
 
Figure 5. Switching the transepithelial potential in H441 monolayers. a, Experimental setup 
with H441 monolayer (ML) on a filter. The apical compartment contains 10 µM PA1 in sodium or 
lithium based buffer and was illuminated with a monochromator. The transepithelial potential VE 
between the apical and basolateral compartment was measured by a voltmeter. b, Switching 
VE with both 500/400 nm (top) and 694(=dark)/400 nm light (bottom). 400 nm were applied for 
10 sec, the longer wavelengths for 20 sec and voltage was recorded at the end of each 
illumination period. Photoeffects are robust and reversible for both protocols c, Comparison of 
the entire amiloride sensitive VE, and PA1 mediated photosensitive VE with apical sodium or 
lithium using both 400/500nm and 400nm/dark switching. (for one filter, first 400/500 nm and 
400nm/dark switching was performed. Then the same series was repeated with Li-based buffer, 
n = 7) d, Comparison of extracellular lithium on αβγ and δβγENaC photocurrents in Xenopus 
oocytes (n ≥ 7). 
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Summary and Outlook 
In summary, the photoswitchable ENaC blocker PA1 has been designed, synthesized, 
and functionally characterized using electrophysiology on Xenopus oocytes, HEK cells 
and H441 cells. Our results provide new insights into the structure-activity 
relationships of the amiloride class of diuretics and outline a strategy to selectively 
address the αβγ and δβγ isoforms of ENaC channels. PA1 can be used to optically 
control δβγENaCs by switching between blue and green light, or by turning on and off 
blue light. We showed that PA1, acts from the intracellular site and can be applied by 
perfusion, cell incubation or loading through the patch pipette. This offers additional 
spatial control and allows reversibly addressing intracellular ENaC gating, which 
would not be possible by conventional methods. We used PA1 to address the 
controversial role of different ENaC isoforms in H441 monolayers and identified 
functional δβγENaC. The combination of photoswitchable PA1 and the non-voltage-
gated δβγENaC is a powerful tool to precisely control the membrane potential with 
light, allowing not only hyper but also depolarization. With its unique function, PA1 
will deliver new insights into δβγENaC function and will enable new non-invasive 
means to investigate these channels in non-epithelial tissue such as the primate brain. 
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Methods 
Chemical synthesis. See supporting information. 
Cell culture and Electrophysiology. HEK293t cells were cultured in dulbeco´s modified 
eagle medium with 10% fetal bovine serum in a 10% CO2 37°C incubator. At 90-95% 
confluency, cells were splitted and used for transient transfection using the jetPRIME 
polyplus transfection reagent following the supplier´s protocol. Poly-L-lysine coated 
acid etched glass coverslips were placed in a 24-well plate and consecutively treated 
with the DNA-mix (150 ng of each ENaC subunit and 50 ng YFP) and 30k to 50k cells 
in growth medium. After 2-4 hours, the supernatant was removed and growth 
medium supplemented with 10 µM amiloride was added. Cells were used for 
electrophysiological recordings 12 – 48 hours post transfection. Only YFP-positive cells 
with an amiloride sensitive current were used for experiments. 
Whole cell patch clamp experiments were performed using a standard electrophysiology 
setup equipped with a HEKA Patch Clamp EPC10 USB amplifier and patch master 
software. Micropipettes were generated from “Science Products GB200-F-8P with 
filament” pipettes using a vertical puller. Resistance varied between 5-8 MΩ. Bath 
solution contained in mM: 140 NaCl, 3 KCl, 2 CaCl2, 1 MgCl2, D-Gluc 10, 20 HEPES 
(NaOH to pH 7.4). Pipette solution contained in mM: 90 K-gluconate, 10 NaCl, 10 KCl, 
1 MgCl2, 10 EGTA, 60 HEPES (KOH to pH 7.3). Photoswitchable ligands and reference 
agonist were dissolved in bath solution from a 1000 x DMSO stock. 
H441 cells were purchased from American Type Culture Collection in the 65th passage 
and cultured under liquid/air conditions in the presence of 200 nM dexamethasone as 
previously described.46 For experiments, H441 containing cell culture inserts were 
placed in 6-well plates containing H441 saline (2ml in the basolateral, and 500 µl in the 
apical compartment). H441 saline contained in mM: 130 NaCl, 2.7 KCl, 1.5 KH2PO4, 1 
mM CaCl2, 0.5 MgCl2, 10 HEPES, and 10 glucose (37°C, pH 7.35 (TRIZMA)). In some 
experiments sodium was substituted by equivalent concentrations of lithium. 
Transepithelial voltage (VE) was measured with an epithelial voltohmmeter (EVOM; 
World Precision Instruments). When VE was stable, amiloride was added to the apical 
compartment to a final concentration of 100 µM in order to investigate the amiloride-
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sensitive fraction of VE. Monolayers were washed 3 times with H441 saline and 
afterwards 10 µM PA1 was added to the apical compartment. When VE stabilized 
again, the EVOM was zeroed (for better comparability between cell preparations) and 
monolayers were exposed to different wavelengths of light. Afterwards, cells were 
rinsed with lithium containing saline and the same measurement protocol was 
employed. Experiments were performed at 37°C on seven H441 monolayers from two 
independent cell preparations. 
Irradiation was performed a TILL Photonics Polychrome 5000 monochromator. In patch 
clapm experiments, the light beam was guided through the microscope objective and 
operated by the amplifier and patch master software. In all other experiments, a light 
fiber was positioned in proximity to the object of interest and the monochromator was 
operated using the PolyCon 3.1 software. 
Heterologous expression of ENaC subunits and microelectrode recordings. 
Defolliculated oocytes (stages V/VI) which were derived from female South African 
Clawed Frogs (Xenopus laevis) were injected with 20-30 nl of cRNA encoding the αβγ or 
δ1βγ subunits of human ENaC (the splice variant δ1βγ is referred to as δβγ in this 
report). The RNA concentration was 10 ng/µl per subunit. Oocytes were incubated for 
24-48 h in a solution containing (in mM): 10 NaCl, 1 KCl, 2 CaCl2, 80 NMDG-Cl, 5 
HEPES, 2.5 sodium pyruvate, 0.06 penicillin G, 0.02 streptomycinsulfate (pH 7.4-HCl). 
Microelectrode recordings were performed with the two-electrode voltage-clamp 
technique (TEVC). ENaC-expressing oocytes were placed into a lucite chamber and 
perfused with oocyte ringer solution (ORI) containing (in mM): 90 NaCl, 1 KCl, 2 
CaCl2, 5 HEPES, 2.5 sodium pyruvate (pH 7.4-NaOH). Glass capillaries with an outer 
diameter of 1.2 mm were pulled to microelectrodes and filled with 1 M KCl. Chloride-
coated silver wires served as bath electrodes. Electrodes were connected to a TEVC 
amplifier (Warner Instruments, Hamden, CT, USA). In order to measure the 
transmembrane ion currents (IM), the membrane potential of ENaC-expressing oocytes 
was clamped to -60 mV. The membrane potential (VM) as well as transmembrane 
current (IM) were continuously recorded with a strip chart recorder (Kipp&Zonen, 
Delft, The Netherlands). For statistical measurements, oocytes from at least two 
animals were used. 
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Additional Photoswitching Experiments 
 
Figure S1. UV-VIS characterization of photo-isomerization of photo-switchable amilorides PA1-
4. 50 µM solutions of PA1-4 in DMSO were placed in a 1 mL quartz cuvette (10 mm diameter, 
VAIRAN Cary 50 Scan UV/Vis Spectrophotometer). A light-fiber cable connected to a Till 
Photonics Polychrome 5000 monochromator was placed in the cuvette. The light fiber cable 
was positioned in a way that it just penetrates the surface of the PA-solution in order to avoid 
diffraction at the liquid/air interface. Monochromatic illumination was screened from wavelengths 
higher than the n→p* transition (500 to 600 nm) to those smaller than the pi→pi* transition (300 
to 400 nm) in 20 nm steps going from higher to smaller wavelengths. Every wavelength was 
applied for 2 min before a UV-Vis-scan was recorded. Illumination conditions yielding the 
highest pi→pi* absorption were used for maximal trans-enrichment (solid line). Illumination 
conditions yielding the lowest pi→pi* absorption were used for maximal cis-enrichment (dashed 
line). 
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Figure S2. Microelectrode recordings for Electrophysiological characterization of PAs. a, 
Single current trace of an αβγENaC expressing Xenopus oocytes sequentially treated with 
increasing concentrations of PA1 followed by saturating amiloride under dimmed room light 
(trans-enriched, IM = membrane current). b, Same experiments with δβγENaC. c, Dose 
response curves of PA1 on αβγ and δβγENaC calculated from experiments as described in a) 
and b). Trans-enriched solutions of PA1 fully block αβγENaC, but only partially block δβγENaC 
(dashed line indicates amiloride baseline). d-f, Dose response curves of PA2-4 on αβγ (square) 
and δβγENaC (triangle), respectively. IC50 values were obtained from a sigmoidal concentration-
response fit according to the Hill equation using Graphpad Prism (version 4), at least 5 
biological repeats ,at least two donor animals. 
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Figure S3. Two electrode voltage clamp recordings from ENaC expressing Xenopus oocytes – 
PAx Screen. Photoswitchable amiloride derivatives PA1-PA4 (left column) were tested on 
αβγENaC (middle column) and δβγENaC (right column).Testing concentrations were chosen 
based on the previously determined IC50 values in order to obtain photoswitching events close 
to the amiloride baseline (dashed) (Fig. S2). Switching wavelengths were chosen based on 
previous UV/Vis experiments (Fig. S1). For all PAs, photoswitching effects were more 
pronounced on δβγENaC, even though overall currents were comparable. PA1 gave the best 
results in terms of overall photocurrent magnitude. Depicted current traces show identical 
amiloride sensitive currents for either ENaC isoform. However, photoswitching is more 
pronounced on δβγENaC. Interestingly, for PA1, PA2 and PA4, the cis-isomer (illumination with 
the shorter wavelength) was the better blocker. In the case of PA3, however, the trans-isomer 
(longer wavelength) blocked δβγENaC currents more efficiently. Based on the presented series, 
there is no structural rational for explaining this result, especially with no X-ray structure of the 
ion channel and the binding site at hand. Based on this screen, we settled on PA1 and 
δβγENaC for further experiments. (Depicted traces are representative. At least two 
concentrations were tested for every molecule. Every experiment was repeated at least two 
times). 
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Figure S4. Photo-switching of PA1 (10 µM) on δβγENaC investigated using microelectrode 
recordings. a, Photocurrents: Perfusion was stopped and illumination was switched between 
500 and 400 nm in 1 min intervals. At the end of each illumination period, current values were 
taken (I500 nm & I400 nm). These data are summarized in Fig. 3b. b, Photoswitching of PA1 on 
δβγENaC. The amplitude of photocurrents is stable over the range of tested concentrations. 
However, events occur closer to the amiloride baseline when 10 µM PA1 are applied indicated 
by a small residual amiloride sensitive current IA under 400 nm. (n ≥ 6, *: p < 0.05, **: p < 0.01).  
 
 
 
Figure S5. Control experiment. δβγENaC expressing Xenopus oocytes do not show innate 
sensitivity to light in both unblocked and blocked state. (n = 3, αβγENaC analogous). 
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Figure S6. Action spectrum of PA1 on a δβγENaC expressing oocyte. Wavelengths were 
switched between 500 nm and 360, 380, 400, 420 and 440 nm. 400 nm illumination translates 
to the most pronounced photo-current. 
 
 
Figure S7. Switching voltage using PA1 on δβγENaC expressing oocytes. As expected from 
photocurrents, switching to 400 nm (blocking ENaCs) polarizes the oocytes, which can be 
reversed by switching to 500 nm. (representative trace). 
 
 
Figure S8. Photoswitching of 10 µM PA1 on δβγENaC expressing HEK cells occurs on the 
timescale of seconds. Exponential curve fitting demonstrates that channel block mediated by 
400 nm illumination is considerably faster than unblock by 500 nm (τ = 250 ms vs 1 sec). 
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Figure S9. Comparison of Amiloride sensitive current IA and photocurrent.IP on αβγENaC (a) 
and δβγENaC (b) expressing HEK cells (black bar indicates perfusion with 10 µM amiloride). 
Both representative traces have 600 pA IA. IP on δβγENaC is 240 pA (compare: average IP = 
180 pA, Fig. 4a). IP on αβγENaC is 12 pA (compare: average IP = 9 pA, Fig 4a). This bias of 
PA1-mediated photoswitching on δβγENaC is in line with data from Xenopus oocytes (e.g. Fig 
S3). Selectivity is probably higher in HEK cells because the entire cell can be illuminated. 
 
 
 
Figure S10. Photoswitching occurs in presence of extracellular PA1 (orange color of bath 
solution) and remains after wash out (blue color). This indicates uptake in the cell as indicated 
by the orange cytoplasm. 
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Figure S11. PA1 cell uptake by short incubation. 24h after transfection, coverslips with HEK 
cells expressing δβγENaC were transferred to a petry dish containing a 10 µM PA1 solution 
(orange color) in extracellular recording buffer. After incubation for 1 min at room temperature, 
the coverslip was washed with extracellular recording buffer (blue color) and investigated using 
the patch clamp technique. Photocurrents could be evoked without further treatment. Cells 
could be fully blocked and unblocked with amiloride.  
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Figure S12. Loading PA1 through the patch pipette. Pipettes were loaded with 10 µM PA1 and 
HEK cells expressing δβγENaC where investigated in whole cell mode. Photocurrents could be 
triggered immediately. a, photoswitching takes place before and after amiloride block with 
identical amplitudes analogously to Fig. S8. b, external amiloride can be displaced by PA1. 
After consecutive wash out of PA1, photocurrents have the same magnitude. It can thus be 
assumed that externally applied PA1 is taken up by cells and acts from the intracellular site. 
 
20 sec
50
 
pA
20 uM
amil.wash
a
20 uM
amil.
10 uM
PA1wash
20 sec
10
0 
pA
b
119 
 
 
Figure S13. Effect of external lithium on overall and photocurrents (δβγENaC, HEK cells, 
biological repeats). HEK cells loaded with PA1 as described in Fig. S8 were switched with 
lithium or sodium containing external solution. a, in line with reported data on δβγENaC lithium 
conductivity, washing out external lithium increases the overall current. b, washing in lithium has 
the opposite effect and decreases both  overall and photocurrents. c, the average photocurrent 
amplitude is significantly reduced when external sodium is exchanged for lithium (* p < 0.05). 
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Experimental procedures for chemical syntheses 
4-Nitro-azobenzene s2 and s3 
 
Oxone oxidation. To a solution of 4-nitroaniline s1 (5.94 g, 43.0 mmol, 1 eq) in 150 mL 
CH2Cl2 was added an aqueous solution of oxone (26.4 g, 43.0 mmol, 1 eq, 150 mL). 
The biphasic mixture was stirred vigorously under N2 atmosphere. After 3 hours, 
phases were separated and the aqueous phase was extracted 2x with CH2Cl2 (30 mL 
aliquots). Pooled organic phases were washed with 1x 1 M HCl, 1x sat. NaCl (75 mL 
aliquots), dried over Na2SO4 and concentrated to 30 mL under reduced pressure. The 
resulting yellow-black solution of nitrosobenzene I in CH2Cl2 was carried on to the next 
step immediately. 
Mills condensation. To the freshly prepared nitrosobenzene solution in DCM described 
above was added sequentially the respective aniline (21.5 mmol, 1 eq) and glacial 
AcOH (6.15 mL, 107.5 µL, 5 eq). The reaction mixture was allowed to stir for 15 hours 
under N2 atmosphere, after which time the reaction mixture was found to be an orange-
black suspension. EtOAc (150 mL) was added and the organic phase was washed with 
3x 1-M-NaOH, 2x sat. NaHCO3, 2x sat. NaCl (50 mL aliquots). The organic phase was 
then dried over Na2SO4 and concentrated under reduced pressure. Crude material was 
purified by flash column chromatography (silica gel, dry loading on bulk sorbent, 
gradient: 1% → 5% →10% EtOAc in Hexanes), affording compounds s2 and s3 (21.0 
mmol, 98%), as orange solids.  
 
1H NMR (400 MHz, CDCl3): δ 8.46 – 8.28 (m, 2H), 8.06 – 7.99 (m, 2H), 7.99 – 7.91 (m, 2H), 
7.58 – 7.49 (m, 3H). Lim, Y.-K., Lee, K.-S. & Cho, C.-G. Novel Route to Azobenzenes via Pd-
Catalyzed Coupling Reactions of Aryl Hydrazides with Aryl Halides, Followed by Direct 
Oxidations. Organic Letters 5, 979-982 (2003). 
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1H NMR (200 MHz, CDCl3): δ 8.35 – 8.23 (m, 2H), 7.97 – 7.82 (m, J=4.8, 2.6, 4H), 6.72 (d, 
J=9.3, 2H), 3.47 (q, J=7.1, 4H), 1.24 (t, J=7.1, 6H). Sigman, M.E. & Leffler, J.E. Supercritical 
carbon dioxide. The cis to trans relaxation and .pi.,.pi.* transition of 4-(diethylamino)-4'-
nitroazobenzene. The Journal of Organic Chemistry 52, 3123-3126 (1987). 
 
 
4-Amino-azobenzene 02 and 03 
 
To a solution of nitrobenzene s2 or s3 (9.16 mmol, 1 eq) in 3:1 THF:H2O (120 mL) was 
added Na2S (2.14 g, 27.5 mmol, 3 eq). The red-black reaction suspension was allowed 
to stir for 3h hours at reflux temperature. THF was removed under reduced pressure, 
and the remaining aqueous material was partitioned between EtOAc (150 mL) and 1-
M-NaOH (50 mL). The organic phase was further washed with 1-M-NaOH, sat. 
NaHCO3 and brine (50 mL aliquots). An orange precipitate was removed through 
vacuum filtration before the filtrate was dried over Na2SO4 and concentrated in vacuo, 
affording anililnes 02 and 03, respectively, as dark orange solids (02, 87%. 03, 83%).  
 
1H NMR (300 MHz, CDCl3): δ 7.89 – 7.75 (m, 5H), 7.54 – 7.33 (m, 2H), 6.82 – 6.69 (m, 2H), 
4.04 (s, 2H). Bahulayan, D., John, L. & Lalithambika, M. Modified Clays as Efficient Acid-Base 
Catalyst Systems for Diazotization and Diazocoupling Reactions. in Synthetic Communications 
Vol. 33 863 (Taylor & Francis Ltd, 2003). 
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1H NMR (599 MHz, CDCl3): δ 7.81 – 7.75 (m, 2H), 7.74 – 7.69 (m, 2H), 6.75 – 6.67 (m, 4H), 
3.88 (s, 2H), 3.42 (q, J=7.1, 4H), 1.20 (t, J=7.1, 6H). Mourot, A. et al. Tuning photochromic ion 
channel blockers. ACS Chem Neurosci 2, 536-43. 
 
 
Arylguanidines s4 and s5 
 
Aniline 02 or 03 (2.02 mmol, 1.0 eq) was suspended in ethanol (1.3 mL), and a 75 % 
ethanolic cyanamide solution (227 µL, 4.06 mmol, 2.0 eq) was added, followed by HCl 
(4 M in dioxane, 507 µL, 2.02 mmol, 1.0 eq). After refluxing for 24 h, the reaction 
mixture was diluted with EtOAc (450 mL), washed with 5-M-NaOH (3 x 20 mL), 
NaHCO3 (20 mL) and brine (20 mL), dried over Na2SO4 and concentrated using rotary 
evaporation. The crude product was purified by column chromatography (SiO2, 
gradient: 10 % NH3/MeOH (1:3)	→20 % NH3/MeOH (1:3)/EtOAc) yielding guanidines s4 
and s5, respectively, as orange amorphous solids. 
 
TLC (SiO2, EtOAc:MeOH:NH3(aq), 80:15:5 v/v/v): Rf = 0.27 (UV); 1H NMR (400 MHz, CD2Cl2): δ 
7.91 – 7.84 (m, 4H), 7.52 (t, J=7.3, 2H), 7.48 – 7.42 (m, 1H), 7.04 (d, J=8.7, 2H), 3.58 (s, 4H); 
13C NMR (100 MHz, CD2Cl2): δ 153.37, 153.31, 151.92, 148.56, 130.90, 129.59, 124.92, 
124.11, 123.01; IR (Diamond-ATR, neat): 3324, 3028, 2760, 1665, 1622, 1562, 1491, 1456, 
1429, 1406, 1307, 1123, 982, 862 cm-1; HRMS (m/z): [M+H]+ calcd. for C13H14N5, 240.1244; 
found, 240.1242. 
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TLC (SiO2, EtOAc:MeOH:NH3(aq), 80:15:5 v/v/v): Rf = 0.16 (UV); 1H NMR (400 MHz, CD2Cl2): δ 
7.83 – 7.73 (m, 4H), 7.04 – 6.97 (m, 2H), 6.78 – 6.69 (m, 2H), 3.46 (q, J=7.1, 4H), 1.23 (t, 
J=7.1, 6H); 13C NMR (101 MHz, CD2Cl2): δ 151.41, 149.99, 149.81, 148.70, 142.92, 124.70, 
123.43, 123.33, 110.90, 44.61, 12.37; IR (Diamond-ATR, neat): 3400 – 2700 (m, br), 3323, 
3050, 2972, 1658, 1569, 1551, 1512, 1446, 1392, 1352, 1266, 1194, 1137, 1074, 1009 cm-1; 
HRMS (m/z): [M+H]+ calcd. for C17H23N6, 311.1979; found, 311.1976;  
 
 
Pyrazinic acid 4b 
 
The title compound was prepared as described in patent literature.1 Analytical data 
matched those reported.  
13C NMR (101 MHz, DMSO-d6) δ 167.69, 156.32, 153.61, 119.07, 110.50. IR (Diamond-ATR, 
neat): 3476, 3422, 3356, 3296, 3194, 2867, 2548, 1665, 1609, 1514, 1442, 1308, 1250, 1144, 
790 cm-1; HRMS (m/z): [M-H]- calcd. for C5H5ClN4O2, 187.0023; found, 187.0028. 
 
 
N-Boc-phenethylamine 05 
 
Aminophenethylamine s6 (1.0 g, 7.3 mmol, 1 eq) was dissolved in 50 mL THF and a 
solution of Boc2O (1.7 g, 7.7 mmol, 1.05 eq) in THF (30 mL) was added dropwise. After 
stirring for 2 h at room temperature, the mixture was diluted with EtOAc (400 mL), 
washed with 1-M-HCl (100 mL), 1-M-NaOH (150 mL), sat. NaHCO3 (150 mL) and brine 
(150 mL) and dried over Na2SO4. The solvent was removed by rotary evaporation and 
                                                           
1
 WO2008106692  (A1) ― 2008-09-04 „PIM KINASE INHIBITORS AND METHODS OF THEIR 
USE”.  
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the crude was purified using silica gel chromatography (gradient: 0 to 30 % EtOAc in 
hexanes) yielding the title 05 compound as a pale white solid (1.7 g, 7.2 mmol. 98%) 
 
TLC (SiO2, EtOAc:hexanes, 1:1 v/v): Rf = 0.48 (UV + ninhydrin stain); 1H NMR (300 MHz, 
CDCl3) δ 7.00 (d, J=8.3, 2H), 6.69 – 6.62 (m, 2H), 4.53 (s, 1H), 3.62 (s, 2H), 3.33 (d, J=6.4, 2H), 
2.70 (t, J=7.0, 2H), 1.45 (s, 9H). Hah, J.-M., Martasek, P., Roman, L.J. & Silverman, R.B. 
Aromatic Reduced Amide Bond Peptidomimetics as Selective Inhibitors of Neuronal Nitric Oxide 
Synthase. Journal of Medicinal Chemistry 46, 1661-1669 (2003). 
 
 
Primary amine 06 
 
Aniline 05 (5.13 g, 21.7 mmol, 1.0 eq) was dissolved in DCM (30 mL) and 
nitrosobenzene s7 (2.56 g, 23.9 mmol, 1.1 eq) was added followed by AcOH (12.4 mL, 
217 mmol, 10 eq). After stirring over night at room temperature, the reaction mixture 
was diluted with EtOAc (300 mL) and the organic phase was washed with 1-M-HCl 
(50 mL), 1-M-NaOH (50 mL), sat. NaHCO3 (50 mL) and brine (1 x 50 mL). After drying 
over Na2SO4, solvent was removed in vacuo. The resulting orange oil was redissolved 
in 10 mL DCM and TFA (16 mL, 217 mmol; 10 eq) was added for Boc-deprotection. 
After stirring for 1 h, the mixture was basified with 5-M-NaOH (60 mL) and extracted 
with EtOAc (4 x 150 mL).  Pooled organic phases were washed with sat. NaHCO3 
(50 mL) and brine (50 mL). The EtOAc layer was filtered and concentrated in vacuo, 
followed by purification using flash column chromatography (SiO2; 10 % MeOH, 90% 
DCM + 1 % TEA), yielding primary amine 06 (3.93 g; 17.5 mmol, 80 %) as orange solid 
(3.93 g; 17.5 mmol, 80 %). 
TLC (SiO2, DCM:MeOH, 1:1 v/v, + 1 % TEA): Rf = 0.26 (UV); 1H NMR (400 MHz, CD3OD) δ 
7.92 – 7.85 (m, 4H), 7.56 – 7.48 (m, 3H), 7.48 – 7.43 (m, 2H), 3.26 – 3.19 (m, 2H), 3.07 – 3.01 
(m, 2H); 13C NMR (101 MHz, DMSO-d6) δ 151.72, 150.77, 140.01, 130.03, 128.45, 128.01, 
122.01, 121.50, 39.98, 33.56; IR (Diamond-ATR, neat): 2936, 1668, 1554, 1203, 1171, 1130, 
1075, 1021, 1013, 943, 839 cm-1; HRMS (m/z): [M+H]+ calcd. for C14H16N3, 226.1339; found, 
226.1339. 
 
 
Primary amine 07 
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Aniline 05 (1.1 g, 4.7 mmol, 1 eq) was dissolved in 100 mL DCM and water (50 mL) 
was added followed by an aqueous solution of oxone (3.2 g, 5.1 mmol, 1.1 eq, in 50 
mL). The heterogeneous mixture was stirred vigorously for 3h before phases were 
separated. The DCM layer was dried over Na2SO4 and concentrated to ~30 mL. Aniline 
s8 (0.77 mL, 4.7 mmol, 1 eq) was added to the nitrosobenzene solution followed by 
AcOH (1.3 mL, 23.3 mmol, 5 eq). After 1h, TLC analysis (SiO2, 1:1 EtOAc/hexanes) 
showed complete azobenzene formation. TFA (4 mL, 53.5 mmol, 12 eq) was added 
and the purple mixture was stirred over night. 100 mL EtOAc were added and the 
organic phase was washed with 30 mL aliquots of 2x 5-M-NaOH, 1-M-NaOH and brine. 
After drying over Na2SO4 and concentrating under reduced pressure, the crude 
material was purified using silica gel chromatography (10% MeOH, 90% DCM, + 1% 
TEA) yielding the product 07 as an orange amorphous solid (668 mg, 2.3 mmol, 49%). 
TLC (SiO2, DCM:MeOH, 1:1 v/v, + 1 % TEA): Rf = 0.55 (UV + ninhydrin stain); 1H NMR (300 
MHz, CDCl3) δ 7.87 – 7.80 (m, 2H), 7.76 (d, J=8.4, 2H), 7.30 (d, J=8.4, 2H), 6.69 (t, J=6.3, 2H), 
5.30 (s, 2H), 3.44 (q, J=7.1, 4H), 3.11 (t, J=7.2, 2H), 2.94 (t, J=7.2, 2H), 1.22 (t, J=7.1, 6H); 13C 
NMR (75 MHz, CDCl3) δ 152.18, 150.05, 143.11, 139.19, 129.38, 125.24, 122.42, 110.96, 
44.67, 42.07, 36.55, 12.66; IR (Diamond-ATR, neat): 3363, 3202, 2964, 2923, 2850, 1660, 
1633, 1601, 1516, 1399, 1140, 820, 801 cm-1; HRMS (EI): [M] calcd. for C18H24N4, 296.2001; 
found, 296.1997. 
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Photo-Amiloride-1 and 2 
 
Pyrazinic acid 4b (18.2 mg, 0.097 mmol, 1.0 eq) was dissolved in anhydrous DMF and 
treated with DIPEA (50 µL, 0.29 mmol, 3.0 eq) followed by HATU (36.7 mg, 0.097 
mmol, 1.0 eq). After stirring at rt for 10 min, respective guanidine (s4 or s5) (30.0 mg, 
0.097 mmol, 1.0 eq) was added as a solid. The reaction mixture was allowed to stir at rt 
for 24 h under N2-atm and was then diluted with 30 mL EtOAc. For removal of DMF, 
the solution was extracted 3x with 10% NaCl(aq). The organic layer was separated, 
dried with NaSO4 and concentrated under reduced pressure. The crude material was 
purified using flash chromatography (Al2O3, gradient 0 to 5% MeOH in CHCl3) affording 
the title compound as an orange oil (34 mg, 0.071 mmol, 73% yield). PA1 was 
transformed to the formic acid (FA) salt using lyophilization of PA1 dissolved in an 
aqueous FA solution. 
 
 
TLC (Al2O3, DCM:MeOH, 9:1 v/v): Rf = 0.60 (UV); 1H NMR (599 MHz, DMSO-d6) δ 8.14 (s, 1H), 
7.87 – 7.79 (m, 4H), 7.58 – 7.52 (m, 2H), 7.52 – 7.47 (m, 1H), 7.43 (s, 2H), 7.24 (s, 2H); 13C 
NMR (101 MHz, DMSO-d6) δ 169.19, 163.71, 155.73, 153.66, 152.56, 151.21, 148.19, 147.64, 
131.20, 129.79, 124.36, 122.83, 122.67, 118.95, 113.15; IR (Diamond-ATR, neat): 3429, 3325, 
3159, 1719, 1683, 1580, 1504, 1417, 1350, 1241, 1096, 763, 678 cm-1; HRMS (m/z): [M+H]+ 
calcd. for C18H16ClN9O, 410.1245; found, 410.1238. 
  
127 
 
 
 
TLC (Al2O3, DCM:MeOH, 9:1 v/v): Rf = 0.64 (UV); 1H NMR (599 MHz, CDCl3) δ 7.86 – 7.79 (m, 
4H), 7.08 (d, J=8.5, 2H), 6.71 (d, J=9.3, 2H), 5.38 (s, 2H), 3.43 (q, J=7.1, 4H), 1.21 (t, J=7.1, 
6H); 13C NMR (151 MHz, CDCl3) δ 154.61, 152.83, 149.77, 149.42, 148.26, 143.19, 124.97, 
123.66, 123.22, 119.74, 113.27, 110.98, 44.65, 12.66, (guanidine and carbonyl signal not 
detected); IR (Diamond-ATR, neat): 3467, 3324, 3182, 2966, 2923, 1639, 1591, 1512, 1393, 
1375, 1251, 1138, 1072, 821 cm-1; HRMS (m/z): [M+H]+ calcd. for C22H25ClN10O, 481.1980; 
found, 481.1967. 
 
 
Photo-amiloride-3 and 4 
 
Guanidine formation (500 mg to 2 g scale).37 Primary amine 06 or 07 (4.44 mmol, 
1.0 eq) was suspended in DMF (5 mL), followed by addition of 1-H-pyrazole-
carboxamidine chloride s9 (775 mg; 5.02 mmol; 1.1 eq) as well as DIPEA (1.7 mL; 
10.2 mmol; 2.3 eq) and the mixture was stirred over night at room temperature. LCMS 
analysis showed quantitative conversion to a less polar species with expected UV/VIS 
spectrum and mass (Agilent 1260 Infinity, C-18, gradient: 20% to 80% MeCN in H2O + 
0.1% formic acid buffer). The crude product was precipitated from the clear, red 
solution by addition of diethyl ether, yielding red oil. Oil and supernatant were 
separated by decantation and the product was dried under high vacuum to yielding the 
corresponding guanidine hydrochloride as an orange solid. 
Acylguanidine formation (20 to 300 mg scale). Freshly prepared guanidine 
hydrochloride described above (1.40 mmol, 2.0 eq) was converted to the free base by 
basic aqueous work up using EtOAc and 5-M-NaOH. After drying under high vacuum, 
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the guanidine was suspended in ethanol (5 mL) followed by addition of pyrazinic ester 
4a (142 mg, 7.01 mmol, 1.0 eq) and the mixture was heated to 100 °C for 48 h. The 
solution was diluted with EtOAc (400 mL), washed with sat. NaHCO3 (3 x 20 mL) and 
brine (1 x 20 mL), dried over Na2SO4 and concentrated by rotary evaporation. The 
crude material was purified using column chromatography, loaded from bulk sorbens 
(SiO2, gradient: 5 % NH3(aq)/MeOH (1:3)	→ 20 % NH3(aq)/MeOH (1:3)/EtOAc). The 
solvent was removed in vacuo and water was added before the product was lyophilized 
yielding PA3 and PA4, respectively, as amorphous orange-red solids (38 % and 15%). 
 
TLC (SiO2, EtOAc:MeOH:NH3(aq), 80:15:5 v/v/v): Rf = 0.69 (UV); 1H NMR (400 MHz, DMSO-d6) 
δ 10.58 (s, 1H), 9.44 (t, J=6.0, 1H), 9.01 (s, 2H), 7.91 – 7.85 (m, 4H), 7.63 – 7.54 (m, 5H), 7.42 
(s, 2H), 3.67 (q, J=13.6, 6.7, 2H), 3.01 (t, J=7.3, 2H); 13C NMR (101 MHz, DMSO-d6) δ 165.77, 
156.35, 154.68, 153.76, 152.35, 151.17, 142.44, 131.86, 130.42, 129.89, 123.10, 122.90, 
120.12, 109.46, 42.37, 34.08; IR (Diamond-ATR, neat): 3286, 3176, 2362, 2339, 1577, 1420, 
1375, 1242, 1155, 1069, 904, 808 cm-1; HRMS (m/z): [M+H]+ calcd. for C20H21ON9Cl, 438.1552; 
found, 438.1549. 
 
 
TLC (SiO2, EtOAc:MeOH:NH3(aq), 80:15:5 v/v/v): Rf = 0.60 (UV); 1H NMR (599 MHz, DMSO-d6) 
δ 8.26 (s, 1H), 7.72 (d, J=9.2, 2H), 7.69 (d, J=8.3, 2H), 7.41 (d, J=8.3, 2H), 6.95 (s, 1H), 6.76 (d, 
J=9.3, 2H), 3.46 (s, 2H), 3.42 (q, J=7.0, 4H), 2.89 (s, 2H), 1.12 (t, J=7.0, 6H); 13C NMR (101 
MHz, DMSO-d6) δ 171.09, 164.83, 158.79, 155.56, 152.68, 151.62, 150.41, 142.51, 140.61, 
130.04, 125.44, 122.22, 118.73, 111.40, 44.47, 42.33, 34.54, 12.93; IR (Diamond-ATR, neat): 
3420, 3309, 3175, 2966, 1678, 1597, 1514, 1425, 1397, 1353, 1245, 1195, 1138, 1076, 1012, 
821, 787, 734 cm-1; HRMS (m/z): [M+H]+ calcd. for C24H29ClN10O, 509.2293; found, 509.2283. 
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Analytical Spectra 
1H-NMR, 4-Nitro-azobenzene s2 
 
1H-NMR, 4-Nitro-azobenzene s3 
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1H-NMR, 4-Amino-azobenzene 02 
 
1H-NMR, Aniline 03  
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1H-NMR, Arylguanidine s4 
13C-NMR, Arylguanidine s4 
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1H-NMR, Arylguanidine s5 
13C-NMR, Arylguanidine s5 
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13C-NMR, pyrazinoic acid 4b 
1H-NMR, Boc-protected amine 05 
 
N
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1H-NMR, primary amine building block 06 
13C-NMR, primary amine building block 06 
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1H-NMR, primary amine 07 
13C-NMR, primary amine 07 
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1H-NMR PA1 
13C-NMR PA1  
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1H-NMR PA2 
 
13C-NMR PA2 
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1H-NMR PA3 
13C-NMR PA3 
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1H-NMR PA4 
13C-NMR PA4 
 
 X-Ray PA1 
 
 
(crystallized from methanl/ethanol by slow 
 
 
  
evaporation at 4 °C) 
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Table 1. 
1. Crystallographic data PA1. This structure is also available at CCDC 976534 
 1 
net formula C19.36H20.73ClN9O2 
Mr/g mol−1 446.934 
crystal size/mm 0.20 × 0.16 × 0.02 
T/K 100(2) 
radiation 'Mo Kα 
diffractometer 'Bruker D8Venture' 
crystal system monoclinic 
space group C2/c 
a/Å 25.833(3) 
b/Å 9.8281(12) 
c/Å 17.894(2) 
α/° 90 
β/° 110.041(4) 
γ/° 90 
V/Å3 4267.9(9) 
Z 8 
calc. density/g cm−3 1.3912(3) 
µ/mm−1 0.217 
absorption correction multi-scan 
transmission factor range 0.8968–0.9579 
refls. measured 36579 
Rint 0.0783 
mean σ(I)/I 0.0459 
θ range 2.40–25.06 
observed refls. 2790 
x, y (weighting scheme) 0.0415, 5.2715 
hydrogen refinement mixed 
refls in refinement 3761 
parameters 327 
restraints 0 
R(Fobs) 0.0399 
Rw(F2) 0.1012 
S 1.006 
shift/errormax 0.001 
max electron density/e Å−3 0.204 
min electron density/e Å−3 −0.225 
 
C-bound H: constr, N- and O-bound H: refall. 
0.36% EtOH, 0.64% MeOH, CH3-group of MeOH disordered. Figure shows EtOH only. 
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IV 
Fotocaine – a new type of Photochromic Ion Channel Blocker 
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Photochromic blockers of voltage gated ion channels are powerful tools for the 
exploration of neuronal systems with high spatial and temporal precision. We now 
introduce fotocaine, a novel type of photochromic channel blocker that is based on 
the long lasting and not permanently charged surface anesthetic fomocaine. 
Fotocaine enables the optical control of action potential firing by switching between 
350 and 450 nm light. 
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Introduction 
Optical methods for investigating neuronal function have boosted neuroscience in 
recent years.1-3 Photoswitchable azobenzene versions of local anesthetics have proven 
to be powerful tools for addressing native voltage gated ion channels4,5 and have been 
used in pain research and vision restoration.6-8 For instance, the doubly-charged QAQ 
and singly-charged DENAQ are in essence derivatives of lidocaine and its permanently 
charged congener QX-314.9 A common feature of these compounds is there permanent 
charge, which may limit their ability to cross biological barriers. In our ongoing efforts 
to develop new and improved photoswitchable ligands, we therefore looked for 
alternative pharmacophores. Local anesthetics research dates back centuries and is a 
very active field of research to date.10-13 Initially, for example the psychoactive alkaloid 
cocaine was used in ophthalmology.14 Novocaine is a representative of the ester local 
anesthetics resembling the anilid local anesthetic lidocaine with a diethylated tertiary 
amine. Our attention was drawn to fomocaine, which is a representative of ether local 
anesthetics with a morpholino group as a pharmacophore that has been used for 
decades as a long-lasting surface anesthetic.14 With its unique structure and function in 
mind, we decided to develop a photoswitchable version of fomocaine. 
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Figure 1. A) Structures of known local anesthetics. Cocaine is a piperidine alkaloid, novocaine 
is a ester local anesthetic and lidocaine is a anilid local anesthetic. All of these compounds 
feature a tertiary amine pharmacophore. QX-314 is a permanently charged derivative of 
lidocaine. Fomocaine is an ether local anesthetic with a morpholino functional group. B) 
Photoswitchable azobenzene derivatives of local anesthetics QAQ and DENAQ that are used 
as photoswitchable blockers of voltage gated ion channels. 
 
 
Results and Discussion 
Fomocaine especially evoked our interest, since it abides to our philosophy of 
“azologization”, i.e. the rational introduction of azobenzenes in drugs (Figure 2). 
Obvious targets for azologization are stilbenes, 1,2-diphenyl ethers, 1,2.diphenyl 
hydrazines, N-benzyl anilines, benzyl-phenyl ethers, benzyl-phenyl thioethers, diaryl 
esters and diaryl amides (Figure 2A). Those “azosters” can be strategically replaced by 
azobenzenes giving access to photoswitchable ligands that highly resemble their 
parent coumpounds in size and shape. We have applied this logic to fomocaine, which 
A
B
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features a benzyl-phenyl ether, by replacing the C-O-bridge with a diazene unit giving 
the azobenzene derivative fotocaine (synthesis see supporting information).  
 
 
 
Figure 2. Azologization. A) Prime isosters of azobenzenes, i.e. azosters, are stilbenes, 1,2-
diphenyl ethers, 1,2.diphenyl hydrazines, N-benzyl anilines, benzyl-phenyl ethers, benzyl-
phenyl thioethers, diaryl esters and diaryl amides. B) Application of the concept of azologization 
to fomocaine. Strategic replacement of the benzyl-phenyl ether bridge by a diazene yields the 
azobenzene derivative fotocaine. 
 
  
fomocaine
stilbenes 1,2-diphenyl ethanes 1,2-diphenyl hydrazines N-benzyl anilines
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We hypothesized that combining the local anesthetics properties of fomocaine with the 
photoisomerization of azobenzenes in this way would yield a photoswitchable ion 
channel blocker. To test fotocaine’s photoswitching properties, we first utilized UV/Vis 
spectroscopy (Figure 3). A 50 µM solution of fotocaine in DMSO was placed in a 
quartz cuvette with 1 cm diameter and illuminated from above using a 
monochromator. The light-induced isomerization of fotocaine and the corresponding 
absorption spectra of cis and trans-isomers are depicted in Figure 3A. As a classical 
azobenzene, isomerization could be followed by monitoring the pi to pi* transition at 
330 nm over time. Switching between 350 nm and 450 nm light reversibly turned the 
molecule into its cis and trans-state, respectively, Figure 3C (i). Wavelengths between 
400 and 360 nm could be used to install mixtures with different cis/trans ratios, Figure 
3C (ii). As expected from an azobenzene devoid of major electronic substituents, the 
thermodynamically less stable cis-state could be maintained in the dark, Figure 3C 
(iii).15,16 Thus, fotocaine provides the desired reversible light-mediated cis/trans-
isomerization. As an added advantage, it stays in its cis-state at least for several 
minutes even without UV-illumination. 
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Figure 3. Photoswitching of fotocaine followed by UV/Vis spectroscopy. A) UV-light (e.g. 350 
nm) isomerizes the azobenzene functional group in fotocaine to its cis-isomer, which is the 
thermodynamically less stable state. Blue light (e.g. 450 nm) triggers isomerization to trans. B) 
Absorption spectra of trans-fotocaine (blue line) and cis-fotocaine (purple line) are distinct. 
The pi to pi* band decreases starkly upon isomerization to cis, while the n to pi* band slightly 
increases. C) In-time photoswitching by following the fotocaine absorption at 330 nm. 
Fotocaine can be reversibly isomerized by switching between, e.g., 450 and 350 nm (i). 
Wavelengths between 400 and 350 nm lead to graded effects (ii). Once switched to cis, 
fotocaine stays in its excited state without further illumination (iii). No decay was detected for 
the investigated time of 10 min. (n = 3, error bar indicates standard deviation) 
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To test if fotocaine provides photoswitching of neuronal function as hypothesized 
above, we investigated dissociated mouse hippocampal neurons using patch clamp 
experiments (Figure 2). Under 450 nm illumination at a starting potential of -80 mV, 
action potential (AP) firing of neurons induced by 50 pA current injection was 
inhibited. When switching to 350 nm, however, AP firing triggered by the same current 
did take place. This process could be repeated reversibly at any desired illumination 
protocol and the same effects were observed when applying 100 µM fotocaine, Figure 
S1. The single action potential at the beginning of each current injection under 450 nm 
indicates that trans-fotocaine acts as an open channel blocker as is the case for its 
permanently charged relatives.9,17 
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Figure 4. Photocontrol of action potential (AP) firing mediated by fotocaine investigated in 
whole cell patch clamp experiments (representative traces). A) Dissociated mouse hippocampal 
neurons, current clamp mode, 50 µM fotocaine. AP-firing was triggered by injecting 50 pA for 
300 ms (cells were held at -80 mV). Under 450 nm (trans-fotocaine), AP-firing was suppressed, 
while and 350 nm illumination (cis-fotocaine), allowed AP-firing. The initial AP under 450 nm is 
indicative of the action of an open channel blocker. B) Acute mouse brain slice, hippocampal 
CA1 neurons, current clamp mode, after 10 min wash-out of fotocaine. 40 pA currents were 
injected and illumination wavelengths were changed simultaneously. Effects of cis- and trans-
fotocaine were identical to A). In addition, when 350 nm or 450 nm were turned off after short 
application, the thereby installed effect maintained. 
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To test the action of fotocaine in vivo and investigate cell both uptake and bistability, 
we performed patch clamp experiments using acute hippocampal mouse brain slices. 
First, the tissue was treated with 100 µM fotocaine for 5 minutes. Then, buffered ringer 
solution was perfused for 10 min to remove the photoswitchable blocker from the 
extracellular solution. As hypothesized and desired by chemical design, fotocaine was 
taken up by the cell and photocontrol of AP firing was possible without extracellular 
fotocaine (Figure 2B). AP firing was triggered by injecting a 40 pA current for several 
seconds and illumination wavelengths where switched during this activation period. 
In line with our observations using dissociated neurons, AP firing was inhibited by 450 
nm illumination and enabled by 350 nm. Furthermore, the bistability that was 
observed during UV/Vis-switching also applied to this physiological experiment. 
When a short pulse of 450 nm or 350 nm light was followed by darkness, the respective 
effect maintained and could be reversed. 
 
Summary and Outlook 
Taken together, we have introduced our philosophy of azologization, which is the 
strategic introduction of azobenzenes in drugs. We have applied this logic to the local 
anesthetic fomocaine and thereby developed the novel photochromic ion channel 
blocker fotocaine. It features a non-permanently charged morpholine functional group 
that provides novel pharmacodynamics compared to existing permanently charged 
photoswitches. We demonstrated that fotocaine gets readily taken up by cells and can 
be used to control action potential firing with light when present extracallularly or 
after cell-loading. Its relatively simple structure will serve as a versatile platform to 
chemically design new photoswitching properties such as cis-stability and red-shifted 
action spectra. As such, fotocaine represents another chemical tool for addressing the 
BRAIN Initiative.18 These investigations and the application of fotocaine in 
neuroscience and vision restoration will be reported in due course.  
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METHODS 
UV/Vis Spectroscopy was performed using a VARIAN Cary 50 Scan UV/Vis 
spectrometer. PCL solution was placed in a standard quartz cuvette (d = 1 cm) 
illuminated by a light fibre cable from above. 
Cell and Tissue Preparation. Dissociated mouse hippocampal neurons were 
prepared and cultured using an astrocyte feeder layer as reported elsewhere.19 For 
acute mouse hippocampal brain slices, BL6 wild type mice (postnatal days 9 to 13) of 
either sex, were quickly decapitated, the brain was removed, and 250 µm horizontal 
slices were prepared using a vibrating microtome (7000smz-2, Campden Instruments). 
Slices were incubated for 30 min at 34°C in carbogenated (5% CO2, 95% O2) sucrose 
medium (mM: 87 NaCl, 2.5 KCl, 7 MgCl2, 0.5 CaCl2, 25 Gluc, 1.25 NaH2PO4, 25 
NaHCO3, 75 sucrose, (319 mOsm)). Slices were perfused with 100 µM Fotocaine in 
bath solution for 5 min, followed by 10 min perfusion with bath solution. Whole cell 
patch clamp recordings where performed on CA1 hippocampal neurons. 
Electrophysiology. Whole cell patch clamp recordings where performed using a 
standard electrophysiology setup equipped with a HEKA Patch Clamp EPC10 USB 
amplifier and patch master software. Micropipettes were generated from “Science 
Products GB200-F-8P with filament” pipettes using a vertical puller (PC-10, Narishige). 
Resistance varied between 5-7 MΩ. Bath solution for dissociated hippocampal neurons 
contained in mM: 140 NaCl, 3 KCl, 2 CaCl2, 1 MgCl2, D-Gluc 10, 20 HEPES (NaOH to 
pH 7.4). Pipette solution for dissociated hippocampal neurons contained in mM: 107 
KCl, 1.2 MgCl2, 1 CaCl2, 10 EGTA, 5 HEPES, 2 MgATP, 0.3 Na2GTP (KOH to pH 7.2). 
Bath solution for acute brain slice contained in mM:  125 NaCl, 2.5 KCl, 1 MgCl2, 2 
CaCl2, 10 Glucose, 1.25 NaH2PO4, 26 NaHCO3, (290 - 295 mOsm). Pipette solution for 
acute brain slice contained in mM: 140 K-gluconate, 4 NaCl, 12 KCl, 10 HEPES, 4 
MgATP, 0.4 Na2ATP (KOH to pH 7.3). Action Potentials (APs) were induced with 50 pA 
current injection. Fotocaine was dissolved in bath solution from a 1000 x DMSO stock 
for either tissue preparation. 
Illumination. Irradiation during electrophysiology and UV/Vis experiments was 
performed using a TILL Photonics Polychrome 5000 monochromator operated by the 
PolyCon software or by the patch clamp amplifier, respectively..  
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ASSOCIATED CONTENT 
Representative traces of AP-firing using different concentrations of fotocaine and 
illumination timing (Figure S1). Synthesis and characterization of organic compounds 
This material is available free of charge via the Internet at http://pubs.acs.org. 
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Figure S1. Optical control of AP firing using 50 µM fotocaine (A) or 100 µM fotocaine (B). APs 
were evoked by 50 pA current injection and enabled or blocked by 350 and 450 nm, 
respectively. 
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Chemical Synthesis 
 
All reactions were performed in oven-dried glassware. All reagents were purchased from 
commercial sources and used without further purification. Chemical shifts (δ) are reported 
using parts per million (ppm) with CDCl3 (δ= 7.26 ppm for 
1
H NMR and δ= 77.0 ppm for 
13
C 
NMR) as an internal reference. 
 
  
Preparation of nitrobenzene (1) 
 
O2N
Cl
1
Cl
0
(52%)
HNO3. H2SO4
C9H10ClNO2
199,63 g/mol  
 
1-chloro-3-phenylpropane 0 (34.9 mmol, 5 mL) was placed in a flame-dried 100 mL round 
bottom flask and cooled to 0°C. A 1:1 mixture of concentrated nitric acid and sulfuric acid (20 
mL) was slowly added. The reaction mixture was stirred for 4 hours and warmed to room 
temperature. The crude product was extracted using dichloromethane (50 mL), dried over 
Na2SO4, and the solvent was removed under reduced pressure. The crude product was purified 
using normal phase column chromatography (SiO2; gradient 0 to 20% EtOAc in Hex) affording 
3.6 g of the desired product as a colorless oil (18 mmol, 52% yield). 
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TLC (SiO2, 8% EtOAc in Hex) Rf = 0.49 (UV) 
1
H NMR (200 MHz, CDCl3) δ = 8.17 (d, J=8.8, 2H), 7.37 (d, J=10.6, 2H), 3.54 (t, J=6.3, 2H), 2.98 – 
2.84 (m, 2H), 2.13 (tt, J=13.1, 6.4, 2H). 
Previously characterized: Baraldi, P., Cacciari,B., Romagnoli, R., Spalluto, G., Monopoli, A., Ongini, E., 
Varani, K., and Borea P. J. Med. Chem. 2002, 45, 115-126 
 
Preparation of azobenzene (2) 
 
 
 
(i) Reduction 
Nitrobenzene 1 (4.0 mmol, 0.800 g) was dissolved in methanol (64 mL) and acetic acid (16 mL) 
was added followed by ammonium formate (20 mmol, 1.28 g). The reaction mixture was 
stirred under nitrogen atmosphere at room temperature and then Pd/C (0.08 mmol, 0.112 g) 
was added. The reaction mixture was stirred for 4 hours or overnight, filtered through celite 
and concentrated to approximately 15 mL. This solution of the crude product was moved on 
directly to the next step. 
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(ii) Mills coupling 
The crude methanolic aniline solution described above was added to a solution of acetic acid 
(16 mL) in dichloromethane (20 mL). Nitrosobenzene (4.0 mmol, 0.430 g) was added and the 
reaction mixture was stirred at room temperature overnight. After concentrating under 
reduced pressure, the crude product was diluted using ethyl acetate. The organic layer was 
washed with distilled water (2 x 15 mL), 1M HCl (2 x 15 mL), 1M NaOH (2 x 15 mL), and brine 
(20 mL), dried over Na2SO4, and the solvent was removed under reduced pressure. The crude 
product was purified using normal phase column chromatography (SiO2; gradient 1 to 3% 
EtOAc in Hex). 650 mg (2.51 mmol, 63% yield) of an orange amorphous solid. 
 
TLC (SiO2, 5% EtOAc in Hex) Rf = 0.51 (UV and Vis) 
IR: ṽ = 3063 (w), 2929 (w), 1601 (w), 1473 (s), 1437 (s), 1328 (w), 1299 (m), 1221 (w), 1154 (m) 
cm
-1
. 
1
H NMR (599 MHz, CDCl3) δ = 7.93 – 7.84 (m, 4H), 7.55 – 7.45 (m, 3H), 7.37 – 7.33 (m, 
2H), 3.56 (t, J=6.4, 2H), 2.89 – 2.85 (m, 2H), 2.14 (dt, J=14.8, 6.4, 2H). 
13
C NMR (151 MHz, CDCl3) δ = 152.68, 151.25, 144.11, 130.81, 129.24, 129.05, 123.03, 
122.74, 44.05, 33.78, 32.63. 
LRMS (ESI): m/z (M+H)+ 259.1. Calculated mass of C15H15ClN2 is 258.09. 
 
 
  
161 
 
Preparation of fotocaine 
 
 
 
Azobenzene 2 (0.9 mmol, 0.233 g) was dissolved in acetonitrile (20 mL) and treated with 
morpholine (9 mmol, 0.776 mL) and diisopropylethylamine (13.5 mmol, 2.40 mL). The reaction 
mixture was stirred at reflux for 48 hours and then concentrated. The crude product was 
diluted using ethyl acetate. The organic layer was washed with distilled water, 1M NaOH, and 
brine, dried over Na2SO4, and the solvent was removed under reduced pressure. The crude 
product was purified using normal phase column chromatography (SiO2; gradient 5 - 15% 
MeOH in CH2Cl2 ). 248 mg (0.8 mmol, 89% yield) of an orange amorphous solid. 
 
TLC (SiO2, 10% MeOH in DCM) Rf = 0.49 (UV and Vis) 
IR: ṽ = 2944 (m), 2854 (m), 2807 (m), 1601 (w), 1499 (w), 1444 (m), 1358 (w), 1304 (w), 1274 
(w), 1168 (s), 1070 (w) cm
-1
. 
1
H NMR (400 MHz, cdcl3) δ = 7.93 – 7.80 (m, 4H), 7.54 – 7.41 (m, 3H), 7.35 – 7.28 (m, 
2H), 3.77 – 3.69 (m, 4H), 2.76 – 2.68 (m, 2H), 2.48 – 2.41 (m, J=4.3, 4H), 2.41 – 2.34 (m, 
2H), 1.86 (dt, J=15.1, 7.6, 2H). 
13
C NMR (101 MHz, cdcl3) δ = 152.69, 151.05, 145.53, 130.71, 129.08, 129.01, 122.89, 
122.69, 66.91, 58.12, 53.65, 33.42, 27.92. 
HRMS: m/z (M+H)+ 310.1916. Calculated mass of C19H23N3O is 309.1919. 
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2
NMR spectra of azobenzenes 2 and fotocaine contain signals of their corresponding 
cis-isomers (“mirrored” peaks, slightly from the major trans-signals). This is a common 
observation and those peaks were not included in integration or peak list. 
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1
H-NMR of fotocaine
 
13
C-NMR fotocaine 
 
 
  
Crystallographic data. fotocaine 
 
 
net formula 
Mr/g mol−1 
crystal size/mm 
T/K 
radiation 
diffractometer 
crystal system 
space group 
a/Å 
b/Å 
c/Å 
α/° 
β/° 
γ/° 
V/Å3 
Z 
calc. density/g cm−3 
µ/mm−1 
absorption correction 
transmission factor range 
refls. measured 
Rint 
mean σ(I)/I 
θ range 
observed refls. 
x, y (weighting scheme) 
hydrogen refinement 
refls in refinement 
parameters 
restraints 
R(Fobs) 
Rw(F2) 
S 
shift/errormax 
max electron density/e Å−3 
min electron density/e Å−3 
 
fotocaine 
C19H23N3O 
309.406 
0.211 × 0.189 × 0.014 
173(2) 
'Mo Kα 
'Bruker D8Quest' 
monoclinic 
P21/c 
29.621(4) 
4.8529(7) 
11.3696(16) 
90 
94.356(3) 
90 
1629.6(4) 
4 
1.2611(3) 
0.080 
multi-scan 
0.8937–0.9580 
18433 
0.0796 
0.0777 
2.76–25.44 
1722 
0.0430, 0.0696 
constr 
2986 
208 
0 
0.0516 
0.1046 
1.017 
0.001 
0.205 
−0.224 
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A Photochromic Agonist for µOpioid Receptors 
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Photofentanyl-1 is a photochromic version of the well-known analgesic fentanyl. It 
is a potent agonist in the dark (or when illuminated with blue light) and looses 
activity when irradiated with UV light. It can be used to optically control the µ-
opioid receptor, converting a G-protein coupled receptor (GPCR) into a 
photoreceptor. As such, it represents a potentially general strategy to convert family 
A GPCRs, other than the rhodopsins, into photoreceptors 
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Introduction 
Opioids have a long cultural and medicinal history and belong to the most useful 
drugs available to humanity. Their best-known member, morphine, has been 
employed since antiquity to alleviate pain and induce euphoria (Fig. 1A).[1, 2] With the 
advent of modern organic chemistry, many synthetic or semisynthetic opioids, such as 
fentanyl, became available, some of which enabled the pharmacological discrimination 
of receptor subtypes.[3, 4] Subsequently, these transmembrane proteins were 
systematically explored through molecular cloning. Today, four human opioid 
receptor (OR) subtypes, viz. δ, µ, κ and NOP, are known, all of which have been 
recently characterized by X-ray crystallography.[5-10] The X-ray structure of a µ−opioid 
receptor (MOR) in conjunction with the covalently bound antagonist β-funaltrexamine 
provided insights into how morphine and its derivatives bind and helped explain 
some of the structure-activity data accumulated over decades (Fig. 1).  
 
 
Results and Discussion 
Opioid receptors belong to the Family A of G-protein coupled receptors (GPCRs), 
which includes many important drug targets.[11-13] GPCRs of this type are closely 
related to the rhodopsin photoreceptors, which enable vision and shape the circadian 
rhythm in humans.[14] The MOR is the major target of morphine and is endogenously 
activated by small peptides, such as Leu-enkephaline (LE), β-endorphin and the 
dynorphins.[15, 16] Upon binding of an agonist, it catalyzes the dissociation of a 
heterotrimeric Gi/o–protein into Gαi and Gβγ subunits (Fig. 1B). The former inhibits 
adenylyl cyclase, resulting in decreased cAMP levels, and the latter activates G-
protein-coupled-inward-rectifying potassium (GIRK) cannels.[17] Both actions translate 
into hyperpolarization and decreased neuronal excitability.[15, 18] 
Given the importance of opioids in medicine and their role in drug abuse, the 
development of new agonists and antagonists for ORs continues to be a very active 
field. One important goal, for instance, is to untangle the analgesic properties of 
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opioids form their euphoric and addictive side effects. Another goal is to take 
advantage of the high precision light provides to elucidate the biological function of 
endogenous opioids and their receptors. Recently, photocaged versions of the 
enkephalins have been used to gain insight into the spatiotemporal scale at which 
neuropeptides act in the brain.[19] A caged version of the antagonist naloxone has been 
employed to reveal opioid deactivation kinetics.[20] To date, however, photoswitchable 
versions of opioids, i.e. compounds that can reversibly turned on and off with light, 
have not been described. We now introduce an azobenzene derivative of the potent 
OR-agonist fentanyl that can be used to optically control MOR in a reversible 
fashion.[21]  
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Figure 1. µ-Opioid (MOR) receptor pharmacology, structure, and function. A) MOR ligands. 
Beta funaltrexamine is a covalently bound agonist. Its binding mode is shown from the 
extracellular side below its molecular formula. Leu-enkephaline is an endogenous ligand, 
whereas morphine and fentanyl is a naturally occurring and synthetic agonist, respectively. B) 
Functional features of MOR. When activated by agonists, MOR acts as a nucleotide exchange 
factor on heterotrimeric Gi/o G-proteins, which results in dissociation of the Gα and Gβγ subunits. 
While Gα has an inhibitory effect on the adenylyl cyclase (AC), the Gβγ complex activates G-
protein coupled inward rectifying potassium channels (GIRK channels). Both modes lead to 
decreased neuronal activity. 
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Although derivatives of morphine were initially considered,[22, 23] fentanyl was 
ultimately chosen as a platform for the design of our photochromic ligands. This was 
due to its potency, its relatively simple structure, and the presence of two aryl rings 
that could be extended to azobenzene photoswitches. As in the design of other 
photochromic ligands (PCLs), the photoswitch had to be installed in such a fashion 
that the biological activity of the ligand was not completely abrogated, whilst aiming 
for a maximum change of its efficacy upon photoisomerization.[21] Scheme 1 shows the 
structure of two candidates, photofentanyl 1 (PF1) and photofentanyl 2 (PF2), which 
we designed, synthesized and evaluated for their biological activities.  
Our synthesis of PF1 started from commercially available N-benzyl piperidone 1, 
which underwent reductive amination with aniline, followed by acylation and 
deprotection to yield piperidine 2 (Scheme 1 and Supporting Information). Reductive 
amination with azobenzene aldehyde 3[24] then provided PF1. The synthesis of PF2 
started from commercially available N-Boc piperidone 5, which underwent reductive 
amination with 4-amino azobenzene 4 to afford 4-amino piperidine 6. Acylation using 
propionic acid anhydride then gave access to propionamide 7. Finally, deprotection 
under acidic conditions, followed by reductive amination of the resulting piperidine 8 
with phenyl acetaldehyde gave PF2.  
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Scheme 1. PCL design and synthesis. A) The known synthetic opiate fentanyl was used as a 
platform for photochromic MOR agonists PF1 and PF2. B) Synthesis of PF1 started from N-
benzyl piperidone 1, which was reductively amminated, N-propionated, deprotected and 
reductively amminated with aldehyde 3. C) Synthesis of PF2 opened with a reductive amination 
followed by propionation, deprotection and another reductive amination.  
 
Preliminary pharmacological testing showed that PF2 is an excellent µOR agonist. PF1, 
on the other hand, lacked MOR agonism at all concentrations. We therefore decided to 
focus on PF2 for further physical and biological characterization. 
Using UV/VIS spectroscopy, we first determined that PF2 has all the hallmarks of a 
“regular” azobenzene (Fig. 2). As shown in Figure 2A, the pi→pi* and n→pi* transitions 
fentanyl photofentanyl_1 photofentanyl_2
A
B
C
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are well separated, allowing for clean photoswitching upon irradiation with 420 nm 
and 340 nm respectively (Fig. S1). PF2 in its cis form was also found to be thermally 
stable in Ringer solution (Fig. 2B). After allowing to relax in the dark for 90 min, no 
back-isomerization to trans was detected. This feature might be helpful in physiological 
or pharmacological experiments were prolonged illumination times might be 
undesired. 
 
 
Figure 2. Photoswitching and thermal stability of PFII. A) Light induced isomerization can be 
followed by UV/Vis spectroscopy. Illumination of a 50 µM PF2 solution in Ringer with different 
wavelengths leads to distinct absorption spectra. B) A solution of PF2 that was previously 
switched to cis stays at this state over hours. 
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We next turned our attention to the functional characterization of PF2. Although 
GPCRs can be assayed with a variety of methods, we decided to use electrophysiology, 
due to its compatibility with optical stimulation protocols (Fig. 3).[26] To this end, 
human MOR was transiently transfected into HEK293t cells together with the G-
protein coupled inward rectifier channels GIRK1 and GIRK2.[17] These channels are 
typical effectors in Gi/o signaling and native signaling partner of MORs in the locus 
coeruleus.[18, 27] Upon testing several concentrations, we found that 25 µM PF2 gave 
optimal results for photoswitching. As shown in Figure 3A, trans-PF2, which 
predominates in the dark or at 420 - 480 nm, acts as an effective agonist of MOR. By 
contrast, cis-PF2 which predominates at 360 nm, is much less active. As a consequence, 
switching from 360 nm to blue light immediately triggers a potassium influx by the 
action of GIRK channels (high external potassium concentrations were applied). This 
process can be terminated by switching back to 360 nm light, which stops MOR 
activation. Thus GIRK currents cease as βγ-G-proteins re-associate with inactive GDP 
bound Gαi/o subunits. Interestingly, GIRK currents evoked by 360 nm through the 
action of PF2 maintain at a plateau and do not sensitize as is the case for certain GPCRs 
and respective agonists.[17]  
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Figure 3. Light-dependent activation of MOR by PF2 . HEK293t cells were transiently 
transfected with the human MOR and both GIRK1 and GIRK2 channels. A) Illuminating a 25 µM 
solution of PF2 with 360 nm light keeps the system in an inactivated state. Switching to 480 nm 
quickly activates the receptor. B) Rapid, repeated photoactivation of GIRK by action of MOR 
and PF2. C) Comparison of photocurrents (consecutive stimulation with a 10 µM solution of the 
native agonist LE (n = 11, one error bar indicates ± SEM). D) Photoswitching can be repeated 
over many cycles without noticeable decrease in photocurrent. 
 
The nature of azobenzene based PCLs allows for multiple repetition of this process at a 
timescale that is dictated by the illumination protocol. For example, photocurrents can 
be evoked by switching from 360 to 440 nm and stopped immediately after reaching 
the maximal current amplitude by illuminating with 360 nm. Comparison between 
photocurrents of three such consecutive fast switching cycles and subsequent 
activation of the same cell with saturating concentration of LE revealed that PF2 is an 
excellent photoswitch (Fig. 3B, C). First, there was no decrease in overall photocurrents 
within a switching cycle despite rapid, consecutive activation (Fig. 3B). In fact, 
photoactivation could be repeated for a arbitrary number of times demonstrating the 
stability of the disclosed system, (Fig 3D). Second, the magnitude of PF2 induced 
photocurrents was in average 80 % of the full LE response (Fig. 3C and S2). Since PF2 
acts as a “trans-agonist”, the pharmacologically active isomer is, at the same time, the 
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thermodynamically more stable one. Therefore, a broad range of wavelengths can be 
applied to induce MOR agonism with light as shown in the action spectrum of PF2 
(Fig. S1). Switching between 360 nm and wavelengths between 400 and 500 nm leads to 
rapid and reliable photoactivation allowing for user-friendly application with 
comparatively simple light sources. In addition, exposure to 360 nm light can be kept 
at a minimum as PF2 provides thermal stability not only in solution (Fig. 2B), but also 
during the pharmacological experiment (Fig. S3). In general, activation and 
deactivation occurred at timescales that can be expected for a metabotropic receptor.[26] 
As azobenzene photoswitching is known to occur on ms timescale or faster[21] and 
MOR ligands dissociate rapidly,[19] it can be assumed that the rate limiting step for the 
presented read out is the signaling cascade between MOR and GIRK by the action of G-
proteins. As such, PF2 provides the first optical tool allowing precise and repeated 
photoactivation of native MORs. The combination of a broad activation spectrum and 
thermal stability further add to its applicability.  
Recently, we described photochromic tethered ligands (PTLs) that are covalently 
attached to Family C GPCRs, viz. metabotropic glutamate receptors.[26] This system, 
termed LimGluR, was used to effectively control neuronal excitability with light. Our 
new results described herein should enable the extension of this concept to family A 
GPCRs. These “LiGPCRs” could provide a valuable alternative to genetically 
encodable light-sensitive GPCRs (Opto-XRs), which are based on a fusion of rhodopsin 
with other Family A GPCRs. [25]  
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Summary and Outlook 
In conclusion, we have developed a method to optically control MORs with a 
photochromic ligand, PF2. In a sense, our PCL imparts the logic of rhodopsin onto a 
light-insensitive family A GPCR. Rhodopsin is a member of this transmembrane 
protein family that uses retinal as covalently bound photoswitchable inverse agonist. 
Our work outlines a potentially general chemical strategy to turn other members of 
Family A GPCRs, such as dopamine receptors or adrenergic receptors, into 
photoreceptors, laying the foundation for a photopharmacology of these targets. PF2 
itself could be used to investigate the role of ORs in various parts of the brain and the 
periphery in a precise spatiotemporal fashion. Its application in neuroscience as well as 
its potential use as a “photoanalgesic” is currently under investigation and will be 
disclosed in due course. 
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Additional Photoswitching Experiments 
 
 
Figure S1. Action spectrum of PF2. At the electrophysiological setup, 360 nm gave the best 
results for switching to cis-PF2. As for switching to the active trans-state, wavelengths between 
420 and 480 nm gave optimal results. (HEK293t cells transiently transfected with hµOR, 
GIRK1/2 and YFP). 
 
 
 
Figure S2. PF2-photoswitching  compared to LE activation. A) HEK293t cells transiently 
transfected with hµOR, GIRK1/2 and YFP were treated with 10 µM PF2 and switched for three 
consecutive cycles. B) The same cell was then perfused with bath solution until PF2 was 
washed out and 10 µM LE were applied. Comparison between the overall LE-current to 
photocurrents S1-3 is shown for 11 cells. 
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Figure S3. Thermal stability of cis-PF2. A) Patch Clamp Recordings. After switching to “cis” 
using 360 nm illumination, PF2 remains in the thermodynamically less stable state. Consecutive 
photoswitching can occur by alternating between 360 nm and blue light. This feature is 
beneficial as illumination times with near-UV light can be minimized. (HEK293t cells transiently 
transfected with hµOR, GIRK1/2 and YFP). B) UV/Vis spectroscopy. A 25 µM solution of PF2 in 
extracellular recording buffer was switched to cis using 360 nm light. The cis-contend was 
nearly unchanged after 30 min incubation at 37 °C. 
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Experimental Procedures 
Cell culture and electrophysiology. HEK293t cells were incubated in dulbeco´s 
minimal essential medium + 10% FBS and splitted at 80 to 90% confluency. For 
detachment, growth medium was removed, cells were washed with calcium free PBS 
buffer and cells were treated with trypsin solution at 37 °C for 2 min. Detached cells 
were diluted with growth medium and singularized by pipetting. For transfection, 
acid-etched coverslips were coated with poly-L-lysin and placed in a 24-well plate. 
50.000 cells were added to each well in 500 µL standard growths medium. DNA (per 
coverslip: 50 ng hµOR, 450 ng GIRK1/2 and 50 ng YFP) was mixed with 1 µL polyplus 
jetprime in 50 µL jetprime buffer. After standing at room temperature for 10-15 min, 
the DNA-mix was added to the cells shortly after seeding them into the 
abovementioned 24-well-plate. After 3-5 hours, medium was exchanged for standard 
growth medium. Cells were used for electrophysiological recordings 24 to 72 hours 
post transfection.  
Whole cell patch clamp experiments were performed using a standard 
electrophysiology setup equipped with a HEKA Patch Clamp EPC10 USB amplifier 
and patch master software. Micropipettes were generated from “Science Products 
GB200-F-8P with filament” pipettes using a vertical puller. Resistance varied between 
5-7 MΩ. Bath solution contained in mM: 140 KCl, 2.6 CaCl2, 1.2 MgCl2, 5 HEPES (KOH 
to pH 7.4). Pipette solution contained in mM: 107 KCl, 1.2 MgCl2, 1 CaCl2, 10 EGTA, 5 
HEPES, 2 MgATP, 0.3 Na2GTP (KOH to pH 7.2).3 
Photoswitchable ligands and reference agonist were dissolved in bath solution from a 
1000 x DMSO stock.  
Irradiation during electrophysiology and UV/Vis experiments was performed using a 
TILL Photonics Polychrome 5000 monochromator. 
  
                                                           
3
 J. L. Leaney, A. Benians, S. Brown, M. Nobles, D. Kelly, A. Tinker, Am J 
Physiol Cell Physiol 2004, 287, C182. 
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Chemicals and Instrumentation 
Commercially available materials were used without further purification. Solvents 
such as ethyl acetate, methanol, dichloromethane and hexane were distilled prior to 
use.  
 
 
 
Abbreviations 
DCM  Dichloromethane 
DMP  Dess Martin Periodinane 
DCE  Dichloroethane 
DIPEA  Diisopropylethylamine 
TEA  Triethylamine 
TFA  Trifluoroacetic acid 
TLC  Thinlayer chromatography 
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Chemical syntheses 
PHOTO-FENTANYL-I 
 
 
Scheme 1. Photo-Fentanyl-I synthesis. 
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Aminopiperidine 2 
 
The synthesis of aminopiperidine 2 was based on a procedure reported in the literature 
and conducted with minor changes.4 (stored as HCl salt) 
TLC (90% CH2Cl2, 10% MeOH +1% Et3N) Rf = 0.25 (UV + ninhydrine) 
1H-NMR (200 MHz, DMSO-d6): δ = 7.47 - 7.44 (m, 3H), 7.21 - 7.17 (m, 2H), 4.59 – 4.44 
(m, 1H), 2.92 - 2.86 (m, 2H), 1.80 (q, J = 7.5 Hz, 2H), 1.66 - 1.61 (m, 2H), 1.08 (m, 2H), 
0.87 (t, J = 7.4 Hz, 3H). 
 
Phenethylalcohol 5 
 
 
4-Aminophenethylalcohol 3 (0.647 g, 4.91 mmol, 1.0 eq) and nitrosobenzene 4 (0.526 
g, 4.91 mmol, 1.0 eq) were dissolved in dichloromethane (10 mL) and treated with 
acetic acid (1.50 mL, 26.2 mmol, 5.42 eq). The reaction mixture was stirred for 
overnight, diluted with EtOAc and washed with 1 M HCl (2 x 25 mL), 1 M NaOH (2 x 25 
mL) and brine (2 x 25 mL). The organic layer was separated, dried over Na2SO4 and 
concentrated using rotary evaporation yielding the title compound 5 as an orange 
powder (1.104 g, 4.88 mmol, 99% yield). Analytical data matched those reported 
previously.5 
 
TLC (50% EtOAc, 50% hexanes) Rf = 0.50 (UV)  
                                                           
4
 Lee, Y. S., J. Nyberg, et al. (2007). "Understanding the structural requirements 
of 4-anilidopiperidine analogues for biological activities at µ and δ opioid 
receptors." Bioorganic &amp; Medicinal Chemistry Letters 17(8): 2161-2165. 
5
 Yu, B.-C., Y. Shirai, et al. (2006). "Syntheses of new functionalized azobenzenes for potential 
molecular electronic devices." Tetrahedron 62(44): 10303-10310. 
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1H NMR (200 MHz, CDCl3) δ = 7.97 – 7.82 (m, J=8.2, 4H), 7.58 – 7.44 (m, J=7.4, 3H), 
7.38 (d, J=8.2, 2H), 3.92 (t, J=6.5, 2H), 2.95 (t, J=6.5, 2H). 
 
Photo-Fentanyl-1 (PF1) 
 
Fresh Aldehyde Preperation 
Alcohol 5 (50 mg, 0.221 mmol, 1.0 eq) was dissolved in 1 mL DCM and DMP (187 mg, 
0.44 mmol, 2.0 eq) was added. The reaction mixture was diluted with EtOAc after 3 h 
and subsequently extracted with concentrated Na2S2O3(aq), 1-M-NaOH and brine. The 
organic layer was dried over Na2SO4 and concentrated in vacuo. 
Reductive Amination 
The HCl salt of aminopiperidine 2 (63 mg, 0.22 mmol, 1.0 eq) was dissolved in 1 mL 
DCE and DIPEA (115 µL, 0.66 mmol, 3.0 eq). The freshly prepared aldehyde 
(described above) was added as a solution in 2 mL DCE before NaHB(OAc)3 was 
added. The reaction suspension was stirred under N2-atm at rt overnight before being 
quenched by partitioning between EtOAc and concentrated NH4Cl(aq). The organic layer 
was further washed with 1-M-NaOH(aq), concentrated NaHCO3(aq) and brine. 
Evaporation of the solvent yielded the crude product, which was purified using silica gel 
chromatography (isogratic, 50% EtOAc, 50% hexanes + 1% TEA) affording the title 
compound PF1 as an orange oil (65 mg, 0.15 mmol, 67%). 
TLC (SiO2, 50% EtOAc, 50% hexanes) Rf = 0.17 (UV). 
1H NMR (400 MHz, CDCl3) δ = 7.92 – 7.84 (m, 2H), 7.84 – 7.78 (m, 2H), 7.54 – 7.42 
(m, 3H), 7.42 – 7.31 (m, 3H), 7.30 – 7.25 (m, 2H), 7.10 – 7.03 (m, 2H), 4.68 (tt, J=12.2, 
3.9, 1H), 2.99 (d, J=11.6, 2H), 2.78 (dd, J=10.0, 6.4, 2H), 2.60 – 2.52 (m, 2H), 2.17 (dd, 
J=11.9, 10.0, 2H), 1.98 – 1.86 (m, 2H), 1.80 (d, J=13.4, 2H), 1.51 – 1.34 (m, 2H), 1.05 
– 0.96 (m, 3H). 
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13C NMR (101 MHz, CDCl3) δ = 173.52, 152.64, 151.10, 143.76, 138.79, 130.76, 
130.39, 129.32, 129.28, 129.03, 128.26, 122.93, 122.72, 60.07, 53.09, 52.09, 33.71, 
30.54, 28.51, 9.62. 
HRMS (ESI) calcd for C28H33N4O [M+H]+: 441.2654; found: 441.2644. 
UV/VIS λmax (pi to pi*)= 325 nm. 
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Analytical Spectra PF1 
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PHOTO-FENTANYL-2 
 
Scheme 1. Photo-Fentanyl-2 synthesis. 
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1-nitro-4-nitrosobenzene I 
 
To a solution of 4-nitroaniline 7 (5.94 g, 43.0 mmol, 1.0 equiv) in CH2Cl2 (150 mL) was 
added Oxone (potassium peroxymonosulfate, 26.4 g, 43.0 mmol, 1.0 equiv) as a 
solution in H2O (150 mL). The green, biphasic suspension was allowed to stir under N2 
atmosphere. After 3 hours, organic and aqueous phases were separated. The aqueous 
phase was extracted 2x with CH2Cl2 (30 mL aliquots). Pooled organic phase was 
washed with 1x 1 M HCl, 1x sat. NaCl (75 mL aliquots). The organic phase was then 
dried over Na2SO4 and concentrated to 30 mL under reduced pressure. The resulting 
yellow-black solution of I in CH2Cl2 was carried on to the next step immediately, without 
characterization. 
 
1-(4-nitrophenyl)-2-phenyldiazene 8 
 
To a solution of I (6.53 g, 43.0 mmol, 2.0 equiv) in CH2Cl2 (30 mL) was added 
sequentially aniline 7 (1.96 mL, 21.5 mmol, 1.0 equiv) and glacial AcOH (6.15 mL, 
107.5 µL, 5.0 equiv). The yellow-black solution was allowed to stir for 15 hours under 
N2 atmosphere, after which time the reaction mixture was found to be an orange-black 
suspension. The reaction was diluted with EtOAc (150 mL) and washed with 3x 1M 
NaOH, 2x sat. NaHCO3, 2x sat. NaCl (50 mL aliquots). The organic phase was then 
dried over Na2SO4 and solvent removed under reduced pressure. Crude material was 
purified by flash column chromatography (silica gel, dry loading on bulk sorbent, 
gradient 1% → 5% →10% EtOAc in Hexanes), affording compound 8 (4.765 g, 21.0 
mmol, 98%), as an orange solid.  
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TLC (SiO2, 10% EtOAc, 90% hexanes) Rf = 0.55 (UV) 
HRMS (EI) calcd for C12H9N3O2 [M]+˙: 227.0695; found: 227.0693 
1H NMR (400 MHz, CDCl3) δ 8.46 – 8.28 (m, 2H), 8.06 – 7.99 (m, 2H), 7.99 – 7.91 (m, 
2H), 7.58 – 7.49 (m, 3H). 
 
13C NMR (101 MHz, CDCl3) δ 155.68 , 152.36 , 148.69 , 132.36 , 129.26 , 124.69 , 
123.39 , 123.37. 
 
 
4-(phenyldiazenyl)aniline 9 
 
To a solution of 8 (2.08 g, 9.16 mmol, 1.0 equiv) in 3:1 THF:H2O (120 mL) was added 
Na2S (2.14 g, 27.5 mmol, 3.0 equiv). The red-black suspension was allowed to stir for 
3h hours at reflux, at which point TLC monitoring indicated the reaction had reached 
completion. THF was removed under reduced pressure, and the remaining aqueous 
material diluted with EtOAc (150 mL) and 1M NaOH (50 mL). The organic phase was 
isolated and washed with 1x 1M NaOH, 1x sat. NaHCO3 and 1x brine (50 mL aliquots). 
An orange precipitate was removed through vacuum filtration, the filtrate dried over 
Na2SO4 and solvent removed in vacuo, affording 9 as a dark orange solid (1.568 g, 7.95 
mmol, 87%).  
TLC (SiO2, 20% EtOAc, 80% hexanes) Rf = 0.25 (UV) 
HRMS (EI) calcd for C12H11N3 [M]+˙: 197.0953; found: 197.0953 
1H NMR (300 MHz, CDCl3) δ 7.89 – 7.75 (m, 5H), 7.54 – 7.33 (m, 2H), 6.82 – 6.69 (m, 
2H), 4.04 (s, 2H). 
 
13C NMR (75 MHz, CDCl3) δ 152.94 , 149.53 , 145.56 , 129.78 , 128.95 , 125.09 , 
122.32 , 114.61  
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tert-butyl 4-((4-(phenyldiazenyl)phenyl)amino)piperidine-1-carboxylate 11 
 
To a solution of 10 (500 mg, 2.51 mmol, 1.0 equiv) was added sequentially 9 (520 mg, 
2.63 mmol, 1.05 equiv), Na(AcO)3BH (745 mg, 3.51 mg, 1.4 equiv) and glacial AcOH 
(144 µL, 2.51 mmol, 1.0 equiv). The bright-orange reaction mixture was allowed to stir 
overnight. After 15 hours, TLC monitoring indicated complete consumption of 10, and 
the reaction mixture appeared to have become a suspension. The reaction mixture was 
diluted with EtOAc (125 mL) and washed with 2x 1M NaOH, 1x sat. NaHCO3, 1x sat. 
NaCl (50 mL aliquots). The organic phase was dried over NasSO4 and solvent removed 
under reduced pressure. Crude material was purified by normal phase chromatography 
on a Biotage Isolera system (Chromabond 120 g SiOH cartridge, 3% → 30% linear 
gradient EtOAc in hexanes over 10 column volumes), affording 11 as a bright orange 
solid (534 mg, 1.40 mmol, 56%).  
TLC (SiO2, 40% EtOAc, 60% hexanes) Rf = 0.63 (UV) 
HRMS (ESI) calcd for C22H28N4O2 [M+H]+: 381.2285; found: 381.2285 
1H NMR (599 MHz, CDCl3) δ 7.89 – 7.78 (m, 4H), 7.47 (t, J = 7.7 Hz, 2H), 7.38 (t, J = 
7.3 Hz, 1H), 6.66 (d, J = 8.4 Hz, 2H), 4.29 – 3.87 (m, 3H), 3.59 – 3.50 (m, 1H), 2.96 (t, 
J = 12.6 Hz, 2H), 2.14 – 1.98 (m, 2H), 1.48 (s, 9H), 1.43 – 1.34 (m, 2H). 
 
13C NMR (151 MHz, CDCl3) δ 154.71, 153.00, 149.44, 144.71, 129.55, 128.93, 125.32, 
122.20, 112.58, 79.74, 49.99, 42.63, 32.21, 28.43.  
IR νmax: 3341, 2975, 2929, 2857, 1674, 1601, 1518, 1428, 1410, 136, 1338, 1316, 
1274, 1234, 1170, 1137, 1096, 868, 829, 767, 690 
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tert-butyl-4-(N-(4-(phenyldiazenyl)phenyl)propionamido)piperidine-1-carboxylate 
12 
 
To a solution of 11 (200 mg, 0.526 mmol, 1.0 equiv.) in dry toluene (5.0 mL) was added 
sequentially DMAP (128 mg, 1.05 mmol, 2.0 equiv), Et3N (365 µL, 2.63 mmol, 5.0 
equiv.) and propionanhydride (137 µL, 1.05 mmol, 2.0 equiv.). The bright orange 
reaction mixture was allowed to stir for 15 hours under N2 atmosphere, after which time 
the reaction was purified directly by flash column chromatography (silica gel, 
gradient10% → 20% → 30% → 40% EtOAc in hexanes) affording 12 as an orange oil  
(123 mg, 0.282 mmol, 54%). Yield based on recovered starting material: 73%.  
TLC (SiO2, 40% EtOAc, 60% hexanes) Rf = 0.36 (UV) 
HRMS (ESI) calcd for C25H32N4O3 [M+Na]+: 459.2367; found: 459.2367 
1H NMR (400 MHz, CDCl3) δ 7.99 – 7.89 (m, 4H), 7.58 – 7.47 (m, 3H), 7.25 – 7.19 (m, 
2H), 4.80 (tt, J=12.7, 3.8, 1H), 4.12 (s, 2H), 2.80 (t, J=12.0, 2H), 1.99 (q, J=7.4, 2H), 
1.80 (d, J=13.7, 2H), 1.41 (s, 2H), 1.38 (s, 9H), 1.04 (t, J=7.4, 3H). 
 
13C NMR (101 MHz, CDCl3) δ 212.92, 173.23, 154.46, 152.46, 152.14, 140.99, 131.51, 
131.06, 129.17, 123.67, 122.99, 79.57, 52.51, 43.19, 30.59, 28.65, 28.34, 9.56. 
 
IR νmax: 3061, 3026, 2935, 2805, 2766, 1656, 1596, 1498, 1449, 1374, 1340, 1258, 
1242, 1149, 1093, 1053, 1018, 981, 928, 862, 772, 749, 700, 689 
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N-(4-(phenyldiazenyl)phenyl)-N-(piperidin-4-yl)propionamide 13 
 
12 (102 mg, 0.234 mmol) was treated with a 1:1 mixture of TFA:DCM (2.0 mL). After 1 
h, TLC monitoring indicated complete deprotection of 12. The reaction mixture was 
cooled to 0 °C and quenched with 1 M NaOH. Combined organic and aqueous phase 
were transferred to a separatory funnel and aqueous phase removed. The organic 
phase was then washed with 1x 1M NaOH, 1x sat. NaHCO3 and 1x brine (5 mL 
aliquots). Organic phase was dried of Na2SO4 and solvent removed in vacuo, affording 
13 as an orange oil (74 mg, 0.220 mmol, 94%).  
TLC (SiO2, 10% MeOH, 90% DCM), Rf = 0.12 (UV) 
HRMS (ESI) calcd for C22H28N4O2 [M+H]+: 381.2285; found: 381.2285 
1H NMR (400 MHz, CDCl3) δ 7.97 – 7.89 (m, 4H), 7.56 – 7.46 (m, 3H), 7.24 – 7.20 (m, 
2H), 4.83 – 4.70 (m, 1H), 3.10 (d, J=12.2, 2H), 2.75 (td, J=12.4, 2.2, 2H), 2.53 (s, 1H), 
1.98 (q, J=7.4, 2H), 1.84 (d, J=13.6, 2H), 1.34 (qd, J=12.4, 4.2, 2H), 1.03 (t, J=7.4, 3H). 
 
13C NMR (101 MHz, CDCl3) δ 173.11, 152.46, 152.06, 141.17, 131.45, 131.11, 129.15, 
123.62, 122.98, 52.45, 45.89, 31.59, 28.67, 9.58. 
 
IR νmax: 3421, 2938, 2817, 2726, 2493, 1651, 1596, 1499, 1461, 1377, 1265, 1154, 
1099, 1071, 1039, 1012, 864, 808, 772, 690 
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Photo-Fentanyl-2 
 
DMP Oxidation 
A suspension of DMP (189 mg, 0.446 mmol, 3.0 equiv.) was cooled to 0 °C. To this 
was added phenethyl alcohol 14 (26.7 µL, 0.223 mmol, 1.5 equiv.) and the reaction 
was allowed to stir at RT under N2 atmosphere. TLC monitoring at 1 hour indicated 
complete consumption of 14. The reaction mixture was transferred to a separatory 
funnel and diluted with EtOAc (15 mL). Organic phase was washed with 1x sat. 
NaS2O3, 1x 1M NaOH, 1x brine (5 mL aliquots). Organic phase was then dried over 
Na2SO4 and solvent removed under removed pressure, affording phenylacetaldehyde II 
as a fragrant, colourless oil (100% conversion assumed). II was carried on to the next 
step immediately without characterization.  
Reductive Amination 
To a solution of 13 (50 mg, 0.149 mmol, 1.0 equiv.) in DCE (1.0 mL) was added II 
(0.223 mmol, 1.5 equiv.) as a solution in DCE (1.5 mL). To this was added 
Na(AcO)3BH (189 mg, 0.892 mmol, 6.0 equiv.) The bright orange suspension was 
allowed to stir for 15 hours at RT under N2 atmosphere. TLC monitoring at this time 
indicated near-complete consumption of 13. The reaction was transferred to a 
separatory funnel and diluted with EtOAc (15 mL). Organic phase was washed with 2x 
1 M NaOH, 1x sat. NaHCO3, 1x brine (5 mL). Organic was dried over Na2SO4 and 
solvent removed in vacuo. Crude material was purified by column chromatography 
(silica gel, gradient 1% → 2% →4% → 6% → 8% MeOH in DCM) affording PF2 as an 
orange oil (46 mg, 0.104 mmol, 70%). Yield based on recovered starting material: 81%.  
TLC (SiO2, 10% MeOH, 90% DCM) Rf = 0.38 (UV) 
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HRMS (ESI) calcd for C28H32N4O [M+H]+: 441.2649; found: 441.2649 
1H NMR (300 MHz, CDCl3) δ 8.00 – 7.88 (m, 4H), 7.61 – 7.46 (m, 2H), 7.31 – 7.21 (m, 
5H), 7.21 – 7.09 (m, 3H), 4.80 – 4.61 (m, 1H), 3.12 – 2.93 (m, 2H), 2.80 – 2.65 (m, 2H), 
2.64 – 2.46 (m, 2H), 2.29 – 2.09 (m, 2H), 2.00 (q, J = 7.4 Hz, 2H), 1.86 (ddd, J = 11.8, 
4.4, 2.3 Hz, 2H), 1.50 (qd, J = 14.0, 13.1, 4.6 Hz, 2H), 1.05 (t, 3H). 
 
13C NMR (75 MHz, CDCl3) δ 173.24, 152.50, 152.09, 141.16, 140.13, 131.42, 131.19, 
129.14, 128.60, 128.36, 126.02, 123.61, 122.99, 60.35, 53.05, 52.48, 33.75, 30.58, 
28.68, 9.59. 
 
IR νmax: 3061, 3026, 2935, 2805, 2766, 1656, 1596, 1498, 1449, 1374, 1340, 1258, 
1242, 1149, 1093, 1053, 1018, 862, 772, 749, 700, 689  
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Analytical Spectra6 
1H-NMR, 8 
 
 
13C-NMR, 8 
 
                                                           
6
 NMR spectra of trans-azobenzenes may include minor signals from their cis-
isomers. For clarity, these are not included in the integration or peak list. 
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Photochromic Agonists for Dopamine Receptors 
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Dopamine receptors (DRs) play a major role in human health and disease, being 
involved in learning, motivation and addiction. All DRs belong to the family A of 
G-protein coupled receptors that also includes rhodopsin, which is operated by light 
through the action of a photoswitchable terpene. We now show how DRs can be 
operated by light using a photoswitchable azobenzene version of the known DR-
agonist PPHT. Racemic and enantiomerically pure photochromic ligands have been 
synthesized and tested on both D2 and D3 receptors using a bioluminescence assay. 
One candidate showed pronounced light dependent changes in potency as well as 
efficacy at the D3R.  
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Introduction 
Dopamine Receptors and GPCRs. Dopamine receptors (DRs) belong to the family 
A of G-protein coupled receptors (GPCRs) that also includes rhodopsin, serotonin 
receptors, muscarinic AChRs, opioid receptors among others.1 GPCRs assemble the 
largest family of transmembrane signaling proteins in the human genome and are a 
prominent drug target.2-4 Their name has been coined based on their function as 
guanidine nucleotide exchange factors on heterotrimeric G-proteins. When activated 
by an agonist, GPCRs catalyze the exchange of GDP to GTP at the alpha subunit of 
heterotrimeric G-proteins. As a consequence, the Gα subunit dissociates from the Gβγ 
complex. Both remnants stay attached to the membrane and trigger individual 
signaling cascades. For instance, the Gβγ complex activates G-protein coupled 
inwardly rectifying potassium (GIRK) channels leading to hyperpolarization of the 
cell.5,6 The Gα subunit can in turn activate (Gαs) or inhibit (Gαi) the adenylyl cyclase, or 
activate phospholipase C (Gαq). Generally, heterotrimeric G-proteins are named after 
the action of their Gα subunit. For example, Gs would be a G-protein consisting of 
Gαsβγ.  
In addition, GPCRs can trigger G-protein independent signaling. For instance, after 
phosphorylation, GPCRs attract arrestins, which prevent further G-protein signaling, 
lead to receptor internalization and prompt individual signaling cascades.7-9 
Many GPCRs display basal activity that can be modulated by different types of 
ligands. An agonist would amplify the basal activity, an inverse agonist would reduce 
it and an antagonist would leave it unchanged while impeding agonists and inverse 
agonists to come to action. Noteworthy, since GPCRs are incredibly versatile signaling 
machines, different agonists can bias certain signaling pathways.10-12 
In the nervous system, DRs are expressed in both presynaptic and postsynaptic 
membranes. They can be divided into activating D1-like receptors (D1 and D5), which 
couple predominantly to Gs G-proteins, and deactivating D2-like receptors (D2, D3 and 
D4), which couple to Gi G-proteins (Figure 1A).13  
Upon synaptic activity, dopamine (DA) (Figure 1A) is released into the synaptic cleft 
by calcium induced vesicle release. DA-signaling is terminated by two major 
mechanisms. First, DA binds to D2-like autoreceptors at the presynaptic cell, leading to 
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hyperpolarization and therefore inhibition of further vesicle release. Second, DA-
transporters guide the catecholamine back into the presyanptic cell, where it is 
metabolized by monoamine oxidases. 
DRs at the postsynaptic side can be activating or deactivating. In general, DA has an 
inhibitory effect on the nervous system due to a predominance of D2-like receptors.14 
Due to the high sequence similarity in the ligand binding pocket, D2 and D3 receptors 
are difficult to differentiate pharmacologically and are often referred to as D2/3 
receptors (D2/3Rs).15 In 2010, the first X-ray structure of a dopamine receptor, viz D3R 
with its antagonist eticlopride, was disclosed (Figure 1A).16  
Dopamine Receptor Ligands. Given the tremendous impact of DRs in human 
health and disease, as well as their role in addiction and drug abuse,17 many synthetic 
DR-ligands have been developed (Figure 1A)13,18. Racemic N-alkylated aminotetraline 
7-OH-DPAT is a D2/3R-agonist with slight preference towards D3R.19 The indolinone 
ropinirol has a similar pharmacological profile as the native ligand DA and is used for 
the treatment of Parkinson´s disease.20 Apomorphine is non-selective DR-agonist that 
is derived from the opioid morphine, but lacks opioid activity.21 PPHT structurally 
resembles 7-OH-DPAT and is also used as a racemate.22 Even though being based on 
different molecular platforms, all of the listed agonists display features of DA, in 
particular a phenethylamine moiety.  
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Figure 1. Dopamine receptor, ligands and design of a photochromic ligand (PCL). A) X-ray 
structure of a D3 dopamine receptor co-crystallized with eticlopride (D3R, pdb 3PBL) from top 
view and table of DR-subtypes and their primary G-protein coupling partners. D1 and D5 have 
an activating effect and are referred to as D1-like. D2-4 have an inhibitory effect and are referred 
to as D2-like.23 B) D2/3R agonists. DPAT = dipropyl-aminotetraline, PPHT = phenethyl-propyl-
hydroxytetraline. C) Isomerization of a photoswitchable version of PPHT called aPPHT. 
 
  
dopamine
(DA)
eticlopride
apomorphine
ropinirol
PPHT NBD-PPHT
7-OH-DPAT
A
B
C
trans- aPPHT cis- aPPHT
receptor G-protein
D1
D2
D3
D4
D5
Gs/olf
Gi/o
Gi/o
Gi/o
Gs/olf
classif ication
D1-like
D1-like
D2-like
210 
 
Results and discussion 
PCL design and synthesis. To broaden the reach of photopharmacology and 
develop novel optical tools for investigating DRs with high spatiotemporal precision,24 
PPHT was chosen as a platform for photochromic DR agonists. Derivatives such as 
NBD-PPHT demonstrate tolerance for aromatic substitution at the 4´-position of the 
pendent phenethyl moiety.25 We therefore designed azobenzene versions of PPHT 
called aPPHT as depicted in Figure 1C. 
To furnish photoswitchable PPHT derivatives as photochromic ligands (PCLs) for DRs, 
different synthetic strategies were established, each having individual advantages. The 
first synthesis led to racemic aPPHT. Commercial tetralone 1 underwent reductive 
amination with building block 2 that was known from our previous syntheses.(chapter III) 
The resulting secondary amine was obtained after aqueous work-up and applied to 
another reductive amination with propanal.  
 
 
Scheme 1. Synthesis of racemic aPPHT. 
 
Even though the parent compound PPHT is used as a racemate, it is known from 
similar DR-agonists such as 5-OH-DPAT that enantiomers can drastically differ in 
pharmacodynamics.26 Accordingly, alternative routes with enantiomerically pure 
aminotetralins were developed. Bakthavachalam et al. developed a synthesis for (R) 
and (S)-PPHT derivatives in 1991 that served as a platform for our approach (Scheme 
2A).25 Permethylation of dihydroxy naphthalene 3 was followed by reduction using 
sodium in ethanol. The resulting methyl enol ether was cleaved during acidic work-up 
and tautomerized to the corresponding tetralone. Reductive amination with 
benzylamine gave rise to amino tetraline 4.  
  
1 2 aPPHT
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Benzylamine delivers the nitrogen for future aPPHT molecules and furthermore 
enables crucial pi−pi-interactions in the subsequent chiral resolution using toluoyl 
tartaric acid derivatives. A crystal structure of the diastereomeric salt I is shown in 
Scheme 2B, demonstrating a strong complex of two pi−pi-interactions and a hydrogen 
bond network that is orchestrated by an additional water molecule. 
 
Scheme 2. Enantiomerically pure aminotetraline building blocks. A) Synthesis started from 
dihydroxy naphtaline 3 that was functionalized to racemic 4 in three steps. Precipitation with 
tartaric acid derivatives was used for resolution of the enantiomers. B) Crystal and X-ray 
structure of the tartaric acid/aminotetraline complex I demonstrates the desired stereochemistry. 
Dotted red lines indicate pi-stacking, dotted blue lines indicates hydrogen bonding. 
 
To furnish the target molecules (R)-aPPHT and (S)-aPPHT, two approaches were 
followed (Scheme 3). First, (R)-5 was propylated and deprotected yielding amino 
tetraline (R)-6 (Scheme 3A). Amide coupling with 7 followed by reduction and 
demethylation gave rise to known aniline (R)-825,27 that served as a nucleophile for a 
consecutive Mills reaction with nitrosobenzene yielding (R)-aPPHT. Employing aniline 
≡
*
*
B
A
3 4 (R)-5
(S)-5
I
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(R)-8 as an azobenzene precursor allows preparing many differently substituted 
aPPHT-derivatives in just one step.  
 
Scheme 3. Synthesis of chiral aPPHTs.  
 
To offer an alternative, more modular synthesis, the order of functional group 
modification after chiral resolution was changed employing an azobenzene building 
block was (Scheme 3B). Starting from secondary amine (S)-6 (Scheme 3B), O-
demethylation was followed by reductive amination with freshly prepared aldehyde 
928 giving (S)-aPPHT. 
A
B
(R)-5 (R)-6
(R)-8 (R)-aPPHT
7
(S)-aPPHT(S)-6 9
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Figure 2. BRET-Assay of aPPHTs.7 A) DR read-out via bioluminescence resonance energy 
transfer (BRET). B) Representative dose-response curves on D3R. DA (black line), PPHT (red 
line), and (S)-aPPHT with (blue line) and without (green line) UV-pre-illumination. C) 
Comparison of potency change after pre-illumination. Black bars indicate the EC50-ratio using 
D3R, white bars using D2R. Potency of (S)-aPPHT changes most drastically after pre-
illumination, especially on D3R. D) Comparison of maximal efficacy after pre-illumination. (S)-
aPPHT activates D3R 40% more when pre-illuminated with UV-light. (Error bars indicate SEM, 
n = 3). 
 
With racemic aPPHT and its single enantiomers in hand, it was next tested if the novel 
PCLs trigger the guanine nucleotide exchange factor activity of DRs. Therefore, an 
assay that is based on a bioluminescence resonance energy transfer (BRET)1 between 
the Gα and Gβγ-subunit of heterotrimeric G-proteins was employed (Figure 2A).15 
Binding of a DR-agonist stabilizes a receptor conformation that catalyzes the exchange 
of GDP for GTP at G-proteins. The consequential dissociation of the heterotrimeric 
                                                           
7
 All BRET-data were acquired and analyzed by Prashant Donthamsetti from 
Columbia University (Javitch research group)  
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protein complex leads to an increased distance between Gα and Gβγ-subunits and 
therefore a reduced BRET signal. Corresponding dose-response curves of DA and 
PPHT are depicted in Figure 2B (black and red line respectively. D3R and (S)-aPPHT 
are chosen as an example). In comparison to these known agonists, dark adapted, i.e. 
trans-enriched, (S)-aPPHT showed both lower potency and efficacy (Fig 2B, green line).  
Addressing the photoswitching properties of aPPHTs in-time was not compatible with 
the BRET-assay. However, we relied on the thermal stability of alkylated cis-
azobenzenes and performed the identical experiment with a solution of the 
photoswitch that was pre-illuminated with UV-light, i.e. cis-enriched (Figure 2B, blue 
line, (S)-aPPHT as an example). Compared to the dark adapted compound, cis-(S)-
aPPHT has not only improved potency, but also efficacy. 
While the experimental setup did not allow in-time investigation of reversible 
photoswitching, it was capable of outlining important trends and allows comparing 
different PCLs and receptors. All molecules – aPPHT, (R)-aPPHT and (S)-aPPHT – 
were compared for their ability to change their potentcy and efficacy on both D2R and 
D3R after UV-pre-illumination. (S)-aPPHT provides the most pronounced change in 
potency with a 4-fold lower EC50 at D2R and 6-fold lower at D3R after UV-pre-
illumination (Figure 2C). Advantageously, the combination of (S)-aPPHT and D3R also 
leads to the highest change in efficacy with a 40% higher receptor activation after cis-
enrichment (related to full DA-activation, Figure 2D). Interestingly, both enantiomers 
change their efficacies in the opposite direction when comparing D2R and D3R. For the 
former, the maximal effect is reduced after pre-illumination, while for the latter it is 
enhanced. These valuable insights demonstrated that there is a significant difference 
between the aPPHT enantiomers. (S)-aPPHT provides the biggest change in both 
potency and efficacy when comparing trans and cis-enriched solutions, in particular at 
the D3R.  
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Summary and Outlook 
 We have developed photochromic ligands for dopamine receptors. Racemic 
and enantiomerically pure azobenzene derivatives of PPHT (aPPHTs) have been 
synthesized. Preliminary testing using a BRET assay has identified (S)-aPPHT as a 
promising candidate for switching the dopamine D3 receptor with light. Future 
electrophysiological testing will reveal the full potential of (S)-aPPHT. 
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Abbreviations 
DR    Dopamine receptor 
AChR    Acetylcholine receptor 
GPCR    G-Protein coupled receptor 
GDP    Guanosine diphosphate 
GTP    Guanosine triphosphate 
GIRK    G-Protein coupled inwardly rectifying potassium 
DA    Dopamine  
DPAT    Dipropyl aminotetraline 
PPHT    Propyl phenethyl aminotetraline 
PCL    Photochromic ligand 
NBD    Nitrobenzoxadiazole 
aPPHT   Azo-PPHT 
TEA    Triethylamine 
DIPEA   Diisopropyl ethyl amine 
BRET    Bioluminescence resonance energy transfer 
 DCM    Dichloromethane 
 DCE    1,2-Dichloroethane 
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Experimental Procedures 
 
aPPHT 
 
Amine 2 (73 mg, 0.32 mmol, 1.05 eq) and hydroxytetralone 1 (50 mg, 0.31 mmol, 1.0 
eq) were dissolved in 2 mL DCE under N2-atm. NaHB(OAc)3 (103 mg, 0.46 mmol, 1.5 
eq) was added and the resulting reaction suspension was stirred overnight. The 
reaction was quenched by partitioning between EtOAc and conc. NaHCO3(aq) and the 
organic phase was further washed with NaHCO3(aq), 10% NaCl(aq) and brine.  The 
EtOAc layer was dried using Na2SO4 and concentrated in vacuo yielding the crude 
alkylation product as an orange oil, which was immediately transferred to the next step. 
The freshly prepared secondary amine (described above) was redissolved in 1.5 mL 
DCE under N2-atm and treated with propionaldehyde (25 µL, 0.34 mmol, 1.2 eq) 
followed by NaHB(OAc)3 (103 mg, 0.46 mmol, 1.5 eq). After 5 h, the reaction was 
quenched and worked up as described above yielding the crude product tertiary amine. 
Medium pressure chromatography (Biotage, 25 g SiO2 column, gradient 10 to 100% 
EtOAc in hexanes) afforded aPPHT as an orange oil (110 mg, 0.27 mmol, 87%). 
TLC (SiO2, 50% EtOAc, 50% hexanes) Rf = 0.6 (UV) 
1H NMR (599 MHz, CDCl3) δ = 7.94 – 7.89 (m, 2H), 7.89 – 7.83 (m, 2H), 7.54 – 7.49 (m, 2H), 
7.49 – 7.44 (m, 1H), 7.37 – 7.32 (m, 2H), 6.99 (t, J=7.8, 1H), 6.68 (d, J=7.7, 1H), 6.60 (d, J=7.9, 
1H), 5.40 (s, 1H), 3.06 – 2.87 (m, 3H), 2.85 (s, 4H), 2.82 – 2.66 (m, J=28.9, 15.2, 9.4, 1H), 2.63 
– 2.53 (m, 3H), 2.13 – 2.07 (m, 1H), 1.68 – 1.57 (m, 1H), 1.57 – 1.47 (m, 2H), 0.91 (t, J=7.3, 
3H). 
13C NMR (151 MHz, CDCl3) δ = 153.46, 152.72, 151.07, 144.48, 138.37, 130.72, 129.52, 
129.04, 126.40, 122.94, 122.83, 122.73, 121.68, 111.97, 56.58, 52.62, 52.54, 35.81, 32.24, 
25.70, 23.60, 22.08, 11.93. 
HRMS (ESI, positive): calcd for C27H32N3O [M+H]+: 414.2545; found: 414.2537. 
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Dimethoxy naphthalene s127 
 
To a solution of K2CO3 (30.2 g, 219.0 mmol, 3.5 eq) in acetone (100 ml) were 
sequentially added 1,6-Dihydronapthalene 3 (10.0 g, 62.4 mmol, 1.0 eq) and Me2SO4 
(23.6 g, 187.0 mmol, 3.5 eq) at room temperature under N2-atmosphere. The solution 
was refluxed for 3.5 h, cooled to RT and filtered. The filtrate was concentrated in 
vacuo, dissolved in EtOAc (250 ml), washed with 1M NaOH(aq) (2x50 ml) and brine 
before drying over MgSO4. The solution was concentrated in vacuo and the resulting 
crude product was purified by flash chromatography (SiO2, gradient 0 to 20% EtOAc in 
hexanes). The product was obtained as a yellow solid ( 11.74 g, 62.4 mmol, 99 %). 
TLC (SiO2, 20 % EtOAc in hexane), Rf = 0.71 (UV) 
1H NMR (400 MHz, dmso-d6) δ = 8.01 (d, J=9.2, 1H), 7.34 (d, J=4.8, 2H), 7.24 (d, J=2.6, 1H), 
7.08 (dd, J=2.6, 9.2, 1H), 6.81 – 6.74 (m, 1H), 3.91 (s, 3H), 3.83 (s, 3H). 
HRMS (EI): calc. for C12H12O2 (M)-: 188.0837; found: 188.0824. 
 
 
 
 
 
 
C12H12O2
188,22 g/mol
OH
OH
OMe
OMe
s1
Me2SO4
(99%)
3
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Methoxytetralone s227 
 
A solution of 1,6-dimethoxynaphatalene s1 (11.74 g, 62.4 mmol, 1.0 eq.) in EtOH (176 
ml) was heated to 50 oC. To this solution, metallic Na (14.33 g, 624 mmol, 10.0 eq.) 
was added in small potions over a period of 30 min. After heat formation had slowed 
down, the solution was heated to reflux for 2.5 h. After the reaction mixture was cooled 
to room temperature and pH was adjusted to pH < 1 with 5 M HCl(aq). The resulting 
mixture was refluxed for 30 min and then stirred overnight at RT. After dilution with H2O 
(100 ml), the aqueous solution was extracted with DCM (4 x 150 ml). Combined 
organic layers were washed with 10% NaCl(aq) (1 x 100 ml) and brine before beign 
dried over MgSO4 and concentrated in vacuo. The resulting crude material was purified 
by flash chromatography (SiO2, gradient 0 - 10% EtOAc in hexane). The product was 
obatained as a yellow oil (6.1342 g, 34.81 mmol, 56 %). 
TLC (SiO2, 20% EtOAc, 80% hexanes) Rf = 0.42 (UV) 
1H NMR (400 MHz, dmso-d6) δ = 7.14 (t, 1H), 6.84 (d, J=8.0, 1H), 6.73 (d, J=8.4, 1H), 3.77 (s, 
3H), 3.53 (s, 2H), 2.96 (t, J=6.7, 2H), 2.41 – 2.35 (m, 2H). 
HRMS (EI): calc. for C11H12O2 (M)-: 176.0837; found: 176.0831. 
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N-Benzyl-aminotetraline 425 
 
To a solution of tetralone s2 (6.13 g, 34.81 mmol, 1.0 eq) in DCE (90 ml) was added 
benzyl amine (4.95 ml, 4.85 g, 45.3 mmol, 1.3 eq) followed by NaBH(OAc)3 (13.3 g, 
62.7 mmol, 1.8 eq). The reaction mixture was stirred over night at room temperature 
and then partitioned between conc. NaHCO3(aq) (90 ml) and EtOAc (90 ml). The layers 
were separated and the aqueous layer was extracted with EtOAc (4 x 90 ml). The 
combined organic layers were washed with brine, dried over MgSO4 and concentrated 
in vacuo. The resulting crude material was purified by flash chromatography (SiO2, 
gradient 0 to 10 % MeOH in DCM + 1 % TEA). The product was obatained as a brown 
oil (8.082 g, 30.23 mmol, 87 %). 
TLC (SiO2, 4 % MeOH in DCM + 1 % TEA), Rf = 0.67 (UV, ninhydrin)  
1H NMR (400 MHz, dmso-d6) δ = 7.34 (dd, J=3.2, 5.2, 2H), 7.30 – 7.24 (m, 2H), 7.21 – 7.15 (m, 
1H), 7.02 (t, J=7.9, 1H), 6.68 (d, J=8.0, 1H), 6.62 (d, J=7.6, 1H), 3.77 (s, 2H), 3.71 (s, 3H), 2.91 
(dd, J=4.2, 16.0, 1H), 2.79 – 2.69 (m, 2H), 2.52 – 2.34 (m, 2H), 2.03 – 1.92 (m, 1H), 1.44 (dtd, 
J=5.8, 10.2, 12.7, 1H). 
13C NMR (101 MHz, dmso-d6) δ = 157.10, 141.70, 137.02, 128.48, 128.37, 126.84, 126.52, 
124.77, 121.66, 107.59, 55.49, 52.12, 50.53, 36.52, 28.83, 22.12. 
HRMS (EI): calc. for C18H21NO (M)-: 267.1623; found: 267.1625. 
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N-Benzyl-aminotetraline (R)-525 
 
To a solution of N-benzyl-5-methoxy-1,2,3,4-tetrahydronaphthalen-2-amine xx (4.9 g, 
18.3 mmol, 1.0 eq) in acetone (60 mL) was added (+)-Di-p-toluoyl-D-tartaric acid 
(7.8 g, 20.2 mmol, 1.1 eq). The solution was refluxed for 1 h and then stirred over night 
at RT. The resulting precipitate was removed by filtration and recrystallized 2 times 
from acetone. The pure tartrate salt (3.6 g, 5.5 mmol, 30 % yield) was converted to the 
HCl salt (1.650 g, 5.43 mmol, 99 % yield). 
[α]D (HCl salt) = + 58.2 ° (c = 2, MeOH). 
 
 
 
 
N-Benzyl-aminotetraline (S)-825 
 
 
The partially enriched aminotetraline from the resolution above was free based and 
treated with 1 eq (-)-Di-p-toluoyl-L-tartaric acid. The precipitated tartrate salt was 
recrystallized until optical rotation was constant. 
[α]D (HCl salt) = - 58.4 ° (c = 2, MeOH). 
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1. Crystallographic data. Diastereomeric salt intermeidate I 
 
I 
net formula C38H41NO10 
Mr/g mol−1 671.733 
crystal size/mm 0.35 × 0.23 × 0.09 
T/K 173(2) 
radiation MoKα 
diffractometer 'KappaCCD' 
crystal system monoclinic 
space group P21 
a/Å 7.4782(2) 
b/Å 29.0521(10) 
c/Å 8.0823(2) 
α/° 90 
β/° 100.029(2) 
γ/° 90 
V/Å3 1729.11(9) 
Z 2 
calc. density/g cm−3 1.29021(7) 
µ/mm−1 0.093 
absorption correction none 
refls. measured 9889 
Rint 0.0374 
mean σ(I)/I 0.0349 
θ range 3.31–25.25 
observed refls. 2678 
x, y (weighting scheme) 0.0673, 0.4279 
hydrogen refinement mixed 
Flack parameter 0.2(13) 
refls in refinement 3115 
parameters 460 
restraints 1 
R(Fobs) 0.0435 
Rw(F2) 0.1179 
S 1.059 
shift/errormax 0.001 
max electron density/e Å−3 0.189 
min electron density/e Å−3 −0.167 
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N-Benzyl-N-propyl-aminotetraline (R)-s325 
 
 
To a solution of (R)-5 (800 mg, 2.6 mmol, 1.0 eq) and TEA (544 mg, 5.27 mmol, 2.0 
eq) in DCE (25 mL) was added propionaldehyde (177 mg, 3.1 mmol, 1.1 eq) followed 
by NaBH(OAc)3 (854 mg, 4.0 mmol, 1.5 eq). The reaction mixture was stirred for 3 h at 
RT and concentrated in vacuo before it was partitioned between conc. NaHCO3(aq) 
(60 mL) and EtOAc (60 mL). The layers were separated and the aqueous layer was 
extracted with EtOAc (3 x 60 mL). Combined organic layers were washed with brine, 
dried on Na2SO4 and concentrated in vacuo. The product was obtained as a white 
amorphous solid (810 mg, 2.62 mmol, 99 %).  
1H NMR (400 MHz, dmso-d6) δ = 7.31 (s, 2H), 7.26 (s, 2H), 7.17 (s, 1H), 7.01 (t, J=7.8, 1H), 
6.66 (d, J=8.3, 1H), 6.63 (d, J=7.8, 1H), 3.69 (s, 3H), 3.62 (s, 2H), 2.84 (d, J=17.6, 2H), 2.74 (s, 
2H), 2.43 (s, 2H), 2.39 – 2.29 (m, 1H), 2.06 – 1.87 (m, 1H), 1.60 – 1.44 (m, 1H), 1.36 (s, 2H), 
0.77 (t, J=7.3, 3H). 
13C NMR (101 MHz, dmso-d6) δ = 157.16, 141.72, 137.98, 128.49, 126.90, 126.62, 124.64, 
121.76, 107.60, 55.61, 55.49, 54.29, 51.82, 32.04, 25.01, 23.93, 21.64, 12.11. 
HRMS (ESI, positive): calc. for C21H28NO (M+1)+: 310.2171; found: 310.2166. 
 [α]D = + 24.5 ° (c = 1, MeOH). 
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N-Propyl-aminotetraline (R)-625,27 
 
 
To a solution of (R)-s3 (760 mg, 2.41 mmol, 1.0 eq) in MeOH (10 mL) was added Pd/C 
(256 mg (10% Pd), 0.24 mmol, 0.1 eq). The reaction mixture was then stirred 
vigorously over night under a H2 atmosphere at RT. The reaction suspension was then 
filtrated and the filtrate concentrated in vacuo. The product was obtained as a brown oil 
(524 mg, 2.39 mmol, 70 %). 
1H NMR (400 MHz, dmso-d6) δ = 7.01 (t, J=7.9, 1H), 6.67 (d, J=8.0, 1H), 6.60 (d, J=7.6, 1H), 
3.70 (s, 3H), 2.86 (dd, J=4.2, 15.9, 1H), 2.71 (ddd, J=4.1, 8.6, 9.9, 2H), 2.52 (t, J=7.3, 2H), 2.46 
– 2.35 (m, 2H), 1.98 – 1.87 (m, 1H), 1.45 – 1.30 (m, 3H), 1.16 (s, 1H), 0.85 (t, J=7.4, 3H). 
13C NMR (75 MHz, dmso-d6) δ = 157.11, 137.11, 126.46, 124.85, 121.65, 107.55, 55.47, 
53.08, 49.03, 36.78, 29.08, 23.59, 22.15, 12.35. 
HRMS (ESI, positive): calc. for C14H22NO (M+1)+: 220.1701; found: 220.1697. 
 [α]D = + 69.8 ° (c = 1, MeOH). 
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Amide (R)-s425,27 
 
  
Preperation of acid chloride. A solution of 4-Nitrophenylacetic acid 7 (826 mg, 
4.56 mmol, 2.0 eq) and SOCl2 (2712 mg, 22.8 mmol, 10.0 eq) in dry THF (15 mL) was 
refluxed for 3 h. The solvent was removed in vacuo und the resulting acid chloride was 
stripped with chloroform (2 x 10 mL) followed by DCM (1 x 10 mL). 
Amide coupling. The freshly prepared acid chloride was redissolved in 15 mL 
DCM and added to an ice-cooled solution of (R)-6 (500 mg, 2.28 mmol, 1.0 eq) in 15 
mL DCM under N2-atmosphere. The solution was warmed to RT and stirred over night 
and DIPEA (1.18 g, 9.12 mmol, 4.0 eq) was added, which turned the orange reaction 
suspension to a dark red solution. This solution was concentrated in vacuo, redissolved 
in EtOAc (50 mL) and washed with conc. NaHCO3(aq) (2 x 20 mL) and brine. The EtOAc 
layer was separated, dried over Na2SO4 and concentrated in vacuo. The resulting 
crude amide was purified by automated flash column chromatography (Biotage, 100 g 
SiO2, gradient 1 – 10 % MeOH in DCM). The product was obtained as a brown oil 
(798 mg, 2.09 mmol, 92 %).  
 
TLC (SiO2, 40% EtOAc, 60% hexanes), Rf = 0.44 (UV) 
1H NMR (300 MHz, dmso) δ = 8.21 – 8.11 (m, 2H), 7.50 (dd, J=11.6, 8.8, 2H), 7.05 (td, J=7.9, 
3.7, 1H), 6.72 (dd, J=8.1, 3.2, 1H), 6.64 (d, J=7.8, 1H), 4.37 – 4.23 (m, 1H), 4.11 – 4.00 (m, 
J=9.6, 1H), 3.88 (t, J=7.8, 1H), 3.73 (s, 3H), 3.17 – 3.08 (m, J=4.7, 1H), 2.99 – 2.77 (m, 3H), 
2.75 – 2.60 (m, 2H), 1.88 – 1.68 (m, J=23.8, 11.8, 2H), 1.67 – 1.42 (m, J=30.8, 3H), 0.84 (dt, 
J=22.9, 7.4, 3H). 
 
13C NMR (75 MHz, dmso-d6) δ = 169.68, 169.36, 157.21, 157.18, 146.60, 146.57, 145.17, 
145.13, 137.10, 136.72, 131.22, 130.93, 126.81, 126.78, 124.02, 123.94, 123.64, 123.57, 
121.57, 121.51, 107.89, 107.83, 55.60, 55.57, 55.34, 53.49, 51.62, 46.31, 43.39, 40.08, 33.89, 
32.96, 27.93, 26.92, 24.59, 23.83, 23.64, 22.82, 11.92, 11.61. 
 
HRMS (ESI, positive): calc. for C22H27N2O4 (M+1)+: 383.1971; found: 383.1967. 
HRMS (ESI, negative): calc. for C22H25N2O4 (M-1)-: 381.1814; found: 381.1829. 
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Tertiary amine (R)-s525,27 
 
 
An ice-cooled solution of (R)-s4 (500 mg, 1.13 mmol, 1.0 eq) in dry THF (20 mL) under 
N2-atmosphere was slowly treated with a 1-M solution of BH3·THF in THF (3.92 mL, 
3.92 mmol, 3.0 eq). After stirring for 5 min at 0 °C, the solution was refluxed for 2 h. 
After cooling to RT, Na2CO3 (624 mg, 5.88 mmol, 5.2 eq) was added. The resulting 
solution was cooled to 0 °C and a 20 % solution of (NH4)2S(aq) (1.21 mL, 3.92 mmol, 3.0 
eq) was added. The reaction mixture was then refluxed over night, cooled to RT and 
quenched with 6 M HCl(aq). It was then dissolved in H2O, basified with conc. NaOH(aq) to 
pH = 14 and extracted with DCM (3 x 20 mL). The combined organic layers were 
washed with brine and dried over Na2SO4. The resulting solution was concentrated in 
vacuo and the crude material was purified by automated flash column chromatography 
(Biotage, 50 g SiO2, gradient 2 – 55 % EtOAc in hexane). The product was obtained as 
a yellow oil (260 mg, 0.71 mmol, 54 %).  
 
TLC (SiO2, 40% EtOAc, 60% hexanes), Rf = 0.61 (UV) 
1H NMR (400 MHz, dmso) δ = 8.12 – 8.05 (m, 2H), 7.51 – 7.43 (m, 2H), 7.00 (t, J=7.9, 1H), 6.64 
(dd, J=21.2, 7.7, 2H), 3.70 (s, 3H), 2.86 – 2.70 (m, 5H), 2.62 (ddd, J=27.2, 16.4, 8.4, 2H), 2.47 
(td, J=3.5, 1.6, 2H), 2.43 (d, J=7.3, 1H), 2.41 – 2.34 (m, 1H), 1.84 (dd, J=9.3, 2.6, 1H), 1.51 – 
1.35 (m, 1H), 1.30 (dq, J=14.3, 7.2, 2H), 0.75 (t, J=7.3, 3H). 
13C NMR (101 MHz, dmso-d6) δ = 157.13, 150.03, 146.18, 137.93, 130.58, 126.55, 124.76, 
123.52, 121.80, 107.55, 55.87, 55.49, 51.89, 51.79, 35.25, 32.25, 25.47, 23.81, 21.96, 12.12. 
HRMS (ESI, positive): calc. for C22H29N2O3 (M+1)+: 369.2178; found: 369.2173. 
HRMS (ESI, negative): calc. for C22H27N2O3 (M-1)-: 367.2022; found: 367.2031. 
 [α]D = + 14.5 ° (c = 1, MeOH). 
 
 
230 
 
Hydroxytetraline (R)-s6 
 
 
A solution of (R)-s5 (225 mg, 0.665 mmol, 1.0 eq) in 1 mL DCM was cooled to - 78 °C 
under N2-atmosphere and treated with a 1-M solution of BBr3 in DCM (1462 µL, 
1.46 mmol, 2.2 eq) was added and the reaction mixture was stirred for 30 min at –
78 °C. The reaction mixture was allowed to warm to room temperature and stirred for 
another 1.5 h before it was quenched with MeOH (2 mL). This solution was partitioned 
between conc. NaHCO3(aq) (20 mL) and DCM (20 mL). The layers were separated and 
the aqueous layer was extracted with DCM (3 x 10 mL). Combined organic layers were 
washed with brine, dried over Na2SO4 and concentrated in vacuo. The residue was 
purified using flash column chromatography (SiO2, gradient 10 – 40 % EtOAc in 
hexane). The product was obtained as an orange oil (210 mg, 0.59 mmol, 97 %).  
 
TLC (SiO2, 40% EtOAc, 60% hexanes), Rf = 0.42 (UV) 
1H NMR (400 MHz, dmso-d6) δ = 9.11 (s, 1H), 8.14 – 8.09 (m, 2H), 7.52 – 7.47 (m, 2H), 6.83 (t, 
J=7.7, 1H), 6.53 (d, J=7.9, 1H), 6.46 (d, J=7.2, 1H), 2.84 – 2.71 (m, 5H), 2.67 – 2.51 (m, 2H), 
2.44 (t, J=7.2, 2H), 2.42 – 2.32 (m, 1H), 1.90 – 1.80 (m, 1H), 1.43 (ddd, J=5.6, 12.0, 23.9, 1H), 
1.31 (tt, J=7.2, 14.5, 2H), 1.23 – 1.18 (m, 1H), 0.75 (t, J=7.3, 3H). 
13C NMR (101 MHz, dmso-d6) δ = 155.16, 150.07, 146.19, 138.06, 130.61, 126.28, 123.53, 
123.35, 120.23, 111.87, 56.09, 51.91, 51.81, 35.28, 32.32, 25.62, 23.94, 21.99, 12.13. 
HRMS (ESI, positive): calc. for C21H27N2O3 (M+1)+: 355.2022; found: 355.2017. 
HRMS (ESI, negative): calc. for C21H25N2O3 (M-1)-: 353.1865; found: 353.1875. 
 [α]D = + 13.4 ° (c = 1, MeOH). 
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Aniline (R)-825,27 
 
 
A solution of (R)-s6 (180 mg, 0.508 mmol, 1.0 eq) was dissolved in 10 mL MeOH at 
room temperature. A small amount of palladium on charcoal (10% Pd) was added and 
the atmosphere was exchanged with H2. After vigorous stirring over night, the reaction 
mixture was filtered through celite and the filtrate was concentrated under reduced 
pressure. Filtration through a small plug of silica (first hexane, then ethyl acetate) 
afforded the product as a white amorphous solid (144 mg, 0.444mmol, 87%). 
 
TLC (SiO2, 10% MeOH, 90% DCM), Rf = 0.31 (UV + ninhydrin) 
HRMS (ESI, positive): calc. for C21H29N2O (M+1)+: 325.2274; found: 325.2272. 
HRMS (ESI, negative): calc. for C21H27N2O (M-1)-: 323.2129; found: 325.2130. 
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(R)-aPPHT 
 
(R)-8 (21 mg, 0.065 mmol, 1 eq) was dissolved in 2 mL DCM and treated with 
nitrosobenzene (10 mg, 0.097 mmol, 1.5 eq) and acetic acid (37 µL, 0.65 mmol, 10 
eq). After stirring for 12 hours, the reaction was diluted with ethylacetate and extracted 
with NaHCO3(aq), water and brine. The organic layer was seperated, dried over Na2SO4 
and concentrated under reduced pressure. Purification of the crude using silica gel 
chromatography (gradient 0% to 5% MeOH in DCM) afforded (R)-aPPHT as an orange 
oil (21 mg, 0.051 mmol, 79%). 
TLC (SiO2, 10% MeOH, 90% DCM), Rf = 0.48 (UV). 
1H NMR (400 MHz, CDCl3) δ = 7.92 – 7.81 (m, 3H), 7.55 – 7.41 (m, 3H), 7.33 (d, J=8.3, 2H), 
6.97 (t, J=7.8, 1H), 6.66 (d, J=7.7, 1H), 6.58 (d, J=7.9, 1H), 3.06 – 2.62 (m, 8H), 2.57 (s, 3H), 
2.14 – 2.02 (m, 1H), 1.48 (s, 4H), 0.89 (t, J=7.4, 3H). 
HRMS (ESI) calcd for C27H32N3O [M+H]+: 414.2545; found: 414.2542. 
HRMS (ESI) calcd for C27H30N3O [M-H]-: 412.2389; found: 412.2398. 
IR νmax: 2952, 2925, 2849, 2358, 2332, 1658, 1585, 1465, 1276, 1261, 1084, 1020, 796, 768, 
687. 
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N-Benzyl-N-propyl-aminotetraline (S)-s325 
 
 
To a solution of (S)-5 (300 mg, 0.987 mmol, 1.0 eq) and TEA (0.27 ml, 200 mg, 1.97 
mmol, 2.0 eq) in DCE (10.5 ml) was added propionaldehyde (86.2 µl, 68.8 mg, 1.18 
mmol, 1.2 eq) followed by NaBH(OAc)3 (314 mg, 1.48 mmol, 1.5 eq). The reaction 
mixture was stirred for 4.5 h at RT and concentrated in vacuo before it was partitioned 
between conc. NH4Cl(aq) (20 ml) and EtOAc (20 ml). The layers were separated and the 
organic layer was washed with conc. NaHCO3(aq) (20 ml) and brine, dried over MgSO4 
and concentrated in vacuo. The product was obtained as a yellow oil (305 mg, 0.98 
mmol, 99 %). 
TLC (SiO2, 2 % EtOH in DCM), Rf = 0.36 (UV, ninhydrin)  
 
1H NMR (400 MHz, CDCl3) δ 7.39 (d, J = 7.2 Hz, 2H), 7.29 (t, J = 7.3 Hz, 2H), 7.21 (t, J = 7.2 
Hz, 1H), 7.08 (t, J = 7.9 Hz, 1H), 6.71 (d, J = 7.6 Hz, 1H), 6.64 (d, J = 8.1 Hz, 1H), 3.80 (s, 3H), 
3.71 (d, J = 6.4 Hz, 2H), 2.99 (dt, J = 21.5, 10.8 Hz, 2H), 2.89 – 2.77 (m, 2H), 2.52 (t, 2H), 2.49 
– 2.43 (m, 1H), 2.17 – 2.05 (m, 1H), 1.66 – 1.54 (m, 1H), 1.46 (h, J = 7.3 Hz, 2H), 0.87 (t, J = 
7.4 Hz, 3H). 
 
13C NMR (101 MHz, CDCl3) δ 157.18, 141.48, 138.29, 128.35, 128.06, 126.45, 126.06, 125.36, 
121.63, 106.79, 55.43, 55.20, 54.40, 51.97, 32.13, 25.04, 23.92, 21.70, 11.85. 
 
HRMS (ESI, positive): calc. for C21H28NO (M+H)+: 310.2165; found 310.2169. 
 
[α]D21 = - 48.8 o (c=1, MeOH) 
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N-Propyl-aminotetraline (S)-625,27 
 
 
A solution of (S)-s3 (344 mg, 1.11 mmol, 1.0 eq.) in MeOH (5 ml) was added to Pd/C 
(10% Pd) under nitrogen atmosphere. The reaction was stirred vigorously over night 
under H2 atmosphere at RT. The resulting suspension was then filtered over celite and 
the filtrate concentrate in vacuo. The product was obtained as a white solid ( 227 mg, 
1.03 mmol, 93 %). 
TLC (SiO2, 5 % MeOH in DCM), Rf = 0.28 (UV, ninhydrin) 
1H NMR (599 MHz, CDCl3) δ 7.09 (t, J = 7.9 Hz, 1H), 6.69 (d, J = 7.7 Hz, 1H), 6.67 (d, J = 8.1 
Hz, 1H), 3.81 (s, 3H), 3.11 (t, 2H), 2.96 (d, J = 20.4 Hz, 1H), 2.91 – 2.76 (m, 3H), 2.62 – 2.51 
(m, 1H), 2.28 (s, 1H), 1.74 (s, 3H), 0.99 (t, J = 7.4 Hz, 3H). 
13C NMR (151 MHz, CDCl3) δ 157.11, 135.53, 126.39, 124.55, 121.39, 107.25, 55.22, 53.74, 
48.18, 35.15, 27.89, 22.20, 22.09, 11.72. 
HRMS (ESI, positive): calc. for C14H22NO (M+H)+: 220.1696; found 220.1699. 
 
[α]D22 = - 74.2 o (c=1, MeOH) 
 
 
 
Hydroxytetraline (S)-s7 
 
 
A solution of (S)-s3 (63 mg, 0.25 mmol, 1.0 eq) in 1 mL DCM was cooled to - 78 °C 
under N2-atmosphere and treated with a 1-M solution of BBr3 in DCM (790 µL, 
0.54 mmol, 2.2 eq). The reaction mixture was stirred for 30 min at –78 °C before being 
allowed to warm to room temperature and stirred for another 1.5 h. Then, the reaction 
was quenched with MeOH (2 mL). This solution was partitioned between water (20 mL) 
and ethyl acetate (20 mL). The organic layer was washed with 1-M-NaOH and brine, 
dried over Na2SO4 and concentrated under reduced pressuer affording the product as 
a colorless oil (37 mg, 0.18 mmol, 73 %). 
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1H NMR (300 MHz, CDCl3) δ = 6.98 (t, J=7.8, 1H), 6.65 (d, J=7.5, 1H), 6.57 (d, J=7.9, 1H), 4.14 
– 3.75 (m, 1H), 2.92 (ddd, J=23.5, 19.6, 9.8, 3H), 2.64 (ddd, J=37.7, 23.2, 11.2, 4H), 2.11 (s, 
1H), 1.57 (dq, J=14.6, 7.3, 3H), 1.01 – 0.92 (m, 3H). (phenol not detected) 
13C NMR (75 MHz, CDCl3) δ = 153.81, 136.90, 126.32, 123.06, 121.22, 112.04, 53.19, 48.91, 
36.53, 28.93, 23.28, 22.00, 11.84. 
 
HRMS (EI): calc. for C13H19NO (M): 205.1467; found 205.1462. 
 
 
 
(S)-aPPHT 
 
 
(S)-s7 (12 mg, 0.059 mmol, 1.0 eq) was dissolved in 3 mL DCE and freshly prepared 
aldehyde 9 was added (from 1.5 eq of the corresponding alcolohl), followed by 
NaHB(OAc)3 (19 mg, 0.09 mmol, 1.5 eq). The reaction suspension was stirred over 
night, diluted with ethyl acetate and extracted with conc. NaHCO3(aq) and brine. The 
organic layer was dried over Na2SO4 and concentrated under vacuo. Flash column 
chromatography (SiO2, gradient 0 to 5% MeOH in DCM) afforded (S)-aPPHT as an 
orange amorphous solid (19 mg, 0.046 mmol, 79%). 
 
Analytical data matched those of its enantiomere and the racemate. 
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Additional Azobenzene Building Blocks 
Phenethyl alcohol 13 & 14  
 
4-Aminophenethyl alcohol 10 or 3-aminophenethyl alcohol 11 (0.5 g, 3.64 mmol, 1 
equiv.) were dissolved in 10 mL DCM. Then, 12 (0.832 g, 5.47 mmol, 1.5 equiv.) was 
added, followed by AcOH (2.1 mL, 36.4 mmol, 10 equiv.) and the reaction was stirred 
at rt under N2 atmosphere for 1.5 hours. The orange-colored mixture was diluted in 60 
mL EtOAc and then washed sequentially with 1M HCl (2 x 30 mL), 1M NaOH (2 x 30 
mL), and brine (1 x 30 mL). Organic phase was collected and dried with Na2SO4 before 
concentrating to dryness using rotary evaporation. Crude material was purified by flash 
column chromatography (silica gel, wet loading, gradient 20% → 30% → 40% → 60% 
EtOAc in Hexanes). The final product 13 and 14 was an orange-red crystalline solid 
(932 mg, 3.44 mmol, 95 %). 
 
TLC (SiO2, 50% EtOAc, 50% hexanes) Rf = 0.4 (UV + Ninhydrin) 
HRMS (EI) calc’d for C14H13N3O3 [M+H]+ = 271.0957; found = 271.0952 
1H NMR (200 MHz, CDCl3) δ = 8.36 (d, J=8.8, 2H), 8.00 (d, J=8.8, 2H), 7.92 (d, J=8.3, 2H), 7.42 
(d, J=8.2, 2H), 3.94 (t, J=6.5, 2H), 2.97 (t, J=6.5, 2H). 
IR vmax: 3518, 3398, 3063, 2945, 2884, 1605, 1590, 1514, 1496, 1454, 1415, 1376, 1325, 1220, 
1200, 1142, 1105, 1041, 944, 860, 828, 793, 755, 729, 686 
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Crystallographic data. 13 
 
 
13 
net formula C14H13N3O3 
Mr/g mol−1 271.271 
crystal size/mm 0.30 × 0.12 × 0.03 
T/K 173(2) 
radiation MoKα 
diffractometer 'KappaCCD' 
crystal system triclinic 
space group P1bar 
a/Å 7.0940(15) 
b/Å 7.4039(16) 
c/Å 25.182(6) 
α/° 95.475(11) 
β/° 90.719(9) 
γ/° 99.206(11) 
V/Å3 1299.1(5) 
Z 4 
calc. density/g cm−3 1.3870(5) 
µ/mm−1 0.100 
absorption correction none 
refls. measured 4271 
Rint 0.0612 
mean σ(I)/I 0.0999 
θ range 3.25–25.29 
observed refls. 1582 
x, y (weighting scheme) 0, 7.5736 
hydrogen refinement constr 
refls in refinement 3330 
parameters 363 
restraints 0 
R(Fobs) 0.1329 
Rw(F2) 0.2548 
S 1.150 
shift/errormax 0.001 
max electron density/e Å−3 0.229 
min electron density/e Å−3 −0.234 
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1H NMR (599 MHz, CDCl3) δ = 8.42 – 8.35 (m, 2H), 8.06 – 8.00 (m, 2H), 7.88 – 7.83 (m, J=2.1, 
1.7, 2H), 7.54 – 7.48 (m, 1H), 7.44 (d, J=7.3, 1H), 3.96 (t, J=6.5, 2H), 3.00 (t, J=6.5, 2H), 1.59 
(s, 1H). 
13C NMR (151 MHz, CDCl3) δ = 155.68, 152.61, 148.70, 140.12, 133.11, 129.44, 124.73, 
123.54, 123.40, 121.95, 63.48, 63.38, 39.03, 38.93. 
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Crystallographic data. 14 
 
 
14 
net formula C14H13N3O3 
Mr/g mol−1 271.271 
crystal size/mm 0.28 × 0.12 × 0.02 
T/K 200(2) 
radiation MoKα 
diffractometer 'KappaCCD' 
crystal system triclinic 
space group P1bar 
a/Å 6.4286(2) 
b/Å 14.1216(6) 
c/Å 16.0098(6) 
α/° 112.830(2) 
β/° 94.583(2) 
γ/° 100.381(2) 
V/Å3 1299.50(8) 
Z 4 
calc. density/g cm−3 1.38657(9) 
µ/mm−1 0.100 
absorption correction none 
refls. measured 8779 
Rint 0.0339 
mean σ(I)/I 0.0534 
θ range 3.22–25.39 
observed refls. 2915 
x, y (weighting scheme) 0.1054, 0.1286 
hydrogen refinement constr 
refls in refinement 4743 
parameters 363 
restraints 0 
R(Fobs) 0.0620 
Rw(F2) 0.1879 
S 1.032 
shift/errormax 0.001 
max electron density/e Å−3 0.435 
min electron density/e Å−3 −0.208 
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Phenethyl alcohol 15  
 
13 (800 mg, 2.95 mmol, 1 equiv.) and Na2S (460 mg, 5.9 mmol, 2 equiv.) were added 
to 30 mL of a 2:1 mixture of dioxane:H2O and heated to 80°C. After allowing the 
reaction to proceed for 1.5 hours, the cloudy, orange reaction mixture was diluted with 
80 mL EtOAc and washed in a separatory funnel with 1M NaOH (2 x 40 mL). The 
combined aqueous layers were extracted using EtOAc (2 x 20 mL). All organic phases 
were pooled and dried with Na2SO4. Removal of solvent via rotary evaporation yielded 
the yellow-orange crystalline product 15 (604.1 mg, 2.54 mmol, 86%). 
TLC (SiO2, 10% MeOH in DCM) - Rf = 0.6 (UV + Ninhydrin) 
HRMS (EI) calc’d for C14H15N3O [M+H]+  = 241.1215; found = 241.1205 
1H NMR (599 MHz, CDCl3) δ = 7.84 – 7.74 (m, 4H), 7.33 (d, J=8.2, 2H), 6.77 – 6.69 (m, 2H), 
4.01 (s, 2H), 3.90 (t, J=6.6, 2H), 2.93 (t, J=6.6, 2H). 
13C NMR (151 MHz, CDCl3) δ = 151.75, 149.42, 145.56, 140.48, 129.59, 125.00, 122.54, 
114.61, 63.53, 39.02. 
IR vmax: 3336, 3213, 3029, 2928, 2877, 1636, 1597, 1502, 1470, 1454, 1428, 1403, 1364, 1306, 
1277, 1232, 1190, 1153, 1141, 1104, 1054, 1023, 1010, 952, 872, 838, 789 
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Crystallographic data. 15 
 
 
15 
net formula C14H15N3O 
Mr/g mol−1 241.289 
crystal size/mm 0.178 × 0.056 × 0.022 
T/K 100(2) 
radiation 'Mo Kα 
diffractometer 'Bruker D8Venture' 
crystal system orthorhombic 
space group Pna21 
a/Å 11.1035(6) 
b/Å 13.9708(7) 
c/Å 7.8951(5) 
α/° 90 
β/° 90 
γ/° 90 
V/Å3 1224.73(12) 
Z 4 
calc. density/g cm−3 1.30861(13) 
µ/mm−1 0.085 
absorption correction multi-scan 
transmission factor range 0.8230–0.9143 
refls. measured 16779 
Rint 0.0684 
mean σ(I)/I 0.0399 
θ range 3.45–25.11 
observed refls. 1792 
x, y (weighting scheme) 0.0461, 0.2715 
hydrogen refinement mixed 
Flack parameter −0.5(19) 
refls in refinement 2128 
parameters 175 
restraints 1 
R(Fobs) 0.0382 
Rw(F2) 0.0910 
S 1.069 
shift/errormax 0.001 
max electron density/e Å−3 0.154 
min electron density/e Å−3 −0.177 
 
C-bound H: constr, N- and O-bound H: refall. 
Flack parameter meaningless, no anomalous scatterer (Mo readiation). 
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Phenethyl alcohol 16 
 
15 (533 mg, 2.21 mmol, 1 equiv.) was dissolved in 20 mL DCM and cooled on an ice 
bath. Both acetic anhydride (622 µL, 6.63 mmol, 3 equiv.) and triethylamine (675 µL, 
4.86 mmol, 2.2 equiv.) were added under N2 atmosphere. After 15 minutes of stirring at 
0-5°C, the flask was then warmed to rt and left to stir overnight under N2 atmosphere. 
60 mL of EtOAc was added to the reaction mixture, which was then washed 
sequentially with NaHCO3 (40 mL), NH4Cl, (40 mL) and brine (40 mL). The organic 
phase was dried with Na2SO4  and the solvent was removed via rotary evaporation, 
yielding a yellow-orange powder (705 mg, 2.17 mmol, 98%).The N- and O-protected 
intermediate was used in the following reaction. 
 
Intermediate: 
TLC (SiO2, 1:1 EtOAc:Hexanes) - Rf = 0.6 (UV + Ninhydrin) 
HRMS (EI) calc’d for C18H19N3O3 [M+H]+  = 325.1426; found = 325.1428 
 
The intermediate (600 mg, 1.84 mmol, 1 equiv.) was mixed with K2CO3 (255 mg, 1.84 
mmol, 1 eq) in 30 mL MeOH and stirred at rt for two hours. The reaction mixture was 
partitioned between 50 mL 10% NaCl and 100 mL EtOAc. The organic layer was 
washed with brine (50 mL) and the combined aqueous phases were extracted with 
chloroform (50 mL) and EtOAc (20 mL). The pooled organic phases was dried over 
Na2SO4 and concentrated via rotary evaporation, yielding the yellow-orange product 16 
in quantitative yield (520 mg, 1.84 mmol). 
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TLC (SiO2, 10% MeOH in DCM) - Rf = 0.5 (UV) 
HRMS (EI) calc’d for C16H17N3O2 [M+H]+  = 283.1321; found = 283.1314 
1H NMR (400 MHz, cd3od) δ = 7.89 – 7.82 (m, 2H), 7.82 – 7.77 (m, 2H), 7.76 – 7.68 (m, 2H), 
7.42 – 7.34 (m, 2H), 3.79 (t, J=6.9, 2H), 2.88 (t, J=6.9, 2H), 2.14 (s, 3H). 
13C NMR (101 MHz, cd3od) δ = 170.36, 151.19, 148.67, 142.56, 141.28, 129.39, 123.13, 
122.25, 119.58, 62.41, 38.61, 22.53. 
IR vmax: 3296, 3126, 3057, 2935, 2892, 2361, 1661, 1599, 1543, 1502, 1437, 1393, 1372, 1333, 
1302, 1270, 1230, 1194, 1156, 1109, 1053, 1020, 962, 950, 898, 846, 827, 809, 726, 704, 662 
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Crystallographic data. 16 
 
 
16 
net formula C16H17N3O2 
Mr/g mol−1 283.325 
crystal size/mm 0.194 × 0.051 × 0.051 
T/K 100(2) 
radiation 'Mo Kα 
diffractometer 'Bruker D8Venture' 
crystal system monoclinic 
space group P21/n 
a/Å 4.67990(10) 
b/Å 13.5414(4) 
c/Å 22.3063(6) 
α/° 90 
β/° 94.1120(10) 
γ/° 90 
V/Å3 1409.96(6) 
Z 4 
calc. density/g cm−3 1.33473(6) 
µ/mm−1 0.090 
absorption correction multi-scan 
transmission factor range 0.8941–0.9143 
refls. measured 22974 
Rint 0.0340 
mean σ(I)/I 0.0212 
θ range 3.01–27.56 
observed refls. 2797 
x, y (weighting scheme) 0.0479, 1.0071 
hydrogen refinement mixed 
refls in refinement 3226 
parameters 199 
restraints 0 
R(Fobs) 0.0442 
Rw(F2) 0.1202 
S 1.094 
shift/errormax 0.001 
max electron density/e Å−3 0.399 
min electron density/e Å−3 −0.222 
 
C-bound H: constr, O- and N-bound H: refall. 
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Phenethyl alcohol 17 
 
Diazonium salt formation 
4-aminophenethyl alcohol 10 (3.5 g, 25.5 mmol, 1 equiv.) was added to 69 mL H20 and 
cooled in an ice bath and concentrated aqueous HCl (8 mL, 76.5 mmol, 3 equiv.) was 
added. A solution of NaNO2 (1.9 g, 28.1 mmol, 1.1 eq) in 22 mL H20 were added 
slowly, keeping the reaction temperature between 0 - 5°C. After stirring at 0 °C for 30 
min the yellow diazonium salt solution was carried to the next step immediately. 
Base 1: NaOH 
NaOH (2.04 g, 51 mmol, 6 equiv.) was dissolved in 30 mL 1:1 H20:MeOH with stirring 
at 0-5°C. N,N-dimethylanilin (1.08 mL, 8.5 mmol, 1 equiv.) was added to this solution. 
Next, one third of the above described diazonium salt solution (1 equiv.) was added 
dropwise. The solution was stirred on an ice bath for 30 min and was then allowed to 
warm to rt overnight. No conversion was observed by TLC. 
 
Base 2: NaOAc 
Experimental procedure was identical to Base 1 with NaOH being substituted with 
NaOAc (4.18 g, 51 mmol, 6 equiv.). After the overnight reaction, TLC confirmed desired 
product formation. The cloudy, yellow-green reaction mixture was diluted with 200 mL 
EtOAc in a separatory funnel and washed sequentially with H20 (1 x 100 mL), 1M 
NaOH (1 x 100 mL), and brine (1 x 100 mL). The pooled organic phases were dried 
with Na2SO4 and concentrated via rotary evaporation. Crude material was purified by 
flash column chromatography (silica gel, wet loading in DCM, gradient 10% → 50% 
EtOAc in hexanes), yielding the yellow-brown product 17 (1.99 g, 7.4 mmol, 87%). 
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Base 3: pyridine 
Experimental procedure was identical to Base 1 with NaOH being substituted with 
pyridine (4.12 mL, 51 mmol, 6 equiv.) dissolved in 30 mL pure MeOH. After reacting 
overnight, TLC confirmed desired product formation and an aqueous workup was 
performed. The reaction mixture was diluted with 100 mL EtOAc and the resulting 
solution was washed sequentially with NH4Cl (200 mL), NaOH (100 mL), 1M NaOH 
(100 mL), H20 (100 mL), and brine (100 mL). After back extraction using EtOAc (2 x 50 
mL), the pooled organic phases were dried with Na2SO4 and the solvent was removed 
via rotary evaporation. The crude material was purified by flash column 
chromatography (silica gel, wet loading in CHCl3, gradient 10% → 50% → 60% → 70% 
→ 80% EtOAc in hexanes) yielding the product as a bright orange powder 17 (2.06 g, 
7.66 mmol, 90%). 
TLC (SiO2, 1:1 EtOAc:Hexanes) - Rf = 0.4 (UV + Ninhydrin) 
HRMS (ESI) calc’d for C16H17N3O2 [M+H]+  = 270.1601, found = 270.1598 
1H NMR (599 MHz, cdcl3) δ = 7.89 – 7.83 (m, 2H), 7.80 – 7.76 (m, 2H), 7.34 – 7.30 (m, 2H), 
6.78 – 6.72 (m, 2H), 3.89 (t, J=6.6, 2H), 3.16 (s, 1H), 2.92 (t, J=6.6, 2H). 
13C NMR (151 MHz, cdcl3) δ = 152.33, 151.99, 143.63, 139.98, 129.56, 124.85, 122.39, 111.49, 
63.56, 40.30, 39.02. 
IR vmax: 3216, 2856, 1599, 1561, 1513, 1472, 1443, 1423, 1403, 1360, 1310, 1227, 1154, 1138, 
1040, 1011, 941, 835, 725, 674, 660 
 Crystallographic data. 17 
 
 
net formula 
Mr/g mol−1 
crystal size/mm 
T/K 
radiation 
diffractometer 
crystal system 
space group 
a/Å 
b/Å 
c/Å 
α/° 
β/° 
γ/° 
V/Å3 
Z 
calc. density/g cm−3 
µ/mm−1 
absorption correction 
transmission factor range 
refls. measured 
Rint 
mean σ(I)/I 
θ range 
observed refls. 
x, y (weighting scheme) 
hydrogen refinement 
refls in refinement 
parameters 
restraints 
R(Fobs) 
Rw(F2) 
S 
shift/errormax 
max electron density/e Å−3 
min electron density/e Å−3 
 
C-bound H: constr, O-bound H: refxyz (3), noref (1).
 
17 
C16H19N3O 
269.342 
0.161 × 0.125 × 0.026 
100(2) 
'Mo Kα 
'Bruker D8Venture' 
triclinic 
P1bar 
8.1881(8) 
9.6270(8) 
18.7815(16) 
90.979(3) 
100.522(3) 
101.182(3) 
1425.8(2) 
4 
1.25476(18) 
0.081 
multi-scan 
0.8718–0.9281 
12957 
0.0329 
0.0444 
2.48–25.39 
3456 
0.0572, 0.5451 
mixed 
5203 
374 
4 
0.0497 
0.1332 
1.034 
0.001 
0.383 
−0.272 
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VII 
Developing Photoswitchable Adenosines for Optical Control of 
Adenosine Receptors 
 
Matthias Schönberger, Dirk Trauner 
 
Ludwig-Maximilians University, Chemistry Department and Center for Integrated Protein 
Science Munich (CIPSM), Munich, Germany 
 
 
Extracellular adenosine is an important signaling molecule as a neuromodulator and 
a cell protecting agent. It binds to adenosine receptors (ARs) of the family A of G-
protein coupled receptors. Caffeine, the most widely used psychoactive drug, 
antagonizes the action of adenosine on ARs. ARs are prime pharmaceutical targets 
for treatment of Parkinson´s disease and anti-inflammatory agents. We have now 
developed a photoswitchable version of adenosine as a potential 
photopharmacological tool for these all-important receptors. 
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Introduction 
Extracellular adenosine is an important signaling molecule in the central nervous 
system.1,2 It binds to A1, A2A and A3 adenosine receptors, which are members of the 
family A of G-Protein coupled receptors GPCRs.  
Caffeine is an adenosine receptor (AR) antagonist and probably the most widely used 
psychoactive drug in the world, even though withdrawal leads to unpleasant 
symptoms such as headache, depressed mood, and muscle pain.3 ARs in the striatum 
orchestrate the psychomotor stimulant effect of caffeine.4 AR receptors in the shell of 
the nucleus accumbens are involved in the arousal effect of caffeine.5  
Some modulatory effects of adenosine are mediated by other transmembrane receptors 
such as the α3β4 nicotinic acetyl choline receptor that is transactivated through 
intracellular signaling cascaeds.6 Activation of the adenosine A2A receptor (A2AR) by 
agonists contributes to motoneuron survival through activation of tyrosine kinase 
receptor TrkB.7 In addition, ARs are involved receptor-receptor-interactions. For 
instance, in the striatum, ARs interact with other metabotropic receptors such as the 
cannabinoid CB1 receptor,8 dopamine D2 receptors,9,10 and mGluR5.11,12  
Being that ARs in the central nervous system modulate a number of physiological 
functions, they are targeted therapeutically in many diseases.13 AR ligands are 
currently intensely investigated in academic and industrial research.14,15 Extensive 
structure activity relationships (SARs) data have been accumulated and many drugs 
are currently investigated in clinical trials.16-18 Especially, potent A2AR antagonists are 
of interest for treatment of Parkinson’s disease.19,20 
Crystal structure analysis by Ray Stevens and coworkers has provided structural data 
for both the activated and inactivated (A2AR).21,22 As is the case for all G-protein 
coupled receptors (GPCRs), A2A receptors have seven membrane spanning helices and 
mainly communicate via eponymous G-protein activation.23-26 The crystal structure of 
A2AR has facilitated the discovery of novel chemotypes for antagonists.22,27-29  
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Figure 1. Adenosine receptor and ligands. A) Structure of the native agonist adenosine; ligand 
binding pocket (LBP) from crystal structures of the A2AR with ZM241385 (left, adapted from 
Stevens 201330) and adenosine (right, adapted from Lebon et al. 201131). Adenosine is shown 
in yellow. Structural data of ZM241385 have been added highlighting the overlay of the 
heterocyclic core and the different side chain interaction made by the ribose functional group. B) 
AR antagonists ZM241385 and caffeine, and AR agonists CGS216805 and NECA. 2-
Substituted ligands ZM241385 and CGS216805 are more selective for A2AR. 
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Figure 1 depicts selected natural and synthetic ligands that, in combination with an 
A2AR crystal structures, guided the design of a photoswitchable AR agonist.32 The 
native agonist adenosine (Figre 1A) is a 6-amino purine with a ribose attached to N9. 
Synthetic agonists NECA and CGS21680 (figure 1B, right) share the hetero aromatic 
purine core. The ribose moiety attached to N9 is slightly modified with an N-ethyl 
carboxamid at C5´. In comparison to adenosine and the non-subtype-specific synthetic 
agonist NECA, CGS21680 carries a comparatively large phenethylamine derivative in 
2-position. The crystal structure of an A2AR with adenosine showed that the ribose 
functional group makes important interactions with amino acids at the bottom of the 
ligand binding pocket (LBP).31 
AR antagonists are devoid of the ribose moiety. Caffeine is a per-N-methylated 
xanthine (Figure 1B) that is not selective for one particular AR. The triazolo-triazine 
ZM241385 is substituted in 8-position with a furan ring. Similar CGS21680, it also 
features a comparatively large phenethylamine substituent in 2-position. The crystal 
structure of A2AR with the synthetic antagonist ZM241385 revealed a narrow LBP 
perpendicular to the membrane and helped explaining SARs.28 The heterocyclic core is 
positioned in the same way as adenosine, however, amino acid residues important for 
receptor activation cannot be reached (Figure 1A, right panel). 
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Results and Discussion 
Based on these findings, 1st generation photoswitchable AR agonists as shown in 
Scheme 1A were synthesized. Azoadenosines are equipped with a 2-amino functional 
group that is further substituted with a phenethyl azobenzene building block 
resembling the substitution pattern of ZM241385 and CGS21680. Ribose was chosen as 
the agonistic pharmacophore resembling the native agonist adenosine. Ribose was 
deliberately chosen over the N-ethyl carboxamido derivative as present in NECA and 
CGS21680 in order to facilitate dissociation from the LBP upon photoswitching. 
Synthesis started from commercial 2-iodo-adenosine 1 that underwent chemoselective 
reaction with neat unprotected 4-amino-phenethylamine 2 (Scheme 1B). The resulting 
aniline could be readily reacted with commercial nitrosobenzene 3 yielding azo-
adenosine-1.  
To provide a photochromic ligand (PCL) with a more pronounced sterical change after 
isomerization, the biphenyl derivative azo-adenosine-2 was synthesized. The required 
nitroso-biphenyl 3 was obtained by oxidation of amino-biphenyl using oxone. Due to 
the poor solubility of biphenyl derivatives in aqueous solvents, the oxidation did not 
proceed as fast and complete as for anilines.33-35 However, using a five-fold excess of 
the amine and prolonged reaction times allowed preparing azo-adenosine-2. 
 
 
Scheme 1. Design and synthesis of azoadenosines. 
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Summary and Outlook 
Photoswitchable versions of the neuromodulator adenosine have been designed and 
synthesized. Future biological testing in will show whether these molecules are 
efficient photochromic ligands for ARs. 
A1 and A3 adenosine receptor subtypes typically couple to Gi G-proteins, leading to 
inhibition of the adenylyl cyclase and activation of G-protein coupled inwardly 
rectifying potassium (GIRK) channels.36,37 Therefore, photopharmacological testing 
could be carried out in analogy to previous work using GIRK channel 
electrophysiologiy.38 
By contrast, A2A adenosine receptor subtypes typically couple to Gs G-proteins, leading 
to activation of the adenylyl cyclase.39 The lack of in-time read-out methods for cAMP 
levels complicates quantitative and qualitative assessment of photoswitching 
associated to A2AR. Redirecting A2AR signaling to phospholipase C using a chimeric 
Gqs G-protein would allow Ca2+ imaging as an alternative.40,41  
GPCRs are famous for their multifunctional activity, which is believed to originate 
from structural flexibility between distinct receptor conformations.19,24 In the case of 
adenosine receptors, this intrinsic versatility is paired with interesting 
heteromerization events.42 Therefore, tools for selective and reversible receptor 
activation will be of great value for GPCR-research. 
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EXPERIMENTAL PROCEDURES 
 
 
General Considerations 
All reagents were purchased from commercial suppliers and used without further 
puri_cation. All reactions were carried out under magnetic stirring. The glassware was 
dried at 120 _C prior to usage. Analytical thin layer chromatography (TLC) was carried 
out on Merck silica gel 60 F254 TLC plates and visualized under UV light.  
Flash chromatography was performed on Dynamic Adsorbents Silica Gel (40-63 _m 
particle size).  
Proton (1H) and carbon (13C) spectra were measured on a Varian Mercury instruments 
at 300 or 400 MHz. Chemical shifts are reported in ppm with the solvent resonance 
employed as the internal standard (CDCl3 at 7.26 and 77.0 ppm respectively). The 
following abbreviations are used to explain the multiplicities: s = singlet, d = doublet, t 
= triplet, q = quartet, m = multiplet, br = broad. 
IR spectra were recorded on a Perkin Elmer Spectrometer BY FT-IR System with a 
Smith Dura sample IR II ATR-unit. The absorption bands are reported in wave 
numbers (cm1). High resolution mass spectra  
(HRMS) were recorded on a Varian MAT CH 7A for electron impact ionization (EI) 
and on a Varian MAT 711 spectrometer for electron spray ionization (ESI). 
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Aniline s1 
 
 
 
2-Iodoadenosine 1 (150 mg, 0.38 mmol, 1.0 eq) was suspended in neat amino 
phenethylamine 2 (251 µL, 1.91 mmol, 5.0 eq) and heated to 110 °C under Ar-gas atm. 
At approximately 70 °C, the mixture turned into a homogeneous solution. TLC 
monitoring (SiO2, 20% MeOH, 80% DCM) indicated complete turnover after 3 h. The 
reaction mixture was allowed to cool to rt (solid gum), diluted with MeOH and purified 
using reverse phase flash column chromatography (C-18, isogratic 30% MeOH, 70% 
H2O). The clean product s1 was obtained as an off-white foam after lyophilization (150 
mg, 0.37 mmol, 98%). 
TLC (SiO2, 20% MeOH, 80% DCM) Rf = 0.47 (UV + ninhydrine) 
1H-NMR (400 MHz, DMSO-d6) δ = 7.90 (s, 1H), 6.90 (d, J=8.4, 2H), 6.71 (s, 2H), 6.56 - 6.44 (m, 
2H), 6.02 (t, J=5.7, 1H), 5.73 (d, J=6.1, 1H), 5.38 (d, J=6.2, 1H), 5.12 (d, J=4.7, 2H), 4.82 (s, 
2H), 4.60 (s, 1H), 4.19 - 4.05 (m, 2H), 3.90 (q, J=4.0, 1H), 3.70 - 3.45 (m, 2H), 3.16 (d, J=5.2, 
1H), 2.63 (dd, J=6.6, 8.6, 2H). 
 
13C NMR (101 MHz, dmso) δ = 159.67, 156.46, 151.91, 147.03, 136.81, 129.48, 127.33, 
114.43, 114.07, 87.62, 85.73, 73.34, 71.13, 62.26, 43.80, 35.08. 
HRMS (ESI) calcd for C18H24N7O4 [M+H]+: 402.1884; found: 402.1881 
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Azo-adenosines 
 
 
Formation of nitrosobenzenes 
Nitrosobenzene 3 was commerzially available. 4-Phenyl-nitrosobenzene 4 was 
prepared freshly. Aminobiphenyl (189 mg, 1.12 mmol, 4.5 eq.) was dissolved in DCM 
(5 mL) and H2O (10 mL). Oxone (689 mg, 1.12 mmol, 4.5 eq.) in 5 mL H2O was slowly 
added to the solution under nitrogen atmosphere. After vigorous stirring for 17 hours, 
the reaction mixture was diluted with EtOAc. The organic layer was washed with 1-M-
HCl, 1-M-NaOH and brine, and dried over Na2SO4. After removal of the solvent in 
vacuo, the crude nitroso arene was submitted to the next step as a DCM solution. 
Mills coupling 
Aniline s1 (1.0 eq., 10 to 150 mg scale) and the corresponding nitrosobenzene (1.5 eq. 
3 and 4.5 eq 4) were dissolved in 2 mL DCM and acetic acid was added (10 eq.). After 
2-23 hours, the reaction mixture was concentrated in vacuo. The reaction mixture was 
dissolved in 20 mL chloroform and washed with 20 mL NaHCO3(conc.). The aqueous 
phase was extracted 3 times with 30 mL ethyl acetate. Combined organic layers were 
dried over Na2SO4 and concentrated in vacuo. Purification using flash column 
chromatography (SiO2, isocratic 10% MeOH, 90% DCM) yielded azo-adenosines as 
orange amorphous solids. 
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Azo-adenosine-1 
 
N
NN
N
NH2
O
OHOH
HO N
H
N
N
azo-adenosine-1
C24H26N8O4
490,52 g/mol  
 
TLC (SiO2, 20% MeOH, 80% DCM) Rf =  0.72 (UV) 
1H-NMR(400 MHz, CD3OD) δ = 7.96 - 7.79 (m, 6H), 7.59 - 7.38 (m, 5H), 7.31 - 7.09 (m, 1H), 
6.88 - 6.74 (m, 1H), 5.84 (dd, J=6.2, 10.7, 1H), 4.83 - 4.72 (m, 2H), 4.39 - 4.26 (m, 1H), 4.18 - 
4.07 (m, 1H), 3.90 - 3.80 (m, 1H), 3.78 - 3.43 (m, 5H), 2.99 (t, J=7.2, 2H). 
 
13C NMR (101 MHz, CD3OD) δ = 159.41, 156.13, 152.60, 151.08, 143.75, 140.00, 137.35, 
130.62, 129.42, 128.79, 127.12, 122.49, 122.26, 113.43, 89.27, 86.08, 73.40, 71.20, 62.09, 
42.58, 35.43.  
HRMS (ESI) calcd for C24H26N8O4 [M+H]+: 491.2150; found: 491.2147 
IR νmax: 3477, 3362, 3206, 2924, 2855, 2362, 1639, 1599, 1538, 1491, 1417, 1123, 1056, 903, 
686. 
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Azo-adenosine-2 
 
N
NN
N
NH2
O
OHOH
HO N
H
N
N
azo-adenosine-2
C30H30N8O4
566,62 g/mol
 
 
TLC (SiO2, 10% MeOH, 90% DCM) Rf = 0.38 (UV) 
 
1H-NMR (400 MHz, DMSO-d6) δ = 8.19 (s, 1H), 8.06 - 7.75 (m, 9H), 7.51 (m, 6H), 6.81 (s, 2H), 
6.35 (s, 1H), 5.81 (d, J=6.0, 1H), 4.69 (s, 1H), 4.20 (s, 1H), 3.96 (d, J=3.5, 1H), 3.65 (m, 5H), 
3.00 (t, J=7.1, 2H). 
 
13C NMR (101 MHz, DMSO-d6) δ = 163.63, 159.64, 156.52, 151.93, 151.55, 150.91, 144.85, 
143.19, 139.42, 136.88, 130.29, 129.53, 128.62, 128.09, 127.21, 123.58, 123.14, 114.14, 
87.61, 85.70, 73.39, 71.13, 62.23, 43.08, 35.73. 
 
HRMS (ESI) calcd. for C30H30N8O4 [M+H]+: 567.2463; found: 567.2459. 
 
IR νmax: 3357, 3175, 2923, 1697, 1633, 1595, 1538, 1483, 1405, 1354, 1321, 1262, 1223, 
1109, 1085, 1051, 901, 848, 788, 765, 725, 693. 
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VIII 
 
Synthesis of Photoswitchable Benzodiazepines 
 
Matthias Schönberger & Dirk Trauner 
 
Department of Chemistry, Ludwig-Maximilians-Universität, and Center for Integrated 
Protein Science, 81377 Munich, Germany.  
 
 
Benzodiazepines (BZDs) are positive allosteric modulators (PAMs) of GABAA 
receptors. They are used as powerful sedative, anticonvulsive and anxiolytic drugs. 
However, BZD use leads to drug addiction and further research is needed to reduce 
side effects. We have developed azobenzene derivatives of the potent BZD 
clonazepam. These photochromic ligands may act as photoswitchable PAMs of 
GABAA receptors. 
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Introduction 
 
GABAA receptors. GABAA receptors are chloride selective ion channels of the 
pentameric ligand gated ion channel (pLGIC) super-family that also includes nicotinic 
acetylcholine receptors (nAChR), glycine receptors (GlyR), Erwinia chrysanthemi ligand 
gated ion channels (ELIC), Gloeobacter violaceus ligand gated ion channels (GLIC) and 5-
hydroxytrytamine-type-3-receptors (5HT3).1 Even though GABAA receptors themselves 
have not been crystallized to date, recent crystal structure elucidation of ELIC and 
GLIC has provided detailed structural insights to the general pentameric channel 
architecture.2 All of the abovementioned receptors share a prominent cysteine loop in 
their amino-terminal domain. Therefore, they are also referred to as the “cys-loop” 
family.3,4 In addition, they share a pentameric architecture with five individual 
subunits assembling a central ion conductive pore. Each subunit consists of a large 
hydrophilic amino-terminal extracellular domain and four membrane spanning 
domains (TM1-4).5-7 
There are eight different classes of subunits making a total of 19 different subunits that 
can form heteropentameric GABAA receptors: α (1-6), β (1-3), γ (1-3), δ, ε, ρ (1-3), θ and 
π.6 GABAA receptors consisting of two α1, two β2 and one γ2 subunit are the major 
isoform in brain. The arrangement of these subunits has been determined to be γ2-β2-
α1-β2-α1 (Figure 1).8,9 Each receptor has individual functional and pharmacological 
properties based on its subunit composition.10,11 
GABAA receptors allow influx of chloride ions when two molecules of the native 
agonist γ-amino-butyric acid (GABA) bind to the channel at the interface of the α and β 
subunit. This results in membrane hyperpolarization (inhibitory postsynaptic 
potential).12,13 Therefore, GABA is the most prime inhibitory neurotransmitter in the 
vertebrate brain.14 
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Figure 1. GABAA receptors. A) Schematic drawing of a GABAA receptor (left) and chemical 
structure of its agonists GABA and muscimol (right). B) Mechanism of action of 
benzodiazepines (BZDs) and chemical structures of the classical BZDs diazepam and 
clonazepam. Flumazenil is a competitive BZD antagonist. 
 
Benzodiazepines. Benzodiazepines (BZDs) are positive allosteric modulators of GABAA 
receptors, binding at the extracellular interface of the α and γ subunit (Figure 1B).15 
BZDs are highly effective anxiolytics and are further used for treatment of insomnia, 
convulsive disorders, muscle relaxation and sedation. Due to undesired side effects 
including drowsiness, confusion and most importantly drug addiction,16,17 their use is, 
however, limited.12,13  
BZDs are positive allosteric modulators of GABAA receptors, enhancing the effect of 
GABA by increasing the channel open frequency.13,18 GABAA receptors with α1-3 or α5 
subunits are involved in phasic inhibition and are BZD sensitive. By contrast, α4 or α6 
containing isoforms lead to tonic inhibition and are BZD insensitive.5 The different α-
subunit isoforms also contribute to different effects by BZDs.19 For instance, receptors 
containing α1 subunits appear to be responsible for the sedative properties of classic 
BZDs and those containing α2 or α3 subunits cause anxiolytic effects.20 
Diazepam was one of the first BZDs that was synthesized and marketed (valium®), 
followed by many other derivates including the more potent clonazepam.21 The 
imidazole flumazenil is a competitive antagonist of BZDs.22 
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Results and Discussion  
Design of photochromic ligands. Given the important role of GABAA receptors in human 
health and disease, and the associated pharmacological impact of BZDs, we decided to 
develop photoswitchable azobenzene derivatives of clonazepam as photochromic 
ligands (PCLs), viz photo-benzodiazepines (pBZs, Figure 2).23 Since PCLs are 
permanently modified with the comparatively large azobenzene moiety, they have to 
be designed carefully. Ideally, one of the photoisomers provides high pharmacological 
activity, while the other isomer does not.24  
Since there is no X-ray structure of a GABAA receptor with a BZD, we developed two 
molecular platforms for combining an azobenzene functional group with clonazepam 
(Figure 2B). pBZs of the first generation carried the azobenzene as an extention of the 
annulated benzo ring (pBZ1.1). Recently published azobenzene-BZD-derivatives with 
this substitution pattern showed only micromolar IC50 values in an antihelmintic test 
against Schistosoma mansoni.25 However, the reported synthetic route of Mahajan et al. 
relied on a diazotization reactions with phenolates. Resulting 4´-hydroxy derivatives, 
which are uncommon for BZDs were not tested for GABAA receptor activity. 25 To 
avoid hydrogen bond donors in 4´-position, we turned to Mills reaction for azobenzene 
formation.26  
 
 
Figure 2. Photo-benzodiazepines (pBZs). A) Proposed mechanism of action of pBZs. B) Two 
representative pBZs with different chemical design. 
pBZs of second generation were alkylated with a benzyl azobenzene at the anilide 
nitrogen of the seven-membered BZD ring (pBZ2.1, Figure 2B). 
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Scheme 1. Chemical synthesis of clonazepam (A) and photoswitchable derivatives pBZ1.1 (B), pBZ1.2 (C) 
and pBZ1.3 (D). 
 
Synthesis of photochromic ligands. First, clonazepam was ssynthesized from commercial 
benzophenone 1. To set up a Sternbach cyclization, Fmoc-glycine was coupled to 1 
using acid chloride activation (Scheme 1A). After deprotection, cyclodehydration was 
achieved by boiling in toluene and acetic acid. 
Clonazepam was then used as a basis for all pBZs. For first generation molecules, 
clonazepam had to be set up for a Mills reaction. To install the required aniline 
functional group, it was reduced using SnCl2 in HCl/MeOH affording 2. Condensation 
with commercial nitrosobenzene in a mixture of acetic acid and DCM yielded pBZ1.1 
(Scheme 1B). Crystal structure analysis demonstrated the planar annulated azobenzene 
and the 2-chloro benzene ring that is oriented perpendicular to the seven-membered 
ring.  
For electron rich 4´-substitution, 2 could also be oxidized to the corresponding nitroso 
intermediate I that was subsequently condensed with commercial N,N-dimethyl-4-
amino-aniline giving pBZ1.2 (Scheme 1C). Hydrogen gas and palladium on charcoal 
reduced not only clonazepam´s nitro group, but also the Schiff base and the 
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chlorobenzene, yielding the dihydro BZD 3 (Scheme 1D). Coupling with freshly 
prepared 4-nitro nitrosobenzene gave access to pBZ1.3.  
 
 
For second generation pBZs, benzyl azobenzene building blocks were prepared and 
equipped with a leaving group. Either corresponding benzyl alcohols were converted 
to mesylates using mesyl chloride or to benzyl bromides via Appel reaction (see 
Experimental section). Best alkylation reactions were obtained when clonazepam was 
deprotonated with K2CO3 in DMF at 0 °C and subsequently treated with the desired 
building block (Table 1). Table 1 shows the resulting pBZ2.1-6 molecules that vary in 
the substitution and of the azobenzene. In addition, the isothiocyanate derivative 
north-NCS was prepared for cystein labeling reactions. 
Biological testing was performed by our collaborators Simon Middendorp and Erwin 
Sigel from Bern University. It was found that all pBZ1 molecules were inactive as 
PAMs on α1β2γ2GABAA receptors at all concentrations regardless of the illumination 
wavelength. The relatively large substituent in 7-position was not tolerated. Wether 
these molecules may act as BZD antagonists has yet to be determined.  
By contrast, all pBZ2 molecules were active. However, photoeffects were small and the 
maximally activating effect could in many cases not be determined due to solubility 
issues. Nevertheless, PAM activity was maintained after substitution and the observed 
photoeffects affirm that the substitution pattern of pBZ2s may be a promising platform 
for future PCLs. 
clonazepam
O2N
N
Cl
O
N
N
N
pBZ2.1 pBZ2.2 pBZ2.3 pBZ2.4
pBZ2.5 pBZ2.6 north-NCS
Table 1. Synthesis of  2nd generation pBZs and list of  molecules.
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Summary and Outlook 
In conclusion, a small series of photoswitchable clonazepam derivatives (pBZs) have 
been synthesized. First generation pBZ1 molecules, substituted in 7-position, were 
inactive as PAMs on α1β2γ2GABAA receptors. Second generation pBZ2 molecules, 
substituted at N1, were PAMs, however, lacked pronounced photoswitching and had 
only poor solubility. 
To improve both photoswitching and solubility, differently substituted azobenzenes 
may be installed in future. In particular ortho- and meta-benzyl derivatives might be 
interesting candidates. Hydrophilic 4´-substitution might also increase both 
photoswitching and solubility. 
Wether existing pBZs have distinct effects on different GABAA receptor isoforms 
remains to be determined. Subtype selective photopharmacology might be very helpful 
for developing novel therapeutics.  
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Abbreviations 
ATR  attenuated total reflectance 
Boc  tert-butyloxycarbonyl 
BPh  benzophenone 
BZD  benzodiazepine 
calc.  calculated 
cat.  catalytic 
Cbz  benzyloxycarbonyl 
CDI  1,1'-carbonyldiimidazole 
δ  chemical shift (NMR) 
DCM  dichloromethane 
DIPEA  N,N-diisopropylethylamine 
DMSO  dimethylsulfoxide 
DMF  dimethylformamide 
eq.  equivalent(s) 
ESI  electron spray ionization 
Et  ethyl 
Fmoc  fluorenylmethoxycarbonyl 
FT  fourier transform 
GABA  γ-aminobutyric acid 
gly.  glycine 
HBTU 2-(1H-benzotriazole-1-yl)-1,1,3,3-tetramethylaminium 
hexafluorophosphate 
HMPA hexamethylphosphoramide 
HPLC  high-performance liquid chromatography 
HRMS  high resolution mass spectrometry 
IC50  half maximal inhibitory concentration 
IR  infrared spectroscopy 
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isohex  iso-hexanes 
λmax  absorption maximum 
Me  methyl 
MPLC  medium pressure liquid chromatography 
NMM  N-methylmorpholine 
NMR  nuclear magnetic resonance 
PCL  photochromic ligand 
PG  protecting group 
ppm  parts per million 
PTL  photoswitched tethered ligands 
Rf  retention factor (TLC) 
rt  room temperature 
Rt  retention time (HPLC) 
sat.  saturated 
sm  starting material 
TEA  triethylamine 
TLC  thin layer chromatography 
THF  tetrahydrofuran 
Ts  tosyl 
UV  ultra-violet 
VIS  visible light 
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Experimentals 
 
General Methods 
All reactions were conducted in oven-dried glassware equipped with a magnetic stir 
bar using freshly distilled solvents. Tetrahydrofuran was distilled from sodium 
benzophenone. All other commercially available reagents were used as received. 
All salt solutions used in aqueous work ups were aqueous and saturated if not 
otherwise noted. 
Thin layer chromatography was performed on E. Merck 0.25 mm silica gel 60 F254 
precoated glass plates and the compounds were detected on thin-layer 
chromatography plates using UV light at 254 nm and/or ninhydrine stain. 
Flash column chromatography was carried out with silica gel 60 (40-63 µm). 
HPLC was performed on a VARIAN PrepStar Model SD-1 system equipped with 
UV/VIS detector VARIAN 380-LC on Microsorb 60 C18 silica (particle size: 8 µm) 
reverse-phase column. Composition of the products was assessed by analytical reverse 
phase HPLC using a column (250 x 4.6 mm) employing following methods:  
Method A: 20% MeOH with 0.1% formic acid in H2O over the first 3 min, 20 to 90%          
MeOH in H2O linear gradient over 52 min; flow rate: 0.75 mL/min. 
Method B: 10% MeOH with 0.1% formic acid in H2O over the first 5 min, 10 to 90%          
MeOH in H2O linear gradient over 52 min; flow rate: 0.75 mL/min. 
Methods for preparative reverse phase HPLC (250 x 21.4 mm): 
Method A: 40% MeOH with 0.1% formic acid in H2O over the first 3 min, 40 to 90%         
MeOH in H2O linear gradient over 52 min; flow rate: 15.75 mL/min. 
Method B: 30% MeOH with 0.1% formic acid in H2O over the first 3 min, 30 to 70%          
MeOH in H2O linear gradient over 52 min; flow rate: 15.75 mL/min. 
NMR spectra (1H-NMR, 13C-NMR) were recorded on VARIAN VNMRS 300, VNMRS 
400, INOVA 400 or VNMRS 600 spectrometers with deuterated chloroform (CDCl3) or 
dimethylsulfoxide (d6-DMSO) as solvents. Chemical shifts δ are reported in ppm 
relative to the known value of residual solvent signal and coupling constants are in Hz. 
The following abbreviations are used to describe peak patterns: s (singlet), d (doublet), 
t (triplet), and m (multiplet). 
IR spectra were recorded as ATR (attenuated total reflectance) on a PERKIN ELMER 
Spectrum BX II (FTIR System) and are reported as wave numbers (cm-1). As detector a 
SMITHS DETEVTION DuraSamplIR II Diamond ATR senor was used. 
275 
 
Mass spectrometry: Molecular weights were assessed by electronspray ionization mass 
spectrometry in high resolution (ESI/HRMS) performed on a THERMO FINNIGAN 
LTQ FT spectrometer at the Department of Chemistry and Pharmaceutical Science of 
Ludwig-Maximilians-Universität Munich. 
Melting points were taken on a Büchi apparatus using open capillary tubes and remain 
uncorrected. 
UV/VIS spectra were recorded on a VARIAN 50 Scan 50 spectrophotometer in 
precision cells made of quartz SUPRASIL®. 
 
 
 
List of Molecules 
 
Table 2. Building blocks.____________________________________________ _____________  
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Table 3. Benzodiazepines.________________________________________________________ 
 
 
 
Table 4. 1
st
 Generation Photo-Benzodiazepines (pBZs)._________________________________ 
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Table 5. 2
nd
 Generation Photo-Benzodiazepines (pBZs).________________________________ 
 
 
 
Table 6. Isolated intermediates and side products.____________________________________ 
 
Experimental Procedures Clonazepam & 1st Generation pBZs 
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Clonazepam  
 
To N-Fmoc-glycine (8.60 g, 28.9 mmol, 2 eq.) in 70 mL freshly distilled tetrahydrofuran, 
10.5 mL thionyl chloride (145 mmol, 10 eq.) were added under argon atmosphere and 
the solution was heated to 60 °C for 1 h. The solvent was removed in vacuo and the 
oily residue was co-evaporated with chloroform twice. The crude material was 
dissolved in 70 mL chloroform benzophenone 1 (4.00 g, 13.4 mmol, 1 eq.) was added. 
The reaction mixture was stirred at 68 °C overnight. After cooling to room temperature, 
the solution was washed with aqueous solution of NaHCO3 (2 x 50 mL). The organic 
layer was dried over Na2SO4, filtered and the solvent was removed in vacuo. The solid 
residue was purified by recrystallization. The product was washed with cold methanol 
yielding 7.82 g (97%) of carbamate intermediate I as a white solid. 
I (4.99 g, 8.97 mmol, 1.0 eq.) was dissolved in 160 mL freshly distilled tetrahydrofuran 
and 4.42 mL piperidine (44.8 mmol, 5.0 eq.) were added. The progress of the reaction 
was monitored using TLC (silica; 10% MeOH/DCM). Over the course of 1.5 h, white 
precipitation occurred. Additional 2.5 eq. of piperidine and 20 mL tetrahydrofuran were 
added. The reaction was terminated after a total reaction time of 16.5 h and the solvent 
was removed under reduced pressure yielding intermediate II. Without further 
purification, the crude was suspended in 200 mL toluene and 2.76 mL (48.3 mmol, 
5.0 eq.) acetic acid were added. The resulting reaction mixture was refluxed for 4 h at 
123 °C. After removal of the solvent using rotary evaporation, the residue was taken up 
in 200 mL ethyl acetate. The solution was washed with sat. NaHCO3 (3 x 80 mL) and 
brine (80 mL). After drying over Na2SO4 the extract was filtered and the solvent was 
removed under reduced pressure. Purification using flash column chromatography 
(silica, gradient: 0-20% MeOH/DCM) yielded clonazepam (1.47 g, 53%) as a pale 
yellow solid. 
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TLC (silica; 10% MeOH, 90% DCM) Rf = 0.56 (UV) 
mp = 237-238 °C 
IR (FT, ATR): 3103, 3057, 2972, 2898, 2843, 1691, 1614, 1538, 1334, 1313, 1300, 1256, 1100, 
1014, 843, 771, 764, 750, 740, 730 cm-1. 
1H NMR (400 MHz, dmso-d6) δ = 11.27 (s, 1H), 8.36 (dd, J=9.0, 2.7, 1H), 7.72 (d, J=2.5, 1H), 
7.66 – 7.62 (m, 1H), 7.56 – 7.47 (m, 3H), 7.41 (d, J=9.0, 1H), 4.29 (s, 2H). 
13C NMR (101 MHz, dmso-d6) δ = 169.74, 168.32, 144.81, 142.02, 138.44, 132.22, 132.01, 
131.92, 130.27, 128.01, 127.38, 126.92, 125.36, 122.62, 57.55. 
HRMS (ESI, positive): calc. for C15H11ClN3O3 (M+H)+: 316.0489; found: 316.0484. 
HRMS (ESI, negative): calc. for C15H9ClN3O3 (M)-: 314.0338; found: 314.0337. 
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Amino Benzodiazepine 2 
 
Clonazepam (200 mg, 0.633 mmol, 1.0 eq.) was treated with 1.2 mL 6M HCl and tin(II) 
chloride dihydrate dissolved in 1.2 mL 6M HCl was added. To the yellow suspension, 
8 mL methanol were added and the suspension turned gradually into a red solution. 
After 5 h stirring at room temperature methanol was removed under reduced pressure 
and the reaction mixture was basified with 1M NaOH. The aqueous solution was 
extracted with dichloromethane (3 x 15 mL) and combined organic layers were dried 
over NaSO4, filtered and concentrated under reduced pressure. The crude product was 
purified using flash column chromatography (silica pretreated with 1% TEA/DCM, 
gradient: 0-5% MeOH/DCM) yielding 2 (168 mg, 93%) as a pale brown solid. 
TLC (silica; 10% MeOH, 90% DCM) Rf = 0.50 (UV) 
mp = 125-126 °C 
IR (FT, ATR): 3339, 3207, 3051, 2886, 1668, 1610, 1500, 1341, 1307, 1231, 1058, 1010, 823, 
765, 752, 736 cm-1. 
1H NMR (400 MHz, dmso-d6) δ = 10.09 (s, 1H), 7.49 – 7.36 (m, 4H), 6.87 (d, J=8.6, 1H), 6.70 
(dd, J=8.6, 2.6, 1H), 6.11 (d, J=2.6, 1H), 5.07 (s, 2H), 4.05 (s, 2H). 
13C NMR (101 MHz, dmso-d6) δ = 169.69, 169.58, 144.73, 139.87, 132.30, 131.53, 130.99, 
130.02, 128.99, 128.48, 127.56, 122.40, 118.56, 112.43, 57.35. 
HRMS (ESI, positive): calc. for C15H13ClN3O (M+H)+: 286.0747; found: 286.0741. 
 
  
281 
 
Amino Dihydobenzodiazepine 3 
 
To a solution clonazepam (43 mg, 0.14 mmol, 1 eq.) in 40 mL methanol and 63 µL 
(1.1 mmol, 8 eq.) acetic acid, 10% palladium on carbon (15 mg, 0.014 mmol, 0.1 eq.) 
were added. The reaction mixture was stirred under a hydrogen atmosphere for 8 h at 
room temperature. After filtration, the solvent was removed under reduced pressure 
and the residue was partitioned between 30 mL ethyl acetate and aqueous solution of 
NaHCO3 (15 mL). The organic phase was washed with aqueous solution of NaHCO3 (2 
x 15 mL) and aqueous solution of NaCl (15 mL). After drying over NaSO4, filtration and 
removal of the solvent using rotary evaporation, the residue was purified using flash 
column chromatography (silica; gradient: 0-10% MeOH/DCM) yielding 3 (7 mg, 20%). 
TLC (silica; 10% MeOH, 90% DCM) Rf = 0.50 (UV) 
1H-NMR (400 MHz, dmso-d6): δ 9.33 (s, 1H), 7.31 (d, 3J = 4.4 Hz, 4H), 7.27-7.21 (m, 1H), 6.70 
(d, 3J = 8.4 Hz, 1H), 6.39 (dd, 3J = 8.4, 4J = 2.6 Hz, 1H), 5.86 (d, 4J = 2.4 Hz, 1H), 5.04 (s, 1H), 
4.79 (s, 2H), 3.44 (s, 1H), 3.16 (s, 2H) ppm. 
13C-NMR (100 MHz, dmso-d6): δ 172.3, 145.7, 143.0, 134.6, 128.6, 128.5, 127.8, 127.4, 122.2, 
114.6, 113.6, 61.4, 50.4 ppm. 
HRMS (ESI, positive): calc. for C15H16N3O (M+H)+: 254.1293; found: 254.1287. 
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pBZ1.1 
 
2 (50 mg, 0.16 mmol, 1 eq.) was dissolved in 2 mL acetic acid, followed by addition of 
nitrosobenzene 17 (17 mg, 0.16 mmol, 1 eq.) and the reaction mixture was stirred for 
12 h at room temperature. The mixture was treated with aqueous solution of NaHCO3 
and was basified with Na2CO3. The aqueous layer was extracted with dichloromethane 
(3 x 15 mL) and the combined organic layers were dried over Na2SO4. After filtration, 
the solvent was removed under reduced pressure and the crude product was purified 
using flash column chromatography (silica; gradient: 0-2% MeOH/DCM) yielding 56 mg 
(94.6%) of pBZ1.1 as an orange solid. 
TLC (silica; 10% MeOH, 90% DCM) Rf = 0.53 (UV) 
mp = 255-257 °C 
λmax = 340 nm 
IR (FT, ATR): 3056, 2959, 1682, 1611, 1488, 1360, 1235, 1060, 1016, 843, 742 cm-1. 
1H-NMR (CDCl3, 400 MHz): δ 8.72 (s, 1H), 8.04 (dd, 3J = 8.6, 4J = 2.2 Hz, 1H), 7.83 (ddd, 3J 
=4.4, 3J = 3.7, 4J = 1.6 Hz, 2H), 7.67 (d, 4J = 2.2 Hz, 1H), 7.63-7.59 (m, 1H), 7.50-7.45 (m, 3H), 
7.42-7.36 (m, 3H), 7.23 (d, 3J = 8.7 Hz, 1H), 4.46 (s, 2H) ppm. 
13C NMR (101 MHz, CDCl3) δ = 170.68, 170.24, 152.33, 148.27, 139.55, 138.63, 133.27, 
131.39, 131.11, 130.94, 130.17, 129.10, 128.96, 128.35, 127.72, 127.01, 126.96, 124.23, 
123.89, 122.87, 122.56, 121.65, 121.33, 56.62. 
HRMS (ESI, positive): calc. for C21H16ClN4O (M+H)+: 375.8309; found: 375.1011. 
HRMS (ESI, negative): calc. for C21H14ClN4O (M)-: 373.0862; found: 373.0857. 
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General procedure I: Oxone oxidation and subsequent Mills reaction yielding 
diazobenzenes 18, 19 and 20 8 
 
A solution of an aniline (1 eq.) in dichloromethane was treated with an aqueous 
solution of Oxone® (3-4.5 eq.). The biphasic reaction mixture was stirred vigorously at 
room temperature until TLC monitoring showed no further consumption of the starting 
material (17-24 h). Phases were separated and the aqueous layer was extracted with 
dichloromethane three times. The combined organic layers were washed with 1M HCl, 
aqueous solution of NaHCO3, water and aqueous solution of NaCl. After drying over 
Na2SO4, extracts were filtered and the solvent was removed under reduced pressure 
yielding crude nitrosoarenes. 
Without further purification, nitosoarenes were dissolved in acetic acid, followed by 
addition of corresponding aniline. The reaction mixture was stirred at room temperature 
until TLC monitoring indicates complete reaction (17-21 h). The mixture was treated 
with aqueous solution of NaHCO3 and was basified with Na2CO3. The aqueous layer 
was extracted with dichloromethane three times and the combined organic layers were 
dried over Na2SO4. After filtration, the solvent was removed under reduced pressure 
and the crude product was purified from major impurities using quick flash column 
chromatography (silica; gradient: 0-5% MeOH/DCM). Purification of the isolated crude 
product using HPLC yielded the desired azobenzenes 18, 19 and 20. 
 
  
                                                           
8
 Priewisch, B. & Rück-Braun, K. Efficient Preparation of Nitrosoarenes for the 
Synthesis of Azobenzenesâ€ The Journal of Organic Chemistry 70, 2350-2352 
(2005). 
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pBZ1.2 
 
Following general procedure I, clonazepam (50 mg, 0.088 mmol, 1 eq.) in 2 mL 
chloroform was treated with Oxone® (242 mg, 0.394 mmol, 4.5 eq.) dissolved in 4 mL 
water. For aqueous work up, the organic layer was washed with aqueous solution of 
NaHCO3, water and aqueous solution of NaCl. 
The resulting crude nitroso compound was dissolved in 2 mL acetic acid and N,N-
dimethyl-p-phenylenediamine (18 mg, 0.13 mmol, 1.5 eq.) was added. Aqueous work 
up und purification (HPLC: method A) yielded 10 mg (33%) of pBZ1.2 as a brown solid. 
HPLC (C-18, analytical HPLC, method A) Rt = 32.4 min 
TLC (silica; 10% MeOH, 90% DCM) Rf = 0.55 (UV) 
mp = 250-253 °C 
λmax = 433 nm 
IR (FT, ATR): 2920, 2853, 1682, 1598, 1517, 1361, 1230, 1141, 1058, 1011, 944, 821, 750 cm-
1
. 
1H-NMR (CDCl3, 600 MHz): 8.81 (s, 1H), 7.96 (dd, 3J = 8.6, 4J = 2.2 Hz, 1H), 7.80-7.76 (m, 2H), 
7.61-7.57 (m, 1H), 7.55 (d, 4J = 2.2 Hz, 1H), 7.41-7.34 (m, 3H), 7.19 (d, 3J = 8.7 Hz, 1H), 6.74-
6.66 (m, 2H), 4.44 (s, 2H), 3.07 (s, 6H) ppm. 
13C-NMR (CDCl3, 150 MHz): δ 170.9, 170.5, 152.6, 149.1, 143.3, 138.9, 138.2, 133.3, 131.1, 
130.8, 130.1, 128.3, 126.9, 125.5, 125.1, 123.7, 121.6, 111.5, 56.6, 40.3 ppm. 
HRMS (ESI, positive): calc. for C23H21ClN5O (M+H)+: 418.1435; found: 418.1428. 
HRMS (ESI, negative): calc. for C23H19ClN5O (M)-: 416.1284; found: 416.1282. 
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pBZ1.3 
 
Following general procedure I. 4-Nitroaniline (29 mg, 0.21 mmol, 1.5 eq.) in 1 mL 
dichloromethane was treated with Oxone® (128 mg, 0.42 mmol, 3 eq.) dissolved in 
4 mL water. The biphasic mixture was stirred for 9 h at room temperature and another 
eq. Oxone® and 1 mL dichloromethane was added.  
Resulting crude nitroso compound was dissolved in 1 mL acetic acid and 3 (40 mg, 
0.14 mmol, 1 eq.) in 2.5 mL acetic acid was added. Aqueous work up und purification 
(HPLC: method B) yielded 10 mg (20%) pBZ1.3 as an orange solid. 
HPLC (C-18, analytical HPLC, method B) Rt = 45.9 min 
TLC (silica; 10% MeOH, 90% DCM) Rf = 0.63 (UV) 
mp = 273-276 °C (decomp.) 
λmax = 375 nm 
IR (FT, ATR):3188, 3060, 1648, 1587, 1516, 1485, 1375, 1339, 1095, 857, 731, 699, 687 cm-1. 
1H NMR (400 MHz, dmso-d6) δ = 10.29 (s, 1H), 8.34 (d, J=9.2, 2H), 7.91 (d, J=9.2, 2H), 7.80 
(dd, J=8.6, 2.3, 1H), 7.42 – 7.24 (m, 7H), 5.36 (s, 1H), 3.72 (s, 1H), 3.50 (d, J=16.4, 1H), 3.34 
(d, J=16.6, 1H). 
13C NMR (101 MHz, dmso-d6) δ = 174.50, 155.65, 148.53, 147.68, 142.53, 141.99, 134.64, 
128.83, 128.68, 127.77, 126.54, 125.45, 123.65, 122.30, 121.70, 62.47, 51.21. 
HRMS (ESI, negative): calc. for C21H16N5O3 (M)-: 386.1259; found: 386.1256. 
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pBZ1.4 
 
Following general procedure I. 4-Aminobenzonitrile (25 mg, 0.21 mmol, 1.5 eq.) in 
1 mL dichloromethane was treated with Oxone® (128 mg, 0.42 mmol, 3 eq.) in 4 mL 
water. The biphasic mixture was stirred for 9 h at room temperature and another eq. 
Oxone® and 1 mL dichloromethane was added. 
Resulting crude nitroso compound was dissolved in 1 mL acetic acid and 3 (40 mg, 
0.14 mmol, 1 eq.) in 2.5 mL acetic acid was added. Aqueous work up und purification 
(HPLC: method B) yielded 15 mg (31%) of pBZ1.4 as an orange solid. 
HPLC (C-18, analytical HPLC, method A) Rt = 28.2 min 
TLC (silica; 10% MeOH, 90% DCM) Rf = 0.63 (UV) 
mp = 250-253 °C 
λmax = 362 nm 
IR (FT, ATR): 3194, 3061, 2922, 2224, 1652, 1588, 1486, 1404, 1376, 1321, 1178, 1095, 844, 
737, 670 cm-1. 
1H NMR (400 MHz, dmso-d6) δ = 10.27 (s, 1H), 7.97 (d, J=8.8, 2H), 7.84 (d, J=8.8, 2H), 7.78 
(dd, J=8.6, 2.3, 1H), 7.39 – 7.24 (m, 7H), 5.35 (s, 1H), 3.71 (s, 1H), 3.41 (dd, J=59.9, 11.6, 2H). 
13C NMR (101 MHz, dmso-d6) δ = 174.46, 154.46, 147.61, 142.32, 141.99, 134.58, 134.16, 
128.82, 128.67, 127.75, 126.39, 123.37, 122.18, 121.67, 118.86, 113.17, 62.47, 51.15. 
HRMS (ESI, negative): calc. for C22H16N5O (M)-: 366.1360; found: 366.1359. 
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Fmoc-protected Benzophenone 13 (isolated intermediate) 
 
1H NMR (400 MHz, CDCl3) δ = 12.26 (s, 1H), 9.02 (d, J=9.3, 1H), 8.42 (dd, J=9.4, 2.4, 1H), 8.25 (d, 
J=2.6, 1H), 7.74 (d, J=7.5, 2H), 7.61 (d, J=7.3, 2H), 7.50 (t, J=7.5, 2H), 7.36 (ddd, J=31.6, 16.3, 7.5, 
4H), 7.22 (t, J=7.4, 2H), 5.60 (s, 1H), 4.48 (d, J=6.9, 2H), 4.26 (t, J=6.9, 1H), 4.18 (d, J=5.7, 2H). 
13C NMR (101 MHz, CDCl3) δ = 197.89, 169.24, 156.67, 145.78, 143.69, 141.93, 141.24, 137.06, 
132.28, 130.98, 130.50, 130.27, 129.65, 128.89, 127.68, 127.22, 127.00, 125.08, 121.28, 121.03, 
119.93, 67.73, 47.06, 45.92. 
 
Primary Amine 14 (isolated intermediate) 
 
TLC (silica; 10% MeOH, 90% DCM) Rf = 0.67 (UV, ninhydrin) 
mp = 191-193 °C 
IR (FT, ATR): 3450, 3318, 3193, 1676, 1624, 1609, 1576, 1502, 1331, 1287, 1267, 1251, 1228, 1158, 
1116, 765, 751 cm-1. 
1H-NMR (400 MHz, dmso-d6): δ 9.87 (t, 3J = 4.9 Hz, 1H), 8.24 (dd, 3J = 9.5, 4J = 2.7 Hz, 1H), 7.93 (d, 
4J = 2.7 Hz, 1H), 7.66 (s, 1H), 7.63 (dt, 3J = 8.0, 4J = 1.1 Hz, 1H), 7.62-7.55 (m, 1H), 7.53-7.51 (m, 
2H), 7.37 (s, 1H), 6.80 (d, 3J = 9.6 Hz, 1H), 4.10 (d, 3J = 5.0 Hz, 2H). 
13C-NMR (100 MHz, dmso-d6): δ 196.0, 169.6, 154.5, 138.4, 135.3, 132.2, 131.8, 130.8, 130.3, 129.8, 
129.3, 128.0, 115.4, 114.0, 45.7 ppm. 
HRMS (ESI, negative): calc. for C15H12Cl2N3O4 (M+Cl)-: 368.0205; found: 368.0210. 
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Experimental Procedures 2nd Generation pBZs 
Benzylalcohol 4 
 
The title compound was synthesized as described in the patent literature.9 
1H NMR (400 MHz, dmso-d6) δ = 9.25 (s, 1H), 7.36 (d, J=8.5, 2H), 7.15 (d, J=8.7, 2H), 5.03 (t, J=5.7, 
1H), 4.38 (d, J=5.7, 2H), 1.45 (s, 9H). 
13C NMR (75 MHz, CDCl3) δ = 158.00, 143.31, 141.29, 132.10, 84.06, 67.84, 33.36. 
TLC (SiO2, 50% EtOAc, 50% hexanes), Rf = 0.54 (UV). 
HRMS (EI) calcd for C12H17NO3 [M]+: 223.1208; found: 223.1196. 
 
 
Boc-protected amine 510 
 
  
                                                           
9
 WO2008034124  (A2) ― 2008-03-20 “Targeted polymeric prodrugs containing multifunctional linkers”. 
10
 US2003220372  (A1) ― 2003-11-27. „Imidazole compounds as anti-inflammatory and analgesic agents”. 
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Benzylalcohol 6 
 
 
Nitrosobenzene 20 (478 mg, 4.47 mmol, 1.1 eq), aniline 21 (500 mg, 4.06 mmol, 1.0 eq) and 
acetic acid (1.16 mL, 20.3 mmol, 5 eq) were mixed in 50 mL DCM and stirred under N2-atm 
over night. The orange reaction solution was concentrated to approximately 10 mL under 
reduced pressure, diluted with 50 mL EtOAc and extracted with 30 mL aliquots of 1-M-
NaOH(aq), 1-M-HCl(aq) and brine. The EtOAc layer was separated, dried over Na2SO4 and 
concentrated using rotary evaporation. The resulting crude orange solid was purified using 
silica gel chromatography (gradient, 0 to 50% EtOAc in hexanes) affording 6 as an 
amorphous orange solid (817 mg, 3.85 mmol, 95% yield, corresponding m-compound from 
3-amino benzyl alcohol). 
Analytics matched those reported in the literature.11 
1H NMR (599 MHz, CDCl3) δ = 7.95 – 7.90 (m, 4H), 7.56 – 7.46 (m, 5H), 4.79 (s, 2H). 
13C NMR (151 MHz, CDCl3) δ = 152.62, 152.10, 143.79, 130.98, 129.07, 127.41, 123.06, 122.82, 
64.88. 
TLC (SiO2, 50% EtOAc, 50% hexanes), Rf = 0.57 (UV). 
HRMS (EI) calcd for C13H12N2O [M]+: 212.0950; found: 212.0946. 
 
 
  
                                                           
11
 Fatás, P., E. Longo, et al. "Bis(azobenzene)-Based Photoswitchable, Prochiral, Cα-
Tetrasubstituted α-Amino Acids for Nanomaterials Applications." Chemistry – A 
European Journal 17(45): 12606-12611. 
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Benzylalcohol 7 
 
 
Nitrosobenzene 22 (1.85 g, 12.2 mmol, 1.5 eq)12 was dissolved in 10 mL DCM and treated 
with AcOH (4.65 mL, 81.2 mmol, 10.0 eq), followed by 3-aminobenzyl alcohol 23 (1.0 g, 8.1 
mmol, 1.0 eq). The reaction mixture was allowed to stir at rt under N2-atm over night and 
purified using silica gel flash chromatography (gradient, 1 to 5% MeOH in DCM) yielding 7 as 
a red powder (1.54 g, 6.0 mmol, 74% yield). 
TLC (SiO2, 10% MeOH, 90% DCM), Rf = 0.69 (UV). 
HRMS (EI) calcd for C13H11N3O3 [M]+: 257.0800; found: 257.0796. 
1H NMR (300 MHz, CDCl3) δ = 8.38 (d, J=8.9, 2H), 8.03 (d, J=8.9, 2H), 7.97 (s, 1H), 7.95 – 7.84 (m, 
1H), 7.55 (d, J=5.4, 2H), 4.83 (s, 2H), 1.90 (s, 1H). 
13C NMR (75 MHz, CDCl3) δ = 155.62, 152.58, 148.74, 142.31, 130.63, 129.47, 124.72, 123.42, 
123.14, 121.05, 64.71. 
 
  
                                                           
12
 Prepared as described before in this report. 
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Benzylalcohol 9 
 
 
4-Aminobenzyl alcohol 25 (1000 mg, 8.12 mmol, 1.2 eq) was dissolved in water (15 ml) and 
HCl conc. (2 ml, 24.00 mmol, 3.6 eq) was added. The solution was cooled to 0°C and after 
10 min, sodium nitrate (630 mg, 9.14 mmol, 1.4 eq) was added carefully as a solution in 
water (5 ml). After stirring for 45 min at 0°C, the diazonium salt solution was added slowly to 
a solution of 4-phenylmorpholine 24 (1000 mg,  8.12 mmol, 1.2 eq) in methanol (125 ml) and 
pyridine (2.74 ml, 33.80 mmol, 5 eq). The resulting reaction solution was stirred for 5 h at 0 
°C and allowed to heated to room temperature over night. The solvent was removed using 
rotary evaporation. Purification using flash column chromatography (silica, gradient 1-3% 
MeOH in CHCl3) yielded 9 as a red amorphous solid (540 mg, 1.82 mmol, 27%). 
TLC (SiO2, 50% EtOAc in hexanes), Rf = 0.46 (UV). 
1H NMR (599 MHz, CDCl3) δ = 7.88 (d, J = 9.1, 2H), 7.85 (d, J = 8.4, 2H), 7.47 (d, J = 8.6, 2H), 6.97 
(d, J = 9.1, 2H), 4.76 (s, 2H), 3.89 – 3.86 (m, 4H), 3.33 – 3.29 (m, 4H). 
 
13C NMR (151 MHz, CDCl3) δ = 153.1, 152.4, 145.7, 142.7, 127.4, 124.6, 122.6, 114.4, 66.6, 65.0, 
48.1. 
 
 IR (FT, ATR) : 3462, 2966, 2871, 2844, 1599, 1504, 1444, 1378, 1343, 1303, 1267, 1230, 1156, 
1114, 1048, 1024, 924, 829 cm-1. 
 
HRMS (ESI, positiv): calcd. for C17H20N3O2 (M+H)+:298.1556; found: 298.1548. 
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Benzylbromide 8 
 
 
Carbontetrabromide (1.56 g, 4.71 mmol, 2.0 eq) and triphenylphosphin (1.24 mg, 4.71 mmol, 
2.0 eq) were dissolved in 10 mL DCM before benzylalcohol 6 (500 mg, 2.36 mmol, 1.0 eq) 
was added. After stirring for 2 h under N2-atm, the reaction was diluted with 50 mL EtOAc 
and and extracted with 30 mL aliquots of 1-M-HCl(aq), 1-M-NaOH(aq) and brine. The EtOAc 
layer was separated, dried over Na2SO4 and concentrated using rotary evaporation. The 
resulting crude orange solid was purified using automated medium pressure chromatography 
(Biotage, 10 g SiO2-column, gradient 0 to 10% EtOAc in hexanes) affording 8 as an 
amorphous orange solid (512 mg, 3.85 mmol, 81% yield, m-compound analogously). 
Analytical data match those reported in the literature.13 
1H NMR (599 MHz, CDCl3) δ = 7.96 – 7.87 (m, 4H), 7.57 – 7.46 (m, 5H), 4.56 (s, 2H). 
TLC (SiO2, 10% EtOAc, 90% hexanes), Rf = 0.55 (UV). 
HRMS (EI) calcd for C13H11BrN2 [M]+: 274.0106; found:  274.0106. 
 
  
                                                           
13
 Yu, G., C. Han, et al. "Pillar[6]arene-Based Photoresponsive Hostâ€“Guest 
Complexation." Journal of the American Chemical Society 134(20): 8711-8717. 
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Benzylbromide 10 
 
Benzylbromide 10 was prepared analogously to benzylbromide 8 via Appel reaction. 
1H NMR (599 MHz, CDCl3) δ = 8.39 (d, J=8.6, 2H), 8.04 (d, J=8.6, 2H), 8.00 (s, 1H), 7.97 – 7.89 (m, 
1H), 7.62 – 7.50 (m, 2H), 4.70 (s, 0H), 4.59 (s, 2H). 
13C NMR (151 MHz, CDCl3) δ = 155.51, 152.54, 148.85, 139.21, 132.71, 129.79, 124.75, 123.84, 
123.50, 123.35, 32.42. 
TLC (SiO2, 20% EtOAc, 80% hexanes), Rf = 0.59 (UV). 
 
 
Benzylbromide 11 
 
9 (200 mg, 0.61 mmol, 1.0 eq) was dissolved in THF (8 ml) and treated with carbon 
tetrabromide (401 mg, 1.21 mmol, 2.0 eq) and triphenylphosphine (318 mg, 1.21 mmol, 
2.0 eq) was added. The Solution was stirred over night and the solvent was removed under 
reduced pressure. Purification using flash column chromatography (silica, gradient 30-40% 
EtOAc in hexanes) yielded 11 as dark powder (120 mg, 0.33 mmol, 55%).  
TLC (SiO2, 30% EtOAc in hexanes), Rf = 0.38 (UV). 
1H NMR (200 MHz, CDCl3) δ = 7.90 (d, J = 9.1, 2H), 7.83 (d, J = 8.4, 2H), 7.50 (d, J = 8.3, 2H), 6.98 
(d, J = 9.2, 2H), 4.55 (s, 2H), 3.97 – 3.80 (m, 4H), 3.39 – 3.26 (m, 4H). 
13C NMR (101 MHz, CDCl3) δ 153.0, 152.5, 145.7, 139.4, 129.8, 124.9, 122.8, 114.6, 66.5, 48.2, 33.1. 
IR (FT, ATR) : 2955, 2855, 2834, 1599, 1568, 1507, 1446, 1404, 1378, 1346, 1304, 1264, 1233, 1159, 
1143, 1119, 1069, 1050, 924, 848, 827, 731 cm-1. 
HRMS (ESI, positiv): calcd. for C17H19BrN3O (M+H)+: 360.0711; found: 360.0706. 
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Toluene 15 
 
 
p-Aminotoluene 26 (1000 mg, 9.33 mmol, 1.5 eq) was dissolved in DCM (25 ml) and Oxone 
(6120 mg, 9.95 mmol, 1.6 eq) was slowly added as an aqueous solution (100 ml) under N2-
atmosphere. The dispersion was stirred vigorously for 3 h before layers were separated. The 
aqueous layer was washed two more times with DCM (12 ml). Combined organic layers were 
washed with 1-M-HCl(aq) (2 × 15 ml), saturated NaHCO3(aq) (2 × 15 ml) and brine (2 × 25 ml). 
The organic phase was dried over Na2SO4 and concentrated to approximately 10 mL under 
reduced pressure and 4-morpholinoaniline 27 (1100 mg, 6.22 mmol, 1.0 eq) was added 
followed by acetic acid (1.8 ml, 31.10 mmol, 5.0 eq). After stirring over night, the red reaction 
solution was washed with 5-M-NaOH(aq) (5 ml), saturated-NaHCO3(aq) (2 × 20 ml), brine 
(2 × 20 ml) and dried over Na2SO4. The solvent was removed under reduced pressure. 
Purification using flash column chromatography (silica, gradient 30-50% EtOAc in hexanes) 
yielded 15 as a red powder (1160 mg, 4.1 mmol, 66%). 
TLC (SiO2, 50% EtOAc, 50% Hexanes), Rf = 0.5 (UV). 
1H NMR (300 MHz, CDCl3) δ = 7.88 (d, J=9.2, 1H), 7.78 (d, J=8.3, 1H), 7.29 (d, J=8.0, 1H), 6.97 (d, 
J=9.2, 1H), 3.92 – 3.82 (m, J=5.7, 4.1, 2H), 3.36 – 3.24 (m, 2H), 2.42 (s, 2H). 
13C NMR (75 MHz, CDCl3) δ = 152.9, 151.0, 145.8, 140.4, 129.6, 124.4, 122.4, 114.5, 66.7, 48.2, 21.4. 
IR (FT, ATR) : 3040, 2966, 2897, 2855, 2834, 1597, 1568, 1504, 1449, 1415, 1375, 1346, 1307, 1267, 
1233, 1156, 1124, 1069, 1053, 927, 827, 731, 708 cm-1. 
HRMS (ESI, positiv): calcd. for C17H20N3O (M+H)+: 282.1606; found: 282.1597. 
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Toluene 16 
 
 
15 (50 mg, 0.178 mmol, 1.0 eq), NBS (35 mg, 0.195 mmol, 1.1 eq) and AIBN (3 mg,  
0.018 mmol, 0.1 eq) were dissolved in CCl4 (6.5 ml) and heated to reflux over night. EtOAc 
(30 ml) was added and the organic resulting solution was washed with 1-M-NaOH (8 ml), 
saturated NaHCO3(aq) (2 × 7 ml) and brine (2 × 7 ml). The organic phase was seperated, dried 
over Na2SO4 and concentrated under reduced pressure. Quick flash column chromatography 
(silica, gradient 10-50% EtOAc in hexanes) followed by a second purification using flash 
column chromatography (silica, gradient 5-15% EtOAc in hexanes) yielded 16 as a dark 
powder (50 mg, 0.139 mmol, 78%). 
TLC (SiO2, 30% EtOAc, 70% hexanes), Rf = 0.6 (UV) 
1H NMR (300 MHz, CDCl3) δ = 8.16 (d, J = 2.2, 1H), 7.87 (dd, J = 8.5, 2.3, 1H), 7.80 (d, J = 8.2, 2H), 
7.35 – 7.25 (m, 2H), 7.13 (d, J = 8.5, 1H), 3.95 – 3.87 (m, 4H), 3.20 – 3.10 (m, 4H), 2.43 (s, 3H). 
 
13C NMR (75 MHz, CDCl3) δ = 152.2, 150.6, 148.8, 141.6, 129.7, 127.1, 124.5, 122.8, 120.3, 119.7, 
67.0, 51.9, 21.5. 
 
IR (FT, ATR) : 3040, 2950, 2913, 2844, 2823, 1602, 1583, 1557, 1475, 1446, 1391, 1370, 1333, 1296, 
1230, 1206, 1114, 1067, 1027, 937, 919, 890, 824, 876 cm-1. 
 
HRMS (ESI, positiv): calcd. for C17H20BrN3O (M+H)+: 360.0711; found: 360.0684. 
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General Procedure II: N-alkylation of Clonazepam using benzyl bromides 
 
Clonazepam (50.0 mg, 0.16 mmol, 1.0 eq) was dissolved in 1 mL dry DMF, treated with 
K2CO3 (43.8 mg, 0.32 mmol, 2.0 eq) and cooled to 0 °C under N2-atm. The corresponding 
benzylbromide (0.19 mmol, 1.2 eq) dissolved in 0.6 mL dry DMF was added and the reaction 
mixture was allowed to stir for 45 min. The reaction solution was diluted with 10 mL EA and 
extracted with 10% NaCl(aq), saturated NH4Cl(aq), saturated NaHCO3(aq) and brine. The organic 
layer was dried using Na2SO4, concentrated in vacuo and purified using MPLC (Biotage,10 g 
SiO2-column, gradient 35% to 100% EtOAc in hexanes)14 yielding the N-alkylated product in 
95 – 98% yield. 
Table 1. N-Benzylated clonazepam derivatives derived from benzyl chlorides. 
N
N
N
N
O2N
H
H
R1 R2 product
pBZ2.1
pBZ2.3
yield
98%
96%
SCN- H North-NCS 95%
H pBZ2.4 96%
N
N
N
O
N
N
H pBZ2.5 86%
 
 
  
                                                           
14
 A mixture of MeOH/DCM, EA/DCM can also be used as a mobile phase for silica 
gel chromatography with equal success. Additionally, reverse phase MPLC (4g C-18, 
gradient 30% to 90% MeCN in H2O) is possible. 
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pBZ2.1 
 
1H NMR (400 MHz, dmso-d6) δ = 8.35 (ddd, J=29.5, 9.2, 2.8, 1H), 7.96 – 7.73 (m, 4H), 7.66 (dd, 
J=8.2, 2.7, 1H), 7.63 – 7.40 (m, 8H), 7.27 – 7.03 (m, 1H), 6.76 (ddd, J=8.5, 5.2, 3.6, 1H), 5.27 (dt, 
J=77.3, 16.0, 2H), 4.77 (dd, J=23.2, 11.1, 1H), 4.05 (dd, J=27.8, 10.9, 1H). 
13C NMR (101 MHz, dmso-d6) δ = 168.35, 168.33, 168.30, 154.01, 153.18, 152.30, 151.63, 146.93, 
146.82, 143.14, 143.03, 140.66, 137.54, 137.51, 135.93, 132.31, 132.24, 132.17, 132.05, 130.56, 
130.52, 130.34, 129.93, 129.25, 128.69, 127.98, 127.53, 126.70, 124.29, 124.23, 123.17, 122.99, 
120.60, 120.18, 57.23, 49.58. 
TLC (SiO2, 60% EtOAc, 40% hexanes), Rf = 0.54 (UV). 
HRMS (ESI) calcd for C12H17NO3 [M]+: 510.1333; found:510.1330. 
 
 
pBZ2.3 
 
1H NMR (599 MHz, CDCl3) δ = 8.35 (d, J=8.9, 2H), 8.30 (dd, J=9.1, 2.7, 1H), 7.96 (d, J=8.9, 2H), 7.90 
(d, J=2.7, 1H), 7.89 – 7.86 (m, 1H), 7.84 (s, 1H), 7.63 – 7.27 (m, 7H), 5.51 (d, J=15.6, 1H), 5.23 (d, 
J=15.6, 1H), 5.10 (d, J=10.7, 1H), 3.97 (d, J=10.7, 1H). 
13C NMR (151 MHz, CDCl3) δ = 168.71, 168.23, 155.43, 152.58, 148.81, 146.65, 143.57, 137.54, 
136.91, 132.93, 131.79, 131.69, 131.47, 131.08, 130.34, 129.91, 127.35, 126.08, 124.78, 124.68, 
123.51, 122.98, 122.59, 122.44, 56.89, 50.43. 
TLC (SiO2, 60% EtOAc, 40% Hex), Rf = 0.42 (UV). 
HRMS (ESI) calcd for [M+H]+: 555.1184; found: 555.1177. 
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pBZ2.4 
 
N
N
O
O2N
Cl
N N
N
O
pBZ2.4
C32H27ClN6O4
595,05 g/mol
 
 
 
TLC (SiO2,10% MeOH, 90% DCM), Rf = 0.64 (UV).  
 
1H NMR (599 MHz, CDCl3) δ = 8.22 (dd, J = 9.1, 2.7, 1H), 7.88 – 7.82 (m, 3H), 7.77 (d, J = 8.4, 2H), 
7.51 (d, J = 9.2, 2H), 7.42 – 7.27 (m, 5H), 6.96 – 6.92 (m, 2H), 5.33 (d, J = 15.8, 1H), 5.25 – 5.15 (m, 
1H), 5.06 (d, J = 10.8, 1H), 3.93 (d, J = 11.0, 1H), 3.87 – 3.83 (m, 4H), 3.32 – 3.28 (m, 4H). 
 
13C NMR (151 MHz, CDCl3) δ = 168.7, 168.1, 153.2, 152.5, 146.8, 145.5, 143.4, 137.8, 137.0, 132.9, 
131.7, 131.6, 130.9, 130.3, 128.3, 127.3, 126.0, 124.7, 124.7, 124.6, 122.9, 122.6, 114.3, 66.6, 56.9, 
50.6, 48.0. 
 
IR (FT, ATR) : 3040, 2960, 2844, 1684, 1597, 1573, 1517, 1504, 1481, 1449, 1417, 1378, 1338, 1262, 
1227, 1156, 1140, 1109, 1067, 1046, 1019, 985, 924, 885, 827, 732, 700 cm-1. 
 
HRMS (ESI, positiv): calcd. for C32H28ClN6O4 (M+H)+: 595.1861; found: 595.1849.  
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pBZ2.5 
 
 
 
1H NMR (400 MHz, CDCl3) δ = 8.28 (dd, J=9.1, 2.7, 1H), 7.91 (d, J=2.6, 1H), 7.89 (dd, J=8.0, 1.7, 2H), 
7.87 – 7.79 (m, J=15.2, 7.3, 2H), 7.60 (d, J=9.1, 1H), 7.58 – 7.45 (m, 5H), 7.43 – 7.31 (m, 4H), 5.46 (d, 
J=15.6, 1H), 5.27 (d, J=15.6, 1H), 5.11 (d, J=10.6, 1H), 3.99 (d, J=10.7, 1H). 
 
13C NMR (101 MHz, CDCl3) δ = 168.74, 168.17, 152.87, 152.45, 146.78, 143.48, 137.28, 136.99, 
132.97, 131.72, 131.62, 131.29, 130.97, 130.36, 130.12, 129.78, 129.11, 127.32, 126.10, 124.77, 
122.95, 122.67, 122.23, 122.10, 56.93, 50.56. 
 
HRMS (ESI, positiv): calcd. for C28H21ClN5O3 (M+H)+: 510.1327; found: 510.1326. 
 
 
North-NCS 
 
 
 
TLC (SiO2, 10% MeOH, 90% DCM), Rf = 0.46 (UV). 
1H NMR (400 MHz, CDCl3) δ = 8.25 (d, J = 2.7, 1H), 7.87 (d, J = 2.4, 1H), 7.55 (dd, J = 7.2, 1.9, 1H), 
7.50 (d, J = 9.1, 1H), 7.46 – 7.38 (m, 2H), 7.33 (dd, J = 7.5, 1.4, 1H), 7.23 (d, J = 8.7, 2H), 7.13 (d, J = 
8.7, 2H), 5.35 (d, J = 15.6, 1H), 5.07 (d, J = 15.8, 1H), 5.02 (d, J = 10.8, 1H), 3.91 (d, J = 10.8, 1H). 
13C NMR (101 MHz, CDCl3) δ = 168.7, 168.1, 146.5, 143.5, 136.9, 135.4, 132.9, 131.9, 131.7, 131.0, 
130.9, 130.4, 129.0, 127.4, 126.2, 126.1, 124.7, 122.5, 56.8, 50.2. 
IR (FT, ATR) : 3060, 2971, 2850, 2179, 2079, 1678, 1604, 1575, 1520, 1501, 1480, 1433, 1417, 1338, 
1311, 1282, 1259, 1217, 1180, 1162, 1098, 1072, 1053, 1017, 982, 929, 908, 882, 837, 779, 729 cm-1. 
HRMS (ESI, positiv): calcd. for C23H16ClN4O3S (M+H)+: 463.0632; found: 463.0621. 
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Benzodiazepine 12  
 
Alcohol 4 (46 mg, 0.21 mmol, 1.3 eq) was dissolved in 1 mL DCM, treated with DIPEA (72 
µL, 0.41 mmol, 2.6 eq) and cooled to 0 °C under N2-atm before MsCl (25 µL, 0.32 mmol, 2.0 
eq) was added. After 15 min, the reaction mixture was allowed to warm to rt over the course 
of two hours. 5 mL EtOAc were added and the organic phase was extracted with 2 mL 
portions of saturated NH4Cl(aq), NaHCO3(aq) and brine. The organic layer was separated, dried 
over Na2SO4 and concentrated under vacuo. 
Clonazepam (50 mg, 0.16 mmol, 1.0 eq) was dissolved in 1 mL anhydrous DMF, treated 
with K2CO3 (57 mg, 0.41 mmol, 2.6 eq) and cooled to 0 °C under N2-atm before the above 
described mesylate was added as a solution in 0.5 mL anhydrous DMF. After reacting for 1 h 
at 0 °C, the reaction suspension was diluted with 20 mL EtOAc and extracted with 5 mL 
portions of saturated NH4Cl(aq), NaHCO3(aq), 10% NaCl(aq) and brine. The organic layer was 
separated, dried over Na2SO4 and concentrated under vacuo. The crude Boc-protected 
material was redissolved in 1 mL anhydrous DCM and treated with 1 mL TFA for 10 min at rt. 
The red solution was diluted with EtOAc and extracted with conc. NaHCO3(aq). The organic 
layer was dried over Na2SO4 and concentrated under vacuo. The resulting orange crude was 
purified using MPLC (Biotage, 10 g SiO2-column, gradient 20 to 100% EtOAc in hexanes) 
affording the title compound as an orange amorphous solid (62 mg, 0.147 mmol, 93% yield). 
1H NMR (400 MHz, dmso-d6) δ = 8.33 (dd, J=9.2, 2.8, 1H), 7.93 (d, J=9.2, 1H), 7.61 (d, J=2.7, 1H), 
7.53 – 7.35 (m, 4H), 6.84 (d, J=8.4, 2H), 6.39 (d, J=8.5, 2H), 5.32 (d, J=15.2, 1H), 4.87 (d, J=15.3, 
1H), 4.73 (d, J=10.7, 1H), 3.94 (d, J=10.8, 1H). 
13C NMR (101 MHz, dmso-d6) δ = 168.14, 167.96, 148.55, 147.00, 142.91, 137.60, 132.27, 132.11, 
130.79, 130.24, 129.43, 127.77, 126.27, 124.70, 124.05, 123.67, 114.10, 57.30, 49.15. 
TLC (SiO2, 70% EtOAc, 30% hexanes), Rf = 0.50 (UV). 
HRMS (EI) calcd for C22H17ClN4O3 [M]+: 420.0989; found: 420.0982. 
IR νmax: 3448, 3360, 3218, 2856, 1678, 1608, 1517, 1342, 909, 730. 
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pBZ2.2 
 
Step 1: Formation of nitrosobenzene  
5 (500 mg, 2.1 mmol, 1.0 eq) was dissolved in 400 mL of a 1:1 H2O/DCM mixture and 
treated with oxone (2.6 g, 4.2 mmol, 2 eq). After stirring intensely for 5h, the green organic 
layer was filtered through a small plug of silica. The filtrate was concentrated (260 mg, 50% 
yield, crude) and immediately used for the next step. 
Step 2: Mills coupling 
12 (25 mg, 0.06 mmol, 1.0 eq) was dissolved in 1 mL DCM and freshly prepared nitroso 
species described above (30 mg, 0.12 mmol, 2.0 eq) was added, followed by AcOH. After 
reacting over night, the orange reaction solution was filtered through a small plug of silica 
and concentrated under reduced pressure. The resulting crude Boc-protected material was 
redissolved in 2 mL of 1:1 TFA/DCM and stirred for 15 min at rt. After dilution with EtOAc, 
TFA was removed by basic extraction with NaHCO3(aq). The EtOAc-layer was separated, 
dried using Na2SO4 and concentrated using rotary evaporation. The resulting crude material 
was purified using silica gel chromatography (gradient 2 to 10% MeOH in DCM, 1% TEA as 
additive) yielding pBZ2.2 as an orange amorphous solid (23 mg, 0.04 mmol, 70% yield, 90% 
yield b.r.s.m.). 
1H NMR (599 MHz, CDCl3) δ = 8.25 (ddd, J=15.3, 9.1, 2.7, 1H), 7.89 (dd, J=4.8, 2.6, 1H), 7.87 – 7.80 
(m, 4H), 7.53 (t, J=6.2, 2H), 7.47 – 7.30 (m, 6H), 7.16 – 6.73 (m, 1H), 5.36 (d, J=15.6, 1H), 5.23 (d, 
J=15.8, 1H), 5.08 (d, J=10.7, 1H), 3.95 (d, J=10.6, 1H), 2.95 (dt, J=71.4, 7.0, 2H), 2.74 (dt, J=102.8, 
6.9, 2H). 
13C NMR (151 MHz, CDCl3) δ = 168.70, 168.09, 152.27, 151.18, 146.76, 143.66, 143.50, 138.69, 
136.98, 132.94, 131.73, 131.59, 130.98, 130.36, 129.54, 128.36, 127.31, 125.99, 124.72, 123.28, 
123.05, 122.56, 56.89, 50.59, 43.38, 40.04. 
TLC (SiO2, 10% MeOH, 90% DCM + 1% TEA), Rf = 0.43 (UV, ninhydrine).  
IR νmax: 3368, 3057, 2961, 2926, 2856, 2226, 1685, 1608, 1522, 1342, 1261, 1102, 1020, 798, 730. 
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pBZ2.6 
O2N
N
Cl
O
N
N
N
N
pBZ2.6
C30H25ClN6O3
553,01 g/mol
(45%)
1) MsCl
clonazepam +
N
N
OH
N
2) K2CO3
28
28 was synthesized from 4-amino-benzyl alcohol and N,N-dimethylaniline by standard 
diazotization conditions (see below). Consecutive mesylation and alkylation was performed 
in analogy to the synthesis of 12. (0.24 mmol scale). 
1H NMR (599 MHz, CDCl3) δ = 8.23 (dd, J=9.1, 2.7, 1H), 7.87 (d, J=2.7, 1H), 7.84 (dd, J=9.7, 2.5, 2H), 
7.77 – 7.73 (m, 2H), 7.53 (t, J=6.2, 1H), 7.42 – 7.34 (m, 2H), 7.34 – 7.31 (m, 3H), 6.73 (d, J=9.3, 2H), 
5.32 (d, J=15.6, 1H), 5.21 (d, J=15.5, 1H), 5.06 (d, J=10.6, 1H), 3.94 (d, J=10.6, 1H), 3.07 (s, 6H). 
13C NMR (151 MHz, CDCl
 3) δ = 168.68, 168.07, 152.80, 152.53, 146.83, 143.51, 143.42, 137.04, 
137.02, 132.96, 131.66, 131.55, 130.92, 130.34, 128.30, 127.26, 125.94, 125.07, 124.66, 122.68, 
122.66, 111.46, 56.93, 50.59, 40.28. 
HRMS (ESI, positiv): calcd. for C30H26ClN6O3 (M+H)+: 553.1749; found: 553.1754. 
 
 
Benzyl alcohol building blocks by diazotization 
 
3-aminobenzyl aclohol (1 g, 8.1 mmol, 1 equiv.) was dissolved in 40 mL H20 at 0 °C and 
concentrated aqueous HCl (2.4 mL, 24.4 mmol, 3 equiv.) was added. A solution of NaNO2 
(616 mg, 8.9 mmol, 1.1 eq) in 15 mL H20 were added slowly (T < 5°C). After stirring at 0 °C 
for 30 min the yellow diazonium salt solution was added to a 0 °C solution of N,N-dimethyl 
aniline (1 mL, 8.1 mmol, 1 equiv.) and NaOAc (4 g, 48.7 mmol, 6 equiv.). After allowing tp 
warm to rt for 3 hours, the reaction mixture was diluted with 100 mL EtOAcl and washed 
sequentially with H20 (1 x 50 mL), 1M NaOH (1 x 50 mL), and brine (1 x 50 mL). The 
combined organic phases were dried with Na2SO4 and concentrated via rotary evaporation. 
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Crude material was purified by flash column chromatography (silica gel, gradient 10% → 
50% EtOAc in hexanes). 
 
1H NMR (300 MHz, CDCl3) δ = 7.87 (dd, J=13.2, 8.8, 4H), 7.56 – 7.39 (m, 2H), 6.77 (d, J=9.2, 2H), 
4.76 (s, 2H), 3.10 (s, 6H). 
13C NMR (75 MHz, CDCl3) δ = 152.69, 152.44, 143.64, 142.02, 127.46, 124.97, 122.39, 111.52, 65.08, 
40.31. 
 
 
1H NMR (400 MHz, CDCl3) δ = 7.91 – 7.84 (m, 2H), 7.84 – 7.80 (m, 1H), 7.78 – 7.73 (m, 1H), 7.45 (dd, 
J=9.6, 5.8, 1H), 7.39 – 7.35 (m, 1H), 6.82 – 6.68 (m, 2H), 4.76 (s, 2H), 3.07 (s, 6H). 
13C NMR (101 MHz, CDCl3) δ = 153.37, 152.47, 143.56, 141.82, 129.13, 127.74, 125.00, 122.00, 
119.97, 111.50, 65.16, 40.28. 
 
 
1H NMR (300 MHz, CDCl3) δ = 7.95 – 7.74 (m, 3H), 7.55 – 7.30 (m, 3H), 6.81 – 6.65 (m, 2H), 4.99 (s, 
2H), 3.16 – 2.97 (m, 6H). 
13C NMR (75 MHz, CDCl3) δ = 152.72, 151.10, 143.46, 137.18, 129.54, 128.99, 128.32, 125.22, 
118.22, 111.54, 63.85, 40.26. 
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X-ray Crystallography 
 
Crystallographic data. pBZ1.1 
 
 
pBZ1.1 
net formula C21H15ClN4O 
Mr/g mol−1 374.823 
crystal size/mm 0.21 × 0.20 × 0.11 
T/K 173(2) 
radiation MoKα 
diffractometer 'KappaCCD' 
crystal system monoclinic 
space group P21/c 
a/Å 14.8963(3) 
b/Å 14.8445(3) 
c/Å 8.0924(2) 
α/° 90 
β/° 101.6300(10) 
γ/° 90 
V/Å3 1752.72(7) 
Z 4 
calc. density/g cm−3 1.42046(6) 
µ/mm−1 0.237 
absorption correction none 
refls. measured 13417 
Rint 0.0287 
mean σ(I)/I 0.0240 
θ range 3.45–27.47 
observed refls. 3276 
x, y (weighting scheme) 0.0536, 0.8023 
hydrogen refinement mixed 
refls in refinement 4001 
parameters 248 
restraints 0 
R(Fobs) 0.0425 
Rw(F2) 0.1174 
S 1.049 
shift/errormax 0.001 
max electron density/e Å−3 0.285 
min electron density/e Å−3 −0.372 
C-bound H: constr., N-bound H: refall. 
 Crystallographic data. 29 
 
 
net formula 
Mr/g mol−1 
crystal size/mm 
T/K 
radiation 
diffractometer 
crystal system 
space group 
a/Å 
b/Å 
c/Å 
α/° 
β/° 
γ/° 
V/Å3 
Z 
calc. density/g cm−3 
µ/mm−1 
absorption correction 
transmission factor range 
refls. measured 
Rint 
mean σ(I)/I 
θ range 
observed refls. 
x, y (weighting scheme) 
hydrogen refinement 
Flack parameter 
refls in refinement 
parameters 
restraints 
R(Fobs) 
Rw(F2) 
S 
shift/errormax 
max electron density/e Å−3 
min electron density/e Å−3 
 
Flack test meaningless, Mo radiation, no anomalous scatterer.
 
 
 
 
29 
C15H17N3O 
255.315 
0.125 × 0.068 × 0.035 
100(2) 
'Mo Kα 
'Bruker D8Venture' 
orthorhombic 
P212121 
5.8740(3) 
7.5687(4) 
28.9814(17) 
90 
90 
90 
1288.47(12) 
4 
1.31619(12) 
0.085 
multi-scan 
0.9359–0.9580 
22213 
0.0339 
0.0183 
3.42–25.34 
2160 
0.0430, 0.3886 
constr 
−0.7(15) 
2341 
175 
0 
0.0329 
0.0854 
1.072 
0.001 
0.327 
−0.160 
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 Crystallographic data. 30 
 
 
net formula 
Mr/g mol−1 
crystal size/mm 
T/K 
radiation 
diffractometer 
crystal system 
space group 
a/Å 
b/Å 
c/Å 
α/° 
β/° 
γ/° 
V/Å3 
Z 
calc. density/g cm−3 
µ/mm−1 
absorption correction 
transmission factor range 
refls. measured 
Rint 
mean σ(I)/I 
θ range 
observed refls. 
x, y (weighting scheme) 
hydrogen refinement 
Flack parameter 
refls in refinement 
parameters 
restraints 
R(Fobs) 
Rw(F2) 
S 
shift/errormax 
max electron density/e Å−3 
min electron density/e Å−3 
  
 
30 
C15H17N3O 
255.315 
0.119 × 0.047 × 0.026 
100(2) 
'Mo Kα 
'Bruker D8Venture' 
monoclinic 
Cc 
20.2378(19) 
18.5558(16) 
27.772(3) 
90 
98.287(3) 
90 
10320.4(17) 
32 
1.3146(2) 
0.085 
multi-scan 
0.9298–0.9580 
91227 
0.0519 
0.0483 
2.19–25.47 
13609 
0.0599, 0.9816 
constr 
−0.2(11) 
18758 
1393 
2 
0.0427 
0.1111 
1.012 
0.001 
0.295 
−0.219 
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Photopharmakologie 
Das Konzept der Photopharmakologie ist eine Erweiterung der Pharmakologie und verfolgt 
das Ziel physiologische Prozesse durch die Wirkung kleiner Moleküle mit Licht zu steuern. 
Die Lichtsensitivität wird hierbei durch Azobenzenphotoschalter installiert, die mit 
pharmakologisch aktiven Molekülen verbunden werden. Die lichtinduzierte cis/trans-
Isomerisierung des Azobenzens führt dann zu Veränderungen der pharmakologischen 
Wirksamkeit und erlaubt somit eine räumlich und zeitlich präzise Kontrolle biologischer 
Prozesse. Demzufolge stellt die Photopharmakologie ein interdisziplinäres Forschungsfeld 
dar, welches das Entwerfen neuer Wirkstoffe, deren Synthese und funktionelle 
Charakterisierung umschließt. In dieser Arbeit wurde diese Herangehensweise auf eine 
Vielzahl von Transmembranproteinen angewendet, die eine Schlüsselstelle in zellulärer 
Kommunikation und wichtige Stellschrauben in physiologischen Prozessen sind. 
1) Ein photoschaltbarer epithelialer Natriumkanal (ENaC). Der ENaC ist ein 
heterotrimerer Komplex aus Transmembranproteinen, die einen Ionenkanal mit hoher 
Leitfähigkeit für Natriumionen bilden. αβγENaCs sind in Niere und Lunge gut untersucht, wo 
sie den transepithelialen Wassertransport kontrollieren. Die Rolle von δβγENaCs ist hingegen 
weniger gut verstanden und wirft vor allem in Gehirn von Primaten nach wie vor Fragen auf.  
Anhand des gut erforschten kaliumsparenden Diuretikums Amilorid wurden lichtschaltbare 
Azobenzenderivate, die Photoamiloride, entworfen, synthetisiert und funktionell mittel 
UV/Vis-Spektroskopie, Zweielektroden Spannungsklemme (TEVC), Membranfleckenklemme 
(patch clamp) und transepithelialer Voltohmmetrie untersucht. Im Zuge dessen wurden 
hochwirksame neue ENaC-Blocker entdeckt, wovon ein Kandidat (PA1) hervorragende 
Eigenschaften als lichtschaltbarer ENaC-Blocker an der δβγ-Isoform zeigte (Abb. 1). Mit 
Elektrophysiologie an Xenopus oocyten und HEK-Zellen, die den menschlichen δβγENaC 
exprimierten, konnte demonstriert werden, dass cis-PA1 ein wesentlich stärkerer δβγENaC-
Blocker ist als trans-PA1 und somit eine  Kontrolle der Kanalaktivität durch einen Wechseln 
zwischen 400 und 500 nm Bestrahlung erlaubt. Da die Effekte an der αβγ-Isoform wesentlich 
geringer waren, konnte dieses neuartige Werkzeug dazu verwendet werden die funktionelle 
Rolle von δβγENaC in einer gemischten Population der beiden Isoformen nachzuweisen.  
Die Entwicklung des ersten lichtschaltbaren ENaC-Blockers stellt eine große Erungenschaft 
dar und erweitert die Möglichkeiten diesen interessanten Ionenkanal weiter zu erforschen. 
Die Selektivität für die wenig verstandene δβγ-Isoform ist eine weitere Bereicherung, ebenso 
wie das Potential der δβγENaC/PA1-Kombination als optogenetisches Werkzeug. 
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Abb. 1. PA1 – Ein photoschaltbarer ENaC-Blocker. A) Die (Kristall)Struktur von PA1 und dessen Isomerisierung 
mit 400 und 500 nm. B) Die Isomerisierung von PA1 (10 µM) erlaubt die robuste, reversible Kontrolle von 
δβγENaC-Strömen in HEK293t Zellen mit Licht (grün = 500 nm, blau = 400 nm, Ganzzellableitung 
Membranfleckenklemme). 
 
2) Ein photoschaltbarer Blocker für Spannungsgesteuerte Ionenkanäle. Neuronale 
Kommunikation fußt in der Weiterleitung elektischer Signale. Spannungsgesteuerte 
Ionenkanäle sind fundamentale Glieder in der neuronalen Kommunikationskette und sind in 
die Generierung und Progagierung von Aktionspotentialen (APs) involviert. 
 Um das neuronale Feuern von APs mit Licht zu kontrollieren, wurde ein Azobenzenderivat 
des langwirkdenden Oberflächenanästhetikums Fomocain entworfen und hergestellt – das 
Fotocain (Abb. 2). Elektrophysiologische Untersuchungen an dissoziierten Neuronen und 
akuten Hirnschnitten der Maus zeigten, dass Fotocain in seiner cis-Form unter 350 nm 
Bestrahlung APs zulässt, diese in seiner trans-Form unter 450 nm Bestrahlung jedoch 
inibiert. Diese gewünschte Funktionalität in Verbindung mit interessanten 
pharmakokinetischen Eigenschaften, die auf die milde Basizität der Morpholingruppe 
zurückzuführen sind, machen Fotocain zu einem äußerst nützlichen neuen Werkzeug, das 
die Reichweite der neuronalen Photopharmakologie erweitert. 
 
cis-PA1
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400 nm 500 nm
20 sec
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0 
pA
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trans-Fotocain B
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m
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50 pA
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Abb. 2. Fotocain – Ein photoschaltbarer Blocker spannungsgesteuertert Ionenkanäle. A) Die (Kristall)Struktur von 
Fotocain und dessen Isomerisierung mit 350, bzw. 450 nm. B) Das Feuern von Aktionspotentialen dissoziierter 
Neurone kann mit Fotocain (50 µM) kontrolliert werden (blau = 450 nm, violett = 350 nm, Ganzzellableitung 
Membranfleckenklemme) 
 
3) Ein photoschaltbarer Agonist des µ-Opioid Rezeptors (MOR). Opioidrezeptoren 
(ORs) gehören zu der Gruppe der G-Protein gekoppelten Rezeptoren (GPCRs) der Klasse A 
und werden im zentralen Nervensystem (ZNS), im Rückenmark und im Verdauungstrackt 
von Säugern exprimiert. Sie sind die Rezeptoren der nativen Endorphine und Dynorphine, 
des natürlich vorkommenden Morphins und der synthetischen Opioide, wie beispielsweise 
Fentanyl. Obwohl Opioide seit Jahrtausenden als Anesthetika  pharmakologisch geschätzt 
und genutzt werden, stellt deren Einsatz wegen ihres Suchtpotentials und zahlreicher 
Nebenwirkungen nach wie vor eine große Herausforderung dar.  
Auf Basis des Fentanyls wurden photoschaltbare Azobenzenderivate entworfen, hergestellt 
und funktionell untersucht (Abb. 3). Dazu wurde der MOR in HEK-Zellen mit einem G-Protein 
aktivierten einwärtsgleichrichtenden Kaliumkanal (GIRK-Kanal) co-exprimiert. Diese 
Kombination greift zum einen die native Signalkaskade des MOR im ZNS auf und ermöglicht 
es zum anderen die reversible Rezeptoraktivierung direkt mit Membranfleckenklemme 
auszulesen. Im Zuge dieser Experimente wurde ein Photofentanylderivat entdeckt, das einen 
ausgezeichneten photoschaltbaren Agonisten des MORs darstellt. In seiner trans-Form 
aktiviert das Molekül den Rezeptor sehr stark, in seiner cis-Form hingegen sehr schwach. 
Somit ist Photofentanyl der erste photoschaltbare Agonist für den MOR. Darüberhinaus ist 
dies die erste Demonstration von Photopharmakologie an einem GPCR der Familie A, zu der 
auch Rhodopsin gehört, und eröffnet möglicherweise die Möglichkeit weitere Mitglieder 
dieser Wichtigen Proteinfamilie lichtschaltbar zu machen. 
 
10 s
480 nm
360 nm
100 pA
25 µM PFII
360 nm
480 nm
cis-PF2trans-PF2
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Abb. 3. Photofentanyl – Ein photoschaltbarer Agonist des µ-Opioid Rezeptors (MOR). A) Die Struktur des 
Photofentanyls-2 (PF2) und dessen lichtinduzierte Isomerisierung. B) Die Wirkung von PF2 an HEK293t Zellen, 
die den MOR und GIRK-Kanäle exprimieren (Ganzzellableitung Membranfleckenklemme). 
 
4) Photoschaltbare Agonisten für den Dopaminrezeptor (DR). Der DR gehört ebenso 
wie der MOR zu der Familie A G-protein gekoppelter Rezeptoren. Die fünf bekannten 
Subtypen D1-D5 sind sowhol prä- als auch postsynaptisch in dopaminergen Neuronen 
anzufinden und werden von dem endogenen Neurotransmitter Dopamin (DA) aktiviert. Das 
Dopaminsystem wird auch als Belohnungssystem bezeichnet und spielt eine elementarere 
Rolle in der Entwicklung von Sucht.  
Anhand des bekannten DR-Agonisten PPHT wurde eine Serie von Azobenzenderivaten 
entworfen und synthetisiert (aPPHT, Abb. 4). Obwohl PPHT racemisch eingesetzt wird, 
wurden verschiedene synthetische Routen ausgearbeitet um enantiomerenreine 
Verbindungen herzustellen. Dabei wurde der Komplex aus einem Weinsäurederivat und 
einem N-Benzylaminotetralin mit Röntgenstrukturanalyse untersucht, womit die wichtige 
Interaktion zwischen den Toloylsäureresten der Weinsäure und der Benzyleinheit des 
Tetralins demonstriert werden konnte. Die letztlich etablierte modulare Syntheseroute mit 
Azobenzenbausteinen und dem chiralen Aminotetralin bieten eine vielseitige Plattform, um 
viele verschiedene photoschaltbare PPHT-Derivate mit robuster Chemie herzustellen. 
Vorläufige Tests der bereits hergestellten Photoschalter durch Kollaborationspartner an der 
Columbia Universität identifizierten bereits einen vielversprechenden Kandidaten für einen 
photoschaltbaren Agonisten des D3R.  
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Abb. 4. aPPHT – Ein photoschaltbarer Agonist des Dopaminrezeptors (DR). A) PPHT ist ein bekannter DR-
Agonist, der racemisch eingesetzt wird. B) Struktur eines representativen chiralen photoschaltbaren PPHTs 
(aPPHT) und dessen Isomerisierung. C) Kristallstruktur eines Komplexes aus einem Weinsäurederivat und und 
einem Aminotetralin, das eine Zwischenstufe in der Synthese chiraler aPPHT-Moleküle ist. D) Kristallstrukturen 
verschiedener Azobenzenbausteine, die durch eine reduktive Amminierung mit einem Aminotetralinbaustein 
verknüpft werden können.  
 
5) Photoschaltbare Agonisten für den Adenosinrezeptor (AR). Der AR gehört ebenso 
wie der MOR und DR zur Familie A der G-protein gekoppelten Rezeptoren. ARs werden im 
ZNS exprimiert und sind vor allem als das Ziel der weltweit meist gebrauchten psychoaktiven 
Substanz, nämlich Koffein, bekannt. Es wird derzeit spekuliert ob ARs in der Zellmembran 
mit DRs wechselwirken und ihre Aktivität gegenseitig in Form von Rezeptorheteromultimeren 
modulieren. 
Anhand des endogenen Liganden Adenosin und abgeleitet von synthetischen AR-Agonisten 
wurden photoschaltbare Azobenzenderivate entworfen und synthetisiert, die wahrscheinlich 
als photoschaltzbare Agonisten am A1- und A2A-AR wirken (Abb. 5). 
 
Abb. 5. Azoadenosin – Ein photoschaltbarer Agonist des Adenosinrezeptors (AR). Adenosin ist der native 
Agonist der ARs. Koffein antagonisiert dessen Effekt. Der synthetische Agonist CGS21680 unterstreicht die 
Toleranz für ausladende Substitutionen am C-2. Anhand dessen wurden die photoschaltbaren Azoadenosine 1 
und 2 entworfen und synthetisiert. 
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6) Photoschaltbare Benzodiazepine (BZ). Benzodiazepine sind weitverbreitete 
sedierende, krampflösende und angstlösende Wirkstoffe, die als allosterische Aktivatoren an 
GABAA-Rezeptoren wirken. Diese Rezeptoren, die nach ihrem endogenen Liganden γ-
Aminobuttersäure (GABA) benannt sind, sind die hauptsächlichen Vermittler inhibitorischer 
Signale in der neuronalen Kommunikation.  
Aufgrund des diversen, hoch interessanten, aber nicht gänzlich unproblematischen 
Wirkungsprofils der Benzodiazepine, wurden zahlreiche Azobenzenderivate hergestellt, die 
möglicherweise die Türen für eine neuartige Erforschung der GABAA-Rezeptor-BZ-
Interaktion öffnen (Abb. 6). 
 
Abb. 6. Photo-Benzodiazepine (pBZs) – Photoschaltbare Aktivatoren für den GABAA-Rezeptor. Clonazepam ist 
ein bekanntes, nicht photoschaltbares BZ. pBZ1.1 (Kristallstruktur) ist ein Repräsentant einer Serie von pBZs, die 
eine Azobenzengruppe als Verlängerung des anelierten Benzenring. pBZ2.1 ist Repräsentant einer Serie von 
pBZs, die mit benzylischen Azobenzenen am Anilidstickstoff des Diazepinrings verknüpft sind. 
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